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Abstract 
Rationale: There are many public health benefits of targeting adolescent for 
immunisation. However, and in many settings, adolescents do not get optimal benefits 
from immunisation. In the decade of vaccines (2011-2020), adolescent immunisation is 
a topical subject. An up-to-date and synthesized research on adolescent immunisation 
is lacking. 
Overall purpose: The purpose of the PhD thesis was to characterize adolescent 
immunisation in the decade of vaccines. 
Research methods: First, we conducted a comprehensive narrative review of the 
literature (chapter 2) on adolescent immunisation. Then, we conducted systematic 
reviews (chapters 3 and 4). One of the systematic reviews assessed the strategies to 
improve uptake of vaccines among adolescents. The other systematic review assessed 
the knowledge, attitudes and practices of adolescents and their parents and teachers 
towards immunisation. Finally (chapter 5), we conducted a cross-sectional study to 
describe the challenges experienced, and lessons learnt during the introduction of 
national human papillomavirus (HPV) vaccination programmes in Africa. 
Findings: Adolescents are an important group to target with primary, booster or catch 
up immunisation. Some global initiatives have advocated for adolescent immunisation. 
Multiple reasons, among them, lack of knowledge and access to immunisation services 
are barriers to adolescent immunisation. There exist multiple strategies to improve 
uptake of vaccines among adolescents. For example, health education, financial 
incentives, mandatory vaccination, and class-based school vaccine delivery. The 
iii 
evidence suggests that a combination of strategies may be more effective than one 
strategy alone in enhancing uptake of vaccines by adolescents. 
Knowledge of vaccines, immunisation and vaccine preventable diseases was found to 
be suboptimal among key stakeholders of adolescent immunisation in Africa. We found 
a disconnect between the level of knowledge on immunisation and the uptake of 
vaccines, an interesting finding that warrants further research in Africa. Six African 
countries shared the lessons learnt and experiences during the national introduction of 
HPV vaccination programmes that targeted adolescent girls. There were similarities in 
the results among the participating countries. The challenges included: logistical co-
ordination, identification of the target population, obtaining political support, integration 
with other school programmes and stakeholder engagement. A lesson learnt was that 
schools are a convenient site to access and vaccinate adolescents.  
Conclusion: Adolescent immunisation is not routinely practiced in many countries. The 
introduction of HPV vaccines has created an ideal opportunity to build platforms for 
adolescent immunisation. Research on adolescent immunisation is limited, more so in 
low and middle-income countries. Existing research shows a combination of strategies 
can be used to enhance uptake of vaccines among adolescents. Strong advocacy 
programmes are required to drive the global agenda of adolescent immunisation, 
particularly in Africa. 
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Chapter 1 
General introduction  
About this chapter: 
The chapter describes the rationale and goal of the PhD project. We also provide a 
preview of different studies conducted, including the methods used to achieve the goal 
of the project. Highlights of the key findings and possible policy implications are also 
provided in this chapter. 
Immunisation is a key global public health strategy used to combat vaccine preventable 
diseases (VPDs) in all population groups. Routine immunisation services delivered via 
the Expanded Programme on Immunisation (EPI) target children because they are the 
most vulnerable population group. (1, 2). Currently, adolescents, an increasing 
population group (3) does not get optimal benefits from immunisation. The main reason 
for this is the absence of structured programmes to vaccinate this population group. 
Furthermore, immunisation research on optimal strategies to reach and vaccinate 
adolescents is limited. Therefore, the research focus for this thesis is to generate new 
and relevant knowledge on adolescent immunisation. The knowledge will be used by 
researchers and policy makers as a starting point to develop or strengthen adolescent 
immunisation programmes. 
Following the eradication of small pox in 1979 (4, 5), global immunisation efforts have 
prioritized the eradication of polio (6), elimination of measles (7) and neonatal tetanus 
(8) as well as the control of several VPDs (9). Crucially global eradication, elimination 
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and control, of VPDs must involve immunisation of all population groups, including 
adolescents. Therefore, targeting adolescents for immunisation should be a key global 
public health strategy in the control of VPDs. For example, a vaccine against human 
papillomavirus (HPV) is primarily targeted to preadolescent (9-12 years old) and 
adolescent (13-19 years old) populations. Optimal uptake of immunisation services by 
adolescents is critical to control VPDs. Synthesized research on effective immunisation 
strategies that can enhance uptake of vaccines by adolescents is limited. 
Therefore, the goal of this PhD thesis was to develop a concise review highlighting the 
critical issues on adolescent immunisation as well as conduct an evidence synthesis on 
the topic. Specific evidence synthesis focused on the strategies or interventions to 
achieve improved uptake of adolescent vaccines. Another focus of the evidence 
synthesis was the knowledge, attitudes and practices (KAP) by adolescents on the 
immunisation. Finally, we characterized experiences, challenges and lessons learnt 
during the introduction of national routine adolescent immunisation with HPV vaccines 
by a few African countries. 
To achieve the goal of this thesis, we used a mixed method approach. First, we 
conducted a narrative review on adolescent immunisation. We chose this method as to 
our knowledge, there was no review that gave a detailed insight on the topic. In this 
narrative review (chapter 2), we defined the adolescent immunisation gap and the 
rationale for providing specific vaccines to adolescents as part of a broader strategy to 
control VPDs. In addition, we provided insights on the need to develop adolescent 
immunisation platforms. As some countries have already introduced routine adolescent 
immunisation, we wanted to collate the existing knowledge on the topic. 
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Second, we conducted an evidence synthesis on strategies or interventions used to 
improve uptake of vaccines among adolescents. For this study (chapter 3), we 
conducted a systematic review through the Cochrane Effective Practice and 
Organisation of Care (EPOC) group. Third, we conducted a Campbell style systematic 
review (chapter 4) on the knowledge, attitudes and practices (KAP) of adolescents, their 
parents and their teachers towards immunisation. In chapter 4, we restricted the 
evidence synthesis to Africa, a continent where routine adolescent immunisation is at 
early stages of development. The introduction of HPV vaccines targeting adolescents is 
a key developmental milestone for adolescent immunisation in Africa. 
Fourth, and finally, we conducted a cross sectional study (chapter 5) to describe the 
experiences, challenges and lessons learnt by key partners during HPV vaccine 
introduction in Africa. The HPV vaccination programme targeted preadolescent and 
adolescent girls. A questionnaire was administered to the key partners from eight 
African countries that had successfully introduced HPV vaccines at a national level by 
the end of 2016. This study involved in-depth face-to-face interviews and self-
administered online questionnaires as qualitative methods for data collection.  
We were able to achieve the goal of the PhD thesis using the mixed method approach. 
From the narrative review, we were able to describe in detail the rationale of 
implementing adolescent immunisation, including the specific vaccines required for this 
population group. From the Cochrane review, we successfully generated and evaluated 
the available evidence on the effects of different interventions to improve uptake of 
vaccines by adolescents. The systematic review on KAP showed the paucity of 
research information on the topic in Africa. Nevertheless, available evidence showed 
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that, although adolescents had low levels of knowledge on immunisation, this population 
group was receptive to vaccination, particularly HPV vaccination. The cross-sectional 
study showed similarity in the lessons learnt, experiences and challenges across the 
participating countries. Fundamentally, the challenges were mainly logistical.  
Taken together, studies in this thesis have contributed to new knowledge on adolescent 
immunisation. Our narrative review advocates for governments to prioritize adolescent 
immunisation programmes. The findings from the Cochrane review are valuable to 
immunisation policy makers interested in improving the uptake of immunisation services 
by adolescents. The KAP study shows gaps in research on adolescent immunisation in 
Africa. A disconnect between the level of knowledge on immunisation versus uptake of 
vaccines was an interesting finding that warrants further research in Africa. Many 
African countries are in the process of introducing national routine HPV vaccination 
targeting preadolescent and adolescent girls. The similarity in lessons learnt, 
experiences and challenges during the introduction of HPV vaccine validates the critical 
need to disseminate adolescent immunisation research in Africa. This information is 
useful for other countries in Africa that are planning to introduce HPV vaccination 
programmes, and possibly, other adolescent vaccines. 
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Chapter 2 
A Literature review on adolescent immunisation: past, present and future 
About this chapter: 
In this chapter, we review the global vaccination initiatives focussing on adolescent 
immunisation. We also introduce and define the concept of adolescent immunisation 
gap as well as provide a detailed insight on the following: importance of adolescent 
immunisation; need to develop primary adolescent vaccination platforms; and, the 
barriers preventing the optimal uptake of adolescent vaccines. We also discuss some 
specific vaccines recommended for adolescents.  
Publication: A slightly modified version of the chapter will be submitted to the Journal 
of Adolescent Health. 
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Abstract 
Globally, uptake of vaccines by adolescents is suboptimal despite evidence showing 
that vaccines are among the most successful and cost-effective public health 
interventions. In many settings, there are no platforms to conduct adolescent 
immunisation. Furthermore, immunisation programmes targeting adolescents are 
relatively new in LMICs where many health challenges are endemic. Significantly recent 
global vaccination initiatives advocate for adolescent immunisation. There are three 
main reasons why adolescents need to be vaccinated with catch-up and booster 
vaccines: achievement of primary immunisation of new vaccines, catch-up on missed 
vaccinations and boosting of waning immunity. 
Prior to achieving optimal uptake of vaccines by adolescents in LMICs, policy 
formulators will first have to understand the multiple factors that may enhance or reduce 
uptake of the vaccines in this age group. 
Currently and in many settings, new adolescent immunisation services and other 
adolescent health interventions are standalone programmes. Hence, for future 
adolescent health programmes to succeed it will be vital that there is integration with the 
Expanded Programme on Immunisation (EPI).   
This is a comprehensive review on the global literature about adolescent vaccination 
with the aim to describe: the immunisation gap during the adolescence period; the 
importance of adolescent immunisation; the need to develop primary adolescent 
vaccination platforms; and, the barriers preventing the optimal uptake of adolescent 
vaccines. 
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Adolescent immunisation: Introduction 
Immunisation is one of the most cost effective public health strategies utilised to 
promote health (10). Immunisation prevents an estimated 2.5 million deaths annually 
and millions more lives are spared from the devastating morbidity associated with VPDs 
(11, 12). The Global Alliance for Vaccines and Immunisation (GAVI) projected that 
vaccinations administered between 2011 and 2020 will avert more than 23 million 
potential deaths (13).  
Globally, the World Health Organisation (WHO) launched the EPI in 1974 (5). The EPI 
remains the main platform used to vaccinate children early in life (5, 9). In contrast, for 
adolescents and adults, there are no globally structured public health vaccination 
platforms (14). Between 2010 and 2018, some countries introduced adolescent 
immunisation but few of these countries are in Africa (Figure 1) (15). Recent global 
vaccination initiatives (16, 17) advocate for life course (including adolescents) 
immunisation. These vaccination initiatives have enabled several countries in Africa to 
commit to adolescent immunisation.  
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Figure 1: Countries that introduced vaccine antigens targeting adolescents 2015-
2018 
 
Source: http://www.who.int/immunization/monitoring_surveillance/routine/reporting/en/ 
(15). 
Global vaccination initiatives  
To effectively control VPDs, there is global appreciation that immunisation of 
adolescents in all settings must be improved. Recent global vaccination initiatives have 
emphasized the need to expand immunisation beyond the childhood phase. Below, we 
describe the major global vaccination initiatives and highlight those with an emphasis on 
adolescent immunisation.  
Expanded Programme on Immunisation 
The global effort to use vaccination as a public health intervention started when EPI was 
launched by the WHO in 1974 (5). Subsequently, small pox was officially eradicated in 
1979 (4, 5, 9). The EPI, which focusses on infants and young children has achieved 
notable successes. For example, global average vaccine coverage rates for vaccines 
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containing diphtheria, pertussis and tetanus antigens increased from less than 5% in 
1974 to over 85% in 2018 (18).  
To maximize the benefits of immunisation, there has been efforts to integrate EPI with 
other health services. For example, with screening programmes, such as eyesight, 
hearing, oral hygiene and deworming (19). The integration of EPI with these other 
health services has been used as a strategy to address some of adolescent health 
needs (20, 21). However, specific immunisation services focused to adolescents remain 
limited in the majority of LMICs.   
Millennium Development Goals 
In the year 2000, the global community made a historic commitment to eradicate 
extreme poverty and improve the health and welfare of the world’s poorest by 2015 
(22). The commitment was embodied in the United Nations (UN) Millennium 
Development Goals (MDGs) that had eight goals (23). Of these goals, specifically 
relevant to immunisation was the fourth MDG goal (MDG4) that committed governments 
to reduce mortality rates among children under five by two-thirds between 1990 and 
2015 (23). Immunisation was considered an essential component of MDG4 (23). The 
MDG4 focussed on immunisation of infants and children, but not adolescents.   
Global Alliance for Vaccines and Immunisation 
The GAVI was established in 2000 (24). The aim of GAVI is to create equal access to 
new and underused vaccines for children, particularly in poor settings (24). By 2016, 
several countries (25) were beneficiaries of GAVI support in many ways among them, 
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the introduction of new vaccines: Pneumococcal Conjugate Vaccine (PCV) and the 
rotavirus vaccine being an example (25).  
Working alongside WHO and United Nations Children Fund (UNICEF), the GAVI 
initiative has supported the improvement of services such as adequate, predictable, and 
affordable supply of vaccines (1, 26). In 2016, the GAVI revised the initiative’s strategic 
plan to include building of sustainable immunisation programs and increasing equitable 
use of vaccines in lower-income countries (27). The GAVI is supporting several LMICs 
to introduce HPV vaccination in adolescent populations (28, 29). 
Global Immunisation Vision and Strategy 
Building on the success of EPI, WHO and UNICEF launched the Global Immunisation 
Vision and Strategy (GIVS) in 2005 (30, 31). The primary objective of GIVS was to 
achieve a two-thirds reduction of mortality and morbidity associated with VPDs by 2015 
(30, 31). To achieve this objective, the GIVS advocated for the expansion of 
immunisation services beyond the traditional paediatric focus (31). The GIVS 
recognised the benefits of providing immunisation services to adolescents and adults.  
The Decade of Vaccines Collaboration 
In 2010 at the World Economic Forum, the Decade of Vaccines Collaboration (DOV) 
initiative was launched with a seed fund of USD10 billion from Bill and Melinda Gates 
Foundation over the next 10 years (32). The aim of the initiative was to bring the 
benefits of vaccines to all people no matter where they live between 2010 and 2020 
(32). The DOV was central to developing the Global Vaccine Action Plan (GVAP). 
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The Global Vaccine Action Plan 
In 2012, the World Health Assembly endorsed the Global Vaccine Action Plan (GVAP) 
2011–2020 (16, 33). The GVAP is guided by six principles: country ownership; shared 
responsibility and partnership; equity; integration; sustainability; and, innovation (16). 
Improving equity, routine vaccination coverage, as well as targeting the hard-to-reach 
and marginalized populations are the key focus areas in the GVAP framework (16). 
GVAP 2011-2020 states that “the benefits of immunisation should be more equitably 
extended to all children, adolescents and adults” (16). The GVAP is thus another global 
initiative that highlights the need for adolescent immunisation. 
Sustainable Development Goals 
In 2015, the UN General Assembly established the Sustainable Development Goals 
(SDGs) which included 17 universal goals, 169 targets, and 230 indicators for a period 
between 2015 and 2030 (17). The SDGs builds on the success and momentum of the 
MDGs, but have a broader scope (17). Health is a core element of the SDGs and the 
aim of improving vaccination programmes is well stated (17, 34). Specifically, SDG goal 
three calls for governments to ensure healthy lives and promote well-being for all ages 
(34). The SDG goal three is in line with addressing adolescent immunisation gap: calling 
for an expansion of the EPI schedule.  
Summary on global vaccination initiatives 
Since 1974, several global initiatives that promotes immunisation have been developed, 
starting with EPI to the SDGs in 2015. The EPI, MDGs, GAVI initiatives, broadly 
focused in the main on childhood immunisation and not adolescents. Promoting equity 
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has become a key strategy for improving routine vaccination coverage for all, as well as 
for hard-to-reach and marginalized populations. Thus, the introduction of GIVS, GVAP 
and the SDGs, which promote expansion of immunisation services beyond the 
traditional paediatric scope, is welcomed. The WHO, as the global leading agency in 
setting immunisation and vaccines-related policies, now advocates for immunisation for 
all, including adolescents. 
Adolescent immunisation gap 
The WHO defines adolescents as young persons aged 10 to 19 years (35). The 
adolescence phase has three stages of development that can be categorised as early 
(10-13 years), mid (14-16 years) and late (>17years) (3, 35). According to the 2014 
United Nations Population Fund (UNFPA) report, adolescents and youths account for 
28% of the total global population (3). Therefore, providing optimal health care to this 
large and young population is crucial for sustainable development, necessary to fulfil the 
vision of the GVIS, GVAP and SDGs. 
The 10-13 years old group is the primary immunisation population for new vaccines like 
HPV while the 10-17 years old group is targeted for booster immunisation with WHO 
recommended vaccines like Tdap (29, 36). Over the last decade, the number of 
recommended vaccines for adolescents has grown substantially (36-38). Currently, 
there are over 13 vaccines available globally that are recommended for use among 
adolescents (36). Later in this review, we discuss the recommended schedules for 
these vaccines. The 13 recommended adolescent vaccines include traditional, 
underutilised and future vaccines (Figure 2) (36). Absence of providing the 
recommended vaccines to the adolescent population create an immunisation gap.     
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Traditional vaccines refer to measles, pertussis, tetanus, diphtheria, polio and hepatitis 
B (2). Vaccination coverage of these vaccines are used as a standard measure of the 
programme’s ability to reach the target population. The term “under-utilised vaccines” 
refers to vaccines that have been available for several decades in High-Income 
Countries (HICs) but are not universally available in LIMCs. Examples are haemophilus 
influenza type b (Hib), influenza and HPV vaccines (39, 40). 
 
Figure 2: Past, current and future adolescent vaccines 
 
 
Source: http://www.who.int/immunization/policy/Immunization_routine_table1.pdf?ua=1 
(36) 
Why vaccinate adolescents?  
There are many benefits of vaccinating adolescents. Firstly, high vaccination coverage 
among adolescents is likely to improve population herd immunity. Vaccination during 
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infancy and childhood may not induce lifelong immunity, and booster doses may, 
therefore, be required during adolescence (41, 42). In the absence of boosting, the 
vaccine-specific immunity among adolescents may decline because some vaccines 
administered early in life induce short-lived immunity that wanes over time, leading to a 
susceptible population later in life (43-45). For example, a population-based study 
showed a declining immunity during adolescence in individuals who received a single 
dose of varicella vaccine in childhood (46).  
In situations of waning immunity, it is recommended that booster doses of the vaccines 
previously administered in childhood should be provided later in life to maintain vaccine-
induced immunity (42-45). For example, with reports showing changing epidemiology of 
pertussis (47), the dogma of lifelong protection after pertussis childhood immunisation 
appears incorrect (47). Pertussis infections cause significant morbidity to adolescents 
and young infants (47, 48), thus the need for a booster dose during adolescence period. 
The second benefit is to catch-up adolescents who may have missed vaccination during 
early childhood. Current WHO guidelines recommend vaccinating adolescents, who 
have not previously received vaccines against measles, mumps, rubella, varicella, 
hepatitis B, and polio (36, 43-45). Despite the recommendations, in Africa, adolescent 
vaccination coverage remains largely suboptimal and poorly documented, save for HPV 
vaccine in some countries (2). 
The third benefit of vaccinating adolescents is the potential to reduce the morbidity and 
mortality associated with VPDs among children (43-45). The VPDs in adolescents 
increase the risk of infections among unvaccinated or under-vaccinated children, as the 
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adolescents can transmit VPDs (42, 44, 45, 48). For instance, in countries where 
Meningococcal B and C disease predominated, meningococcal carriage prevalence 
peaked at 23.7% in 19-year-olds, versus 4.5% in infants, 7.7% in 10-year-olds, and 
7.8% in 50-year–olds (49). Thus, in some settings, adolescents have the highest burden 
of meningococcal carriage compared to infants and children. Therefore, adolescents 
should be prioritized for booster vaccination against Neisseria menengitidis (48, 49).  
Invasive meningococcal disease (IMD) risk is associated with the carriage of Neisseria 
meningitidis pathogen and closeness of interpersonal contacts of asymptomatic 
carriers; therefore, university settings are an ideal environment for meningococcal 
transmission (50). Among first year university students, the IMD prevalence in an 
institution increased from 6.9% on day 1 to 23.1% on day 4 in the first week of term in 
October, and was up to 34.2% in some groups in December (51). 
The fourth benefit of immunising adolescents is the reduction of the school absenteeism 
which can interfere with continuity in education and healthy development towards 
adulthood (41, 44, 45). Influenza infections are an important cause of excess school 
absenteeism in adolescents (52). Due to seasonal influenza, school going adolescents 
miss important academic time in school and their parents often miss work or other 
activities to care for the sick offspring (52). The classic study by Monto et al. 
demonstrated that vaccinating 86% of all school children and adolescents against 
influenza resulted in a reduction of student absenteeism during influenza outbreaks 
(53). Hence, reduction of morbid events during adolescence period can reduce the 
absenteeism associated with illness (41, 44, 45).  
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The fifth benefit is that adolescents are at risk of developing several VPDs, including 
HPV, a virus that is associated with onset of sexual activities, likely occurring during this 
age period. Infection with HPV during adolescence is mostly asymptomatic. The 
symptoms are mainly detected later in adulthood. It must be stressed that relevant 
evidence must guide the prioritization of specific vaccines targeting adolescents. For 
example, booster vaccination due to waned immunity following childhood vaccination 
may not be a priority in settings where subsequent exposure to infection is likely to 
stimulate anamnestic response and subsequent protection from the VPD. In contrast, 
high coverage for primary vaccination with novel vaccines (e.g HPV) should be 
prioritized in settings where HPV vaccination programme is not optimal or non-existent. 
Therefore, providing HPV immunisation during adolescence and not any other phase of 
life is currently the most optimal strategy to control cancers associated with the virus 
(29). Furthermore, vaccines currently under development, like those against human 
immunodeficiency virus (HIV) and Mycobacterium tuberculosis (M.tb), are likely to target 
adolescents (37). Therefore, studies focussing on improved understanding of 
adolescent vaccination are critical and will become increasingly relevant in the future.  
The last reason is an indirect benefit of adolescent immunisation that is also observed in 
the case of HPV vaccination. Evidence shows that optimal HPV vaccination coverage in 
girls alone can protect boys from HPV associated illnesses (54, 55). Other vaccines with 
indirect benefit are those against pneumococcus and influenza (56, 57). 
Elimination and eradication of VPDs is the quintessential public health goal for an 
immunisation programme. For many VPDs, this public health goal will be achieved by 
complementing the existing immunisation services with the implementation of 
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adolescent immunisation (58). Despite the global recommendations to vaccinate 
adolescents, several hurdles have prevented the closure of the adolescent 
immunisation gap in many settings. These hurdles include lack of optimal knowledge, 
attitude and practices towards immunisation, vaccines and VPDs. Other hurdles include 
health infrastructural inadequacies, and financial constraints (59-61). These hurdles 
need to be addressed for immunisation programmes to introduce adolescent 
vaccination or improve the uptake of adolescent vaccines.  
Challenges preventing optimal uptake of adolescent vaccines 
Adolescent immunisation against pathogens such as HPV, Neisseria menengitidis 
Clostridium tetani, Corynebacterium diphtheriae, Bordetella pertussis and poliovirus 
have been successfully rolled out in some HICs (2, 62). Some LMICs are also making 
steady progress in the introduction and implementation of adolescent immunisation 
(62). The delay in the introduction of adolescent immunisation in LMICs could be due to 
many reasons such as awareness, resource limitations and lack of political will from the 
governments (60, 61).  
Barriers to achieving optimal vaccination uptake among adolescents are multifactorial. 
The barriers can be broadly categorised into individual-level determinants and health 
system determinants. Figure 3 shows a conceptual framework summarizing the factors 
that could lead to suboptimal uptake of adolescent vaccines as well as possible 
interventions. Understanding these challenges will be the first step to design 
interventions aimed at improving the uptake of immunisation services targeted to 
adolescents. 
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Figure 3: Potential factors influencing the uptake of immunisation 
 
Source: Adapted from  conceptual model developed by Briss et al 2000 (63). 
Healthcare workers play a vital role in promoting vaccination (64). However, in many 
settings, adolescents usually visit health care workers only when unwell, and so, there 
are limited opportunities to inform the adolescents about the importance of 
immunisation (64, 65). In addition, most LMICs lack or have poor infrastructural 
programmes specific for delivering immunisation services to adolescents, leading to 
less contacts between adolescents and the healthcare system (65-67).  
Another challenge that hinders optimal adolescent vaccine uptake is lack of knowledge 
about immunisation, vaccines and VPDs among key role players like parents, teachers, 
adolescents and health care providers (60, 61). For example, due to lack of accurate 
immunisation knowledge among parents, they may decline to give parental consent for 
their adolescents to be vaccinated (59). This may in turn lead to low vaccine uptake. 
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Evidence from two systematic reviews discussed the importance of immunisation 
knowledge among key stakeholders in relation to improving adolescent vaccination 
uptake (61, 68). One of the systematic review showed a high acceptance and uptake of 
HPV vaccine by the targeted population, in settings where adolescents, parents and 
teachers had positive attitudes and practices towards the vaccines (61). Therefore, 
adequate knowledge and positive attitudes towards vaccination among parents, 
teachers and adolescents is crucial to improve uptake of vaccines among adolescents 
(61). 
High cost of new vaccines and unavailability of vaccines are known barriers to achieving 
high vaccination coverage among adolescents in LMICs (69, 70). In a 2014 modelling 
study,  the cost of delivering three doses of HPV vaccine in South Africa was estimated 
to be ZAR510 (US$50) per learner in a government school where the fees are 
subsidised (69). Ironically, in the private sector where the parents pay out of pocket, the 
cost of the same HPV vaccine was US$130 for the three doses (69). GAVI recognizes 
the benefits of adolescent immunisation against HPV and therefore, the initiative has 
included HPV vaccines in the portfolio of new vaccines that countries can seek support 
(28). Hence, LMICs, which are GAVI-eligible have now immensely improved their 
chances of introducing HPV vaccination (28, 71). By the end of 2017, six countries were 
approved for GAVI HPV national vaccine introduction support: Bolivia, Guyana, 
Honduras, Rwanda, Sri Lanka and Uganda (25).  
Another factor that may influence vaccine uptake among adolescents is misinformation 
on vaccine safety. For example, adolescents’ fear of adverse events following 
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vaccination may cause less interest in vaccination which in turn causes the adolescent 
to refuse assenting to immunisation, resulting to reduced vaccination coverage (72).  
Recommendations on adolescent immunisation 
The WHO recommends routinely vaccinating 11 or 12 years old with meningococcal 
conjugate vaccines (MCV), the combined tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis (Tdap) vaccine, influenza and the HPV vaccines (36). Additionally, 
WHO recommends vaccination against measles, mumps, rubella, varicella, hepatitis B, 
and polio for those who were previously not fully immunised (Table 1) (36). 
Furthermore, WHO also recommends vaccines for high-risk adolescents as highlighted 
in Table 1 (36). Future adolescent vaccines may include those against tuberculosis (TB) 
and HIV.  
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Table 1: WHO recommended routine immunisation schedule for children aged 10 
to 18 years (June 2016) 
Vaccines Disease targeted 10yrs 11-12yrs 13-15yrs 16-18yrs 
Vaccines for routine administration to all Adolescents 
Meningococcal conjugate vaccine Meningitis  1st dose  booster 
Tetanus, diphtheria, & acellular 
pertussis (Tdap) vaccine 
Tetanus, 
diphtheria, & 
pertussis  
 1st dose   
Human papillomavirus (HPV) 
vaccine 
Human 
papillomavirus 
 3 dose 
series 
  
Influenza vaccine (live attenuated 
influenza vaccine or inactivated 
influenza vaccine) 
Influenza Annual vaccination 1 dose only 
Catch-up vaccines for adolescents not fully immunized previously 
Inactivated poliovirus (IPV) 
vaccine 
Polio 1 dose  
Measles, mumps, rubella (MMR) 
vaccine 
Measles, mumps, 
rubella (MMR) 
1 dose 
Varicella (VAR) vaccine Varicella (VAR) 1 dose 
Hepatitis A (HepA) vaccine Hepatitis A (HepA) 1 dose 
Hepatitis B (HepB) vaccine Hepatitis B (HepB) 1 dose 
Vaccines for certain high-risk adolescents 
Pneumococcal conjugate vaccine Pneumonia 1 dose 
Hepatitis A (HepA) vaccine Hepatitis 1 dose 
Meningococcal conjugate vaccine Meningitis 1 dose  
Source: World Health Organisation (36). 
Globally, WHO leads the development of evidence-based immunisation policy 
recommendations. The independent Strategic Advisory Group of Experts (SAGE) on 
Immunisation is tasked with providing guidance to WHO on global policy 
recommendations and strategies (73). The WHO has placed a high priority on each 
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country to take ownership in the development of national decision-making process 
regarding immunisation and vaccine related issues (73). The ownership at national level 
is aided by presence of functional National Immunisation Technical Advisory Groups 
(NITAGs) (74). 
To recommend the introduction of adolescent vaccines among adolescents, NITAGs 
need to use evidence-based approaches. Such approaches include development of a 
clear policy question as well as recommendation framework (74). Important elements to 
consider for the recommendation framework on the introduction of vaccines for 
adolescents are the local epidemiology of VPDs and socio-cultural and economic 
factors (74). 
Recommended adolescent vaccines: 
Human Papillomavirus Vaccine 
The HPV vaccine is administered to prevent HPV infection and cervical cancer (75-77). 
The HPV causes virtually all cases of genital warts and cervical cancer (29). Cervical 
cancer is the second most commonly diagnosed cancer in women globally and the 
disease is highly prevalent in LMICs (78).  
The risk for HPV infection is high soon after sexual debut and there is a peak 
prevalence of 24% in women younger than 25 years (29, 78, 79). Reports suggest the 
estimated HPV prevalence globally among women is 11.7% (79). By region, the highest 
reported adjusted HPV prevalence is in sub-Saharan Africa, with a prevalence of 24% 
(79). 
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Since 2006, three vaccines are available, namely Cervarix®, Gardasil® and Gardasil 
9®. The vaccines are recommended for use in young women and these vaccines target 
at least two of the high-risk HPV types (16 and 18) (29, 77-79). Despite the HPV 
vaccines’ proven safety, efficacy and cost-effectiveness, Africa and Asia are the two 
continents that as of 2018 lagged in the introduction of the HPV vaccines, (see Figure 
4) (80). 
 
Figure 4: Global introduction of human papillomavirus vaccination programme 
 
Source: https://www.who.int/immunization/monitoring_surveillance/data/en/ (80). 
Meningococcal Conjugate Vaccines 
The MCV are administered to prevent invasive meningococcal infections caused by 
Neisseria meningitides (81). Six serogroups A, B, C, W135, X and Y of Neisseria 
meningitides can cause epidemics (81). Crowding is an important risk factor associated 
with an increased risk for meningococcal disease (81).  
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Meningococcal disease occurs primarily in children and adolescents (81). In Africa, 
major epidemics have been attributed to serogroup A and occur in the African 
"meningitis belt” (81). In the African “meningitis belt”, the WHO definition of a 
meningococcal epidemic is >100 cases/100 000 population/year (81). An outbreak 
outside the meningitis belt may be defined as a substantial increase in IMD (81). 
The target age for meningococcal A vaccine is 1-29 years (81). As of 2017, 21 countries 
in the African meningitis belt had introduced the vaccine at a national level with the 
hope of eliminating meningococcal A epidemics from this region (82).  
Tetanus, Diphtheria, and Pertussis Vaccines 
The Tdap (tetanus, diphtheria, and acellular pertussis) vaccine is administered to 
prevent tetanus, diphtheria and pertussis (83, 84). Interestingly, pertussis had been 
largely a forgotten public health disease after the introduction and attainment of high 
coverage for routine pertussis immunisation programmes (83, 84). However, pertussis 
continues to be a public health concern despite high vaccination coverage among 
infants.  
Pertussis disease has been reported to show resurgence in some countries (83, 84). 
There are many reasons for this including a rapid waning of the immunity after 
childhood vaccination, particularly with acellular vaccines (83). The Tdap vaccine 
contains a reduced dose of the pertussis antigens and is approved for use in 
adolescents and adults (36, 84). Adolescents and adults serve as the reservoir of 
pertussis infection and source of transmission to infants who are too young to receive a 
full series of pertussis immunisations (83). 
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Pertussis is estimated to cause 50 million cases and 300 000 deaths every year (85). 
Case-fatality rates in developing countries are estimated to be as high as 4% in infants 
(85). The WHO recommends a booster dose of the tetanus, diphtheria and acellular 
Tdap vaccine at age 11-12 years old (36). Currently and globally, only a few countries 
have implemented the Tdap vaccine among adolescents (15, 80).  
Influenza 
Influenza A and B viruses are respiratory pathogens that causes seasonal influenza 
epidemics and sporadic outbreaks (86) . Influenza occurs globally with an annual attack 
rate estimated at 5%–10% in adults and 20%–30% in children (86, 87). In temperate 
climates, seasonal epidemics are experienced mainly during the winter while in tropical 
regions, influenza may occur throughout the year, causing outbreaks more irregularly 
(86, 87). 
The influenza vaccine is administered to prevent infection caused by the influenza virus 
(86). Influenza vaccination is recommended on an annual basis for all persons older 
than 6 months including adolescents (36). Influenza vaccine uptake is generally low, 
even among the high-risk groups such as pregnant women (87). For instance, in United 
States during the 2011- 2012 influenza season, the vaccination rate for individuals aged 
5 to 17 years was 45.1% (87). Few, if any, African countries have a policy for 
adolescent influenza vaccination. 
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Additional adolescent vaccines: 
In addition to the above vaccines, WHO guidelines recommend vaccination against 
measles, mumps, rubella, varicella, hepatitis B, and inactivated polio for those who have 
not previously received these vaccines as a catch-up dose (36).  
Measles, mumps and rubella (MMR) is a live attenuated vaccine. Measles is a highly 
infectious respiratory disease that can result in severe to permanent complications while 
mumps virus causes an acute viral syndrome with parotid swelling (88, 89). The rubella 
virus causes German measles, which is a generally mild infection with a characteristic 
rash (90). Adolescents who are not previously vaccinated should get two doses of MMR 
while those who only received one dose previously, should get the second dose as a 
booster (36). 
Varicella (chickenpox) is an acute, highly contagious disease  caused by the varicella 
zoster virus (VZV) and is widely distributed (91). Burden of severe disease and mortality 
due to varicella and herpes zoster is substantially lower than that of other currently 
VPDs (91). However, the public health value of varicella vaccination in lowering 
morbidity and mortality due to VZV, particularly in vulnerable population groups, is well 
established (47, 91). Therefore, it is recommended that adolescents who were not fully 
vaccinated or have no history of immunity from the disease should get two doses of the 
vaccine against varicella (36). 
Polio is a highly infectious disease caused by a virus that invades the nervous system 
(92). Most individuals infected with the virus will not experience any symptoms at all 
(92). Since widespread use of the vaccine globally in the 1950’s, polio has been 
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eliminated in most countries (92). According to WHO, the polio virus circulates among 
the world's poorest and most marginalized communities particularly in Pakistan, 
Somalia, Afghanistan and Nigeria (93), and recently, Democratic republic of Congo (94). 
Therefore, it is recommended that adolescents who did not receive a complete vaccine 
series as a child should complete the series (36). 
Hepatitis A is a contagious liver disease caused by the hepatitis A virus (HAV) (95). 
Risk factors for hepatitis A include travel from low to high endemic settings (95). If not 
naturally immunised early in life and in the absence of vaccination, HAV infection can be 
a large public health concern among adolescents and adults (95). Effective vaccines 
against the virus are available and the local epidemiology data need to be considered 
prior the introduction of vaccines against hep A in adolescents (36, 95).  
Hepatitis B is a serious liver disease caused by the hepatitis B virus (HBV) (96). 
Hepatitis B virus (HBV) immunisation before HBV exposure is the most effective means 
to prevent HBV transmission (96). Each year about 3,000-5,000 people die from 
cirrhosis or liver cancer caused by HBV (96). The hepatitis B vaccine is currently 
administered as three doses over a six-month period (36). The hepatitis B vaccine 
should be given to adolescents not previously immunized (36). 
Pneumococcal disease is caused by a common bacterium (Streptococcus pneumoniae) 
that invades different parts of the body including lungs, bloodstream, brain and ears 
(97). The PCV is recommended for adolescents with certain underlying conditions like 
diabetes or chronic heart, lung, liver, or kidney disorders (97). Globally about 6.8 million 
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children and adolescents aged 2 to 18 years have these chronic illnesses that place 
them at high risk for pneumococcal disease (36, 97).  
Future vaccines 
Future vaccines under development, such as those against HIV and TB will likely target 
adolescents, because this age group has the highest risk of contracting and transmitting 
these diseases (37, 42). 
Vaccination strategies targeting adolescents  
Maintaining high vaccine uptake rates is an essential component to the success of any 
vaccination programme and various strategies to reach adolescents have been used 
globally (98, 99). The strategies include school-based approaches, mass immunisation 
campaigns, child health days and immunisation weeks (98, 100).  
Currently, schools have been used most often as the delivery platform for vaccinating 
school-aged children (101, 102). This approach has the advantage that the children can 
easily be reached with minimal logistic costs and time constraints (98, 101). By 2012, of 
the countries that have implemented or demonstrated HPV vaccination, school-based 
approaches to immunisation delivery was used in most of the countries (95 countries 
[49%]), Figure 5 (98). School-based immunisation was used more commonly in HICs 
64% compared to LMICs 28% (98). 
 Figure 5: School-based approaches to immunisation delivery 
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Source: https://doi.org/10.1016/j.vaccine.2014.11.037 (98). 
School-based vaccination programmes may not be entirely successful in countries with 
suboptimal school attendance rate, especially in LMICs (98). However, remarkable 
progress has been made on school enrolment, particularly in the early 2000s, in pursuit 
of the MDG goal of Education for all (103). As a result, the number of out-of-school 
children of primary school-age worldwide fell by 42% between 2000 and 2012 (103). 
However, millions of children remain unreached in LMICs. In 2016, about 67 million 
primary children were out of school (Figure 6) (103). Of the 67 million out of school, half 
the number were adolescents mainly living in sub-Saharan Africa (103). 
Figure 6: Out of school primary children & adolescents by region and sex, 2000-
2016 
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Source: http://uis.unesco.org/sites/default/files/documents/fs48-one-five-children-
adolescents-youth-out-school-2018-en.pdf (103). 
In addition to the challenge of poor school attendance, it is costly to use school-based 
delivery method to reach adolescents in countries that do not have an existing 
integrative health platform at schools (98, 100). The LMICs currently introducing HPV 
vaccination have reported intense resource requirements for the school-based delivery 
strategy (100). Most of the LMICs have reported optimal uptake of HPV vaccines 
through the demonstration projects (62, 100). Therefore, other strategies such as mass 
immunisation campaigns, facility-based, child health days and immunisation weeks can 
be used to complement school-based vaccination programmes in settings with poor 
school attendance rates (98).  
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Various interventions have been found to enhance the strategies towards improving 
adolescent immunisation uptake (67). Some of the interventions like vaccination policy 
requirements for entrance to school and financial incentives for adolescents and parents 
have been shown to improve the uptake on adolescent vaccines (67). 
Adolescent immunisation coverage - a focus on HPV vaccine 
Most programmes on adolescent vaccination have targeted the ages between 11 to 12 
years, although vaccines such as MCV4 target older adolescents between 16-17 years 
(36, 77). Since 2006, 64 countries have introduced HPV vaccines through national 
immunisation programmes (62). Most of the 64 are high or upper middle- income 
countries where a platform for the adolescent vaccination is well-established (100). By 
2015, 33 million (32%) of females aged 10–20 years had received the full dose of HPV 
vaccine and 42 million (41%) had received at least one dose (62). Strikingly, only 1.4 
million HPV vaccinated adolescent girls that received at least one dose were from 
LMICs (62).  
Despite the lack of established adolescent vaccination platforms in LIMCs, estimated 
HPV vaccination coverage among targeted cohorts was higher (89%) in LMICs 
compared to 44% in HICs (62). This data may partly be explained by the growing 
concerns of HPV vaccine safety in HICs (62). Northern Europe, Australia, and New 
Zealand presented the highest age-specific coverage rates, all reaching 69% of females 
currently aged 15–19 years (62). 
Figure 7: HPV vaccine coverage rates by geographical region and age 
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Source: https://doi.org/10.1016/S2214-109X(16)30099-7 (62). 
Of the 62 HPV national programmes implemented, 42 (67%) programmes delivered the 
vaccine through schools (62). However, if adolescents missed these school visits, 
supplementary immunisation methods, such as following up at primary health-care 
centres, were used to complement the school-based programme (62). In Africa, all the 
seven African countries that nationally implemented the HPV vaccine as at 2018 used 
schools as a delivery strategy (104). Additional 23 African countries were reported to 
have conducted pilot studies to introduce the HPV vaccine in 2016 (80). 
During the national HPV implementation in Africa, one of the important lessons learnt is 
that of political will (105, 106). For example, in South Africa, active early involvement of 
high-level stakeholders, including parliamentarians and representatives of the Ministry 
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of Health and Ministry of Education, led to rapid acceptance of the vaccine and the 
programme.  
Optimal understanding of the lessons learnt and challenges facing HPV vaccine delivery 
will guide the developments of better adolescent immunisation programmes in all 
settings. Improved adolescent HPV immunisation programmes will result in significant 
improvements in other adolescent vaccinations, like MCV, Tdap, influenza and other 
additional catch-up vaccines. Establishing and strengthening adolescent immunisation 
programmes by improving equity, routine vaccination coverage, and hard-to-reach 
populations are essential measures required to achieve the GVAP 2011-2020 (31).  
Conclusions 
Introduction and implementation of adolescent immunisation is feasible in all settings, 
as demonstrated by HPV vaccination. Although the adolescence and young adulthood 
periods are generally thought to be healthy time periods, several public health and 
social problems either peak or start during these periods. Hence, adolescents are an 
important group to target with vaccination, which is a proven and one of the most cost 
effective public health interventions to promote health. 
School-age is an entry point for targeting adolescent health. Therefore, adolescent 
vaccination will be cost efficient if integrated with existing adolescent school health 
programmes. In addition, there is an opportunity for strengthening integration, including 
vaccination. Over and above, strengthening the integration will improve coordination 
and ownership between the departments of health and education. 
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Engagement with key stakeholders is crucial. Adolescents, parents, teachers and health 
care workers are the important key stakeholders that need to be educated and engaged 
during implementation of adolescent vaccination. Early face-to-face engagement with 
communities will improve their knowledge and awareness, leading to improved 
vaccination uptake among adolescents. Engagement of other key stakeholders like 
parliamentarians and government parties is vital in building political will at all levels and 
ensuring provision of funding for successful vaccine introduction. 
Currently new adolescent vaccines like HPV and other adolescent health programme 
are standalone programmes, which may create confusion as to which department 
should coordinate delivery. For future adolescent health programme to succeed, it will 
be vital to be owned and driven by EPI. Even though GIVS aimed to address adolescent 
immunisation gap ten years ago, there is still no success in improving the uptake and 
establishments of adolescent vaccination programmes. We, therefore, suggest the 
development and implementation of up-to-date and evidence-based adolescent 
immunisation policies in all settings. 
Contributions 
Leila Abdullahi wrote this chapter under supervision of Prof. Greg Hussey, Dr. Benjamin 
Kagina and Prof. Charles Wiysonge. 
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Chapter 3 
Improving vaccination uptake among adolescents; a systematic review 
About this chapter: 
In this chapter, we evaluate the existing evidence on the different interventions that can 
be used to improve the uptake of vaccines among adolescents. To minimize repetition 
in the thesis, the background section has been modified. The background section is 
therefore not the same as that of the version submitted to Cochrane for publication.  
Publication: Submitted to the Cochrane Effective Practice and Organisation of Care 
group (Currently under editorial review) 
A protocol was published from this chapter. See the link below: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011895/pdf   
Abdullahi LH, Kagina BMN, Wiysonge CS, Hussey GD. Improving vaccination uptake 
among adolescents (Protocol). Cochrane Database of Systematic Reviews 2015, Issue 
9. Art. No: CD011895. DOI: 10.1002/14651858.CD011895. 
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Abstract 
Background   
Adolescent immunisation is a rapidly growing topic in the field of vaccinology. The topic 
has received more attention since the launch of the GVAP initiative, advocating for an 
extension of the benefits of immunisation more equitably and beyond the childhood 
period. In recent years, large numbers of programmes have been launched to increase 
the uptake of different vaccines in adolescent populations; however, vaccination 
coverage among adolescents remains sub-optimal. Therefore, understanding and 
evaluating the various interventions that can be used to improve adolescent 
immunisation is crucial. The review evaluates the effects of different interventions to 
improve vaccines uptake among adolescents. 
Objectives   
To evaluate the effects of interventions to improve vaccine uptake among adolescents. 
Search methods   
Between February and April 2017, we conducted a literature search for relevant studies 
conducted from the inception time of the databases to April 2017. The following 
databases were searched: Cochrane Central Register of Controlled Trials (CENTRAL), 
which is part of The Cochrane Library, MEDLINE, Ovid; PubMed, NLM (for studies not 
in MEDLINE), EMBASE, Ovid, CINAHL, EBSCOhost, Africa-Wide Information, 
EBSCOhost, Global Health, Cab Direct, Scopus, and Science Citation Index and Social 
Sciences Citation Index and ISI Web of Knowledge (for papers citing any of the included 
studies in the review). For related systematic reviews we searched Cochrane Database 
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of Systematic Reviews (CDSR), part of The Cochrane Library; Database of Abstracts of 
Reviews of Effectiveness (DARE), part of The Cochrane Library, and PDQ-Evidence. In 
addition, we searched the reference lists of relevant articles, WHO International Clinical 
Trials Registry Platform, Clinicaltrials.gov, and various electronic databases of grey 
literature. 
Selection criteria   
Eligible studies were randomised control trials (RCTs), non- randomised control trials 
(non-RCTs), interrupted time series studies (ITS) and controlled before-after studies 
(CBAs). The eligible participants are adolescents (defined as girls and boys aged 10 to 
19 years). The participants are eligible for WHO-recommended vaccines. Additional 
eligible participants are the parents of the adolescents as well as healthcare providers. 
Data collection and analysis   
Two authors independently screened the literature search outputs, reviewed full texts to 
identify potentially eligible studies, extracted data and assessed risk of bias for the 
selected studies. The two authors extracted data from the selected studies in duplicate, 
resolving discrepancies by consensus. Data analysis included calculation of the risk 
ratios (RR) or mean differences (MD) with 95% confidence intervals (CI) where 
appropriate. We pooled study results using random-effects meta-analyses and 
assessed the certainty of the evidence using Grades of Recommendation, Assessment, 
Development and Evaluation (GRADE). 
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Main results   
From the literature search, we identified 16 studies that met the inclusion criteria (eight 
RCTs, four cluster randomised control trials (cRCTs), three nRCTs and one CBA. 
Twelve studies were conducted in the United States of America (USA), while there was 
one study from each of the following countries: Australia, Sweden, Tanzania and the 
United Kingdom (UK). Ten studies had unclear or high risk of bias. We broadly 
categorised three interventions as adolescent-oriented, provider-oriented, or health-
system-oriented. Further sub-categorization of two of the three broad interventions were 
as follows; for the interventions targeting adolescents, the sub-categories were health 
education, health education plus financial incentives, financial and non-financial 
incentives and finally, legislative interventions such as vaccination requirements for 
school attendance; for the provider-oriented interventions, sub-categorization included 
multi-component provider intervention (i.e. repeated contacts, individualized feedback, 
education sessions), provider prompt intervention (education and performance 
feedback) and multi-faceted provider and parent intervention. 
The interventions to improve adolescent vaccine uptake targeted different participants: 
parents (reported by four studies), providers (two studies) and adolescents boys and/or 
girls (seven studies). Five studies had mixed participants that included healthcare 
providers and parents, healthcare providers and adolescents, as well as parents and 
adolescents. The main outcome of interest was the vaccination coverage among 
adolescents. Eleven studies evaluated the uptake of human papillomavirus (HPV) and 
three evaluated the uptake of vaccines against hepatitis B virus. Additionally, three 
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studies evaluated the uptake of various vaccines including Tdap, MCV, HPV, and 
influenza. 
Health education probably improves HPV vaccine uptake compared to usual care (four 
studies, 3876 participants: RR 1.56, 95%CI 1.26 to 1.93; I2 = 17%; moderate certainty 
evidence). One large study showed that a complex multi-component health education 
intervention probably leads to a marginal decrease in hepatitis B vaccine uptake, 
compared to simplified information leaflets on the vaccine (17411 participants: RR 0.98, 
95%CI 0.97 to 0.99; moderate certainty evidence). 
Financial incentives may improve HPV vaccine uptake compared to no incentives (one 
study, 500 participants: RR 1.45, 95%CI 1.05 to 1.99; low certainty evidence) and 
health education and financial incentives may improve hepatitis B vaccine uptake 
compared to usual care (one study, 104 participants: RR 1.38, 95%CI 0.96 to 2.00; low 
certainty evidence). 
Mandatory vaccination probably also improves hepatitis B vaccine uptake compared to 
no mandatory vaccination (one study, 6462 participants: RR 4.24, 95%CI 3.94 to 4.56; 
moderate certainty evidence). 
With moderate certainty of evidence, provider prompts probably have little or no effect, 
compared to usual care, on completion of Tdap (one study, 3520 participants: RR 1.05, 
95%CI 0.99 to 1.11), MCV (one study, 3520 participants: RR 1.05, 95%CI 0.99 to 1.11), 
HPV vaccine (one study, 1771 participants: RR 1.06, 95%CI 0.87 to 1.30), and 
influenza vaccine (one study, 3520 participants: RR 1.05, 95%CI 0.96 to 1.15) 
vaccination schedules. 
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A multi-facetted intervention targeting providers and parents involving social marketing 
and health education probably improves HPV vaccine uptake (two studies, 26206 
participants: RR 1.42, 95%CI 1.26 to 1.60; I2 = 0%; moderate certainty evidence). 
A class-based school vaccination strategy probably increases HPV vaccine uptake 
more than an age-based school vaccination strategy (one study, 5537 participants: RR 
1.09, 95%CI 1.06 to 1.13; moderate certainty evidence). 
Authors' conclusions   
Our review findings suggest there are various strategies that have been evaluated to 
improve adolescent immunisation, including health education, financial incentives, 
mandatory vaccination, and class-based school vaccine delivery. However, all the 
evidence is of low to moderate certainty. This implies a high likelihood that the true 
effect sizes of the interventions will be substantially different from those found in this 
review, with availability of higher quality evidence on the topic. Additional research on 
interventions to improve uptake of vaccines among adolescents is therefore needed, 
especially in LMICs where the information on the topic is limited. 
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Plain language summary   
Improving vaccination uptake among adolescents 
This Cochrane Review aimed to assess the effects of diverse approaches to increase 
the number of adolescents who get vaccinated. Cochrane researchers collected and 
analysed all relevant studies to answer this question and found 16 studies. 
Key messages 
This review shows that several different approaches may increase the number of 
adolescents who get vaccinated. The approaches include giving health education, 
offering gifts, and passing laws. However, more research is needed to understand what 
approaches work best, especially in LMICs. 
What was studied in the review? 
The WHO recommend several vaccines for 10 and 19 years old (adolescents). One of 
the vaccines is offered specifically to this age group, the HPV vaccine. Others are 
booster vaccines, also given to younger children, such as hepatitis B vaccines, and 
diphtheria, tetanus, and pertussis vaccines. 
Many adolescents do not get the recommended vaccines. Governments and 
organisations have tried different approaches to vaccinate adolescents. One approach 
is to target adolescents, their parents and communities. This can be done, for instance, 
by giving information and education about vaccines; reminding when the vaccines are 
due; or giving adolescents a reward or gift to get vaccinated. Another approach is to 
target healthcare providers, for instance through information, reminders, or feedback 
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about their practice. A third approach is to make vaccines more accessible to 
adolescents. This can be done, for instance, by making vaccines free or cheap or by 
offering vaccines closer to home, including at schools. A fourth approach is to pass laws 
about vaccination for adolescents. For instance, in some countries, students must prove 
they have been vaccinated before being enrolled at school. 
What are the main results of the review? 
The review authors found 16 relevant studies. Twelve of the studies were from USA. 
The other studies were from Australia, Sweden, Tanzania, and UK. These studies 
showed the following: 
 When adolescents (girl or/and boys) and their parents are given vaccination 
information and education, more adolescents probably get HPV vaccines, but 
slightly fewer adolescents probably get hepatitis B vaccines (moderate certainty 
evidence) 
 When adolescents are given gift vouchers, more adolescents may get HPV vaccines 
(low certainty evidence). When adolescents and their parents are given vaccination 
education, cash and gift packages, more adolescents may get hepatitis B vaccines 
(low certainty evidence) 
 When laws are passed stating that adolescents must be vaccinated to go to school, 
more adolescents probably get hepatitis B vaccines (moderate certainty evidence) 
 When healthcare providers are reminded to vaccinate adolescents when they open 
their electronic medical charts, this probably has little or no effect on the number of 
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adolescents who get Tdap, meningococcal, HPV, or influenza vaccines (moderate 
certainty evidence) 
 When healthcare providers and parents are targeted in several ways, including 
through vaccination education, phone calls and radio messages, more adolescents 
probably get HPV vaccines (moderate certainty evidence). 
These studies compared the use of these approaches (health education, gifts and 
rewards, laws, or reminders) to using no approaches. 
In addition, one study from Tanzania gave vaccination information to all girls that were 
in school class 6 but were not necessarily of the same age. They were compared to 
girls who were given vaccination information because they were all born in the same 
year but were not necessarily in the same class. This study showed that the class-
based approach probably led to more girls getting HPV vaccines (moderate certainty 
evidence) than age-based approach. 
How up-to-date is this review? 
The review authors searched for studies that had been published up to April 2017. 
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Background   
Description of the condition 
Immunisation of adolescent is a key global strategy in the control, elimination and 
eradication of VPDs. In many settings, adolescents usually turn to physicians only when 
they are ill and so, there are limited opportunities to inform them that vaccines are 
important and should be administered (64, 102). Adolescents visiting the physicians are 
more interested in their current health condition than possible benefits of preventing 
future VPDs (64). Schools have been used extensively as a delivery platform for 
vaccinating large numbers of school-aged children (65, 66, 101, 102, 107). However, 
school-based vaccination programmes may not be entirely successful in countries with 
sub-optimal school attendance rates (44, 108). School attendance rates in LMICs are 
variable due to factors such as geographical location, socio-cultural and economic 
status (43, 44, 108). Strategies such as mass immunisation campaigns can be used to 
complement school-based vaccination programmes in settings with poor school 
attendance rates (109). 
46 
 
The most commonly reported barriers to adolescent vaccination include lack of 
knowledge about immunisation, vaccines and VPDs; negative attitudes towards 
vaccination by adolescents, parents, teachers and healthcare providers; poor access to 
vaccines; and financial constraints (59, 60, 110, 111). 
Description of the intervention   
Interventions to enhance the uptake of vaccines by adolescents may be multi-pronged, 
targeting adolescents and their communities as well as targeting healthcare providers, 
and/or the health system. 
Recipient-oriented interventions 
Interventions targeting adolescents and their communities (including their parents and 
teachers) may include education, reminders, incentives, and mandatory vaccination. 
Interventions to 'inform' or 'educate' enable adolescents and their communities to 
understand the meaning and relevance of vaccination (112). Such interventions may be 
delivered face-to-face or via written mail, telephone conversation, audio visual 
presentation or drama, printed materials, web sites, multi-media campaigns, or 
community events (112). These types of interventions may be directed at individuals or 
groups, and may include information about VPDs; the risks and benefits of vaccines; 
where, how and when to access vaccine services; and/or who should be vaccinated 
(112-114). Adolescents and communities may receive education about vaccines 
through prominently displayed posters in waiting rooms, brochures, e-mails, and 
website resources (115). 
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Client reminder or recall interventions involve reminding members of a target population 
that vaccinations are due (reminders) or late (recall). Reminders and recalls are 
delivered using various methods, such as telephone calls, letters, or postcards (63, 112-
116). The contents of reminder/recalls may include personalised information related to a 
specific upcoming or missed appointment (112, 115).  
Adolescent or community incentives involve providing financial or other incentives to 
motivate people to accept vaccinations (63, 113, 116). Incentives can be rewards or 
gifts (116). 
Mandatory vaccination refers to a law or policy that requires students to show proof of 
immunisation records prior to school admission; and failure to do this denies admission 
(63, 113, 116). 
Provider-oriented interventions 
Provider-oriented interventions may include reminders, audit and feedback, and 
education. 
Provider reminder interventions inform vaccinators that individual clients are due for 
vaccinations. Reminders may be delivered through client charts, computer, electronic 
mail, or postal mail, among many others (63, 113, 114, 116, 117)  
Audit and feedback for vaccinators involves retrospectively evaluating the performance 
of the vaccinators in administering vaccines and providing feedback to them (63, 113-
116). This information is given to providers to motivate them to improve immunisation 
services. 
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Provider education involves giving information regarding vaccinations to providers to 
increase their knowledge and to encourage them to adopt positive attitudes towards 
vaccination. Techniques by which information is delivered can include written materials, 
videos, lectures, continuing medical education programmes, and computerised software 
(63, 114-117). 
Health system interventions 
Outreach programmes include school-based immunisation and mass campaigns. 
School-based immunisation outreach is intended to improve delivery of vaccinations to 
school-going children (116). School-based interventions usually include vaccination-
related education of students about either provision of vaccinations or referral for 
vaccinations (63, 113, 116). Mass campaign programmes target adolescents both in 
school and out of school (109). 
Expanding access in healthcare settings is used to increase the availability of vaccines 
in the medical or public health settings in which vaccinations are offered. This can be 
achieved using several methods such as: increasing or changing the hours during which 
vaccination services are provided; delivering vaccinations in clinical settings in which 
they were previously not provided (e.g. emergency departments, inpatient units or 
subspecialty clinics); or reducing administrative barriers to obtaining vaccination 
services within clinics (e.g. developing a 'drop-in' clinic or an 'express lane' vaccination 
service) (63, 115, 116). 
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Reducing out-of-pocket costs can be implemented by subsiding the costs of vaccines, 
paying for vaccinations, providing insurance coverage, or reducing co-payments for 
vaccinations at the point of service (63, 113, 116). 
Multi-component interventions 
Multi-component interventions are approaches that include more than one strategy, with 
the aim of addressing a variety of barriers to adolescent vaccine uptake. Such 
interventions could enable communities to be aware of the immunisation services 
available to them, demonstrate the utility and relevance of these services, provide 
community members with the knowledge and information base to effectively take 
advantage of the services, and incorporate a variety of associated provider or health 
system strategies to improve immunisation uptake (63, 113, 116). 
How the intervention might work   
We have proposed a logic model (Figure 8), which shows how different interventions, 
alone or in combination, will have an influence on adolescent vaccination. 
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Figure 8: Logic framework on interventions for improving uptake of adolescent 
vaccines 
 
Source: 
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011895/epdf/full (67) 
No logic model or conceptual framework has been described that shows an integrated 
perspective on interventions to increase vaccination among adolescents. The evidence-
based conceptual model of factors that influence HPV vaccination among adolescent 
girls has, however, been described (118). This model suggested a useful framework for 
examining the impact of personal, interpersonal, organisational and broader community 
as well as societal factors on vaccination (118). Our logic model proposes that such 
factors, alone or in combination, will have an influence on adolescent vaccination. 
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Why it is important to do this review   
Adolescents represent 25% of the global population (3) yet, there is a knowledge gap 
around interventions to improve vaccine uptake among adolescents, especially in 
LMICs. Our review proposes to evaluate the evidence on strategies that can be adopted 
to improve vaccine uptake among adolescents. Such strategies will not only improve the 
uptake of current vaccines among adolescents but are also likely to increase the uptake 
of future vaccines targeted to this population group. In addition, this review could be 
used to advocate for strengthening of existing adolescent vaccination policies and to 
formulate new policies on the vaccination of adolescents where none currently exist.  
We are not aware of any previous Cochrane systematic review that has evaluated 
interventions to improve adolescent vaccine uptake. However, some reviews have 
evaluated various interventions to improve adolescent HPV vaccination (119-121). The 
interventions evaluated in these reviews are not categorised as intended in our review.  
There are also reviews that have evaluated various strategies to improve immunisation 
coverage in children or the whole population (113, 114, 122-124). These reviews 
considered general barriers to immunisation and assessed the effects of a variety of 
interventions (113, 114, 122-124).  
Objectives   
To evaluate the effects of interventions/strategies to improve vaccine uptake among 
adolescents. 
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Methods   
This is a Cochrane review and therefore, we used the Methodological Expectations of 
Cochrane Intervention Reviews (MECIR). The methods used conformed to the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). The 
MECIR checklist is included in Appendix 1.  
Criteria for considering studies for this review   
Types of studies   
We included the following study designs: RCTs, non-RCTs, ITS and CBAs. All these 
study designs meet the quality criteria used by the EPOC Group (125). The EPOC 
Group Risk of Bias criteria is an adaptation of the Cochrane Risk of Bias tool in chapter 
eight and published in the Cochrane Handbook (126).  We included both individually 
randomised and cluster-randomised control trials. For cRCTs, we only included those 
with at least two interventions and two control clusters. Following the EPOC criteria, we 
included an ITS study only if outcomes were measured during at least three points 
before and three points after the intervention. For a CBA study to be included in the 
review, it must include at least two intervention groups and at least two comparable 
control groups, with simultaneous data collection. 
We excluded simple pre-post designs, cRCTs and non-RCTs with only one intervention 
or control site and CBA studies without concurrent data collection in intervention and 
comparison groups; in accordance with the EPOC criteria for inclusion of studies in 
systematic reviews of effects (125). 
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Types of participants   
Boys and girls aged 10 to 19 years eligible for WHO-recommended vaccines and their 
parents or healthcare providers. 
In the case of studies with interventions directed at mixed populations of children and 
adolescents or adolescents and adults, we excluded a study if specific data for 
adolescents was not reported. 
Types of interventions   
Intervention 
 Recipient oriented interventions (i.e. interventions targeting adolescents and their 
communities), for example: 
o interventions to communicate with adolescents and/or their 
caregivers/parents about adolescent immunisation; 
o financial and non-financial incentives for adolescents and/or their 
caregivers/parents and; 
o Mandatory vaccination: vaccination requirement for high school and 
university attendance. 
 Provider-oriented interventions, for example: 
o any intervention to reduce missed opportunities for vaccination (e.g. audit 
and feedback); and 
o health education, training, and supportive supervision. 
 Health system interventions, for example: 
o interventions to improve the quality of services, such as provision of 
reliable cold chain systems, provision of transport for vaccination, vaccine 
stock management; 
o outreach programmes, e.g. school-based immunisation and mass 
vaccination campaign for out-of-school adolescents; 
o expanded services, e.g. extended hours for immunisation services; 
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o increased immunisation budget; and 
o integration of immunisation services with other services. 
 Multi-component interventions. 
Exclusions 
We excluded interventions to remind or recall recipients or providers of immunisation 
services, as there is already a Cochrane review on this topic (122). 
Comparisons 
 Standard immunisation practices in the study setting;  
 Alternative interventions; and 
 Similar interventions implemented with different degrees of intensity. 
Types of outcome measures   
Primary outcomes   
Adolescent vaccination coverage, that is, the proportion of adolescents who have 
received the recommended dose(s) of the vaccine studied. 
Secondary outcomes   
 Proportion of adolescents completing the schedule; 
 Equitable uptake of immunisation (as defined by the study authors);  
 Knowledge, attitudes, and beliefs; 
 Adverse events following immunisation; 
 Adverse effects of the intervention; 
 Cost of the intervention; and 
 Incidence of VPDs 
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Search methods for identification of studies   
With the assistance of the Cochrane EPOC Information Specialist, we developed 
comprehensive and highly sensitive search strategies on both published and 
unpublished databases, with no restrictions on language or publication date. The search 
strategies for the electronic databases incorporated the Cochrane EPOC search 
strategy for RCTs, non-RCTs, CBAs and ITS studies (125), combined selected MeSH 
and free-text terms relating to adolescent vaccination uptake literature globally. 
Electronic searches   
We searched from the following databases for primary studies: 
 Cochrane Central Register of Controlled Trials (CENTRAL) Issue 1 2017, part of 
The Cochrane Library (www.cochranelibrary.com) (searched 15.02.2017); 
 MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
MEDLINE Daily and MEDLINE 1946 to 2017, Ovid (searched 15.02.2017); 
 Embase 1974 to 2017 February 14, Ovid (searched 15.02.2017); 
 CINAHL 1981 to 2017, EBSCOhost (searched 17.02.2017); 
 Africa-Wide Information from the 19th century until 2017, EBSCOhost (searched 
15.02.2017); 
 Global Health 1973 to 2017 Week 05, Ovid (searched 15.02.2017); 
 Scopus, Elsevier (searched 17.02.2017); and 
 Science Citation Index Expanded; Social Sciences Citation Index, 1987-present, 
and Emerging Sources Citation Index 2015-present, Web of Science Core 
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Collection, Thompson Reuters (searched 24.04.2017) (for papers citing any of 
the included studies in the review). 
We searched from the following databases for related reviews: 
 Cochrane Database of Systematic Reviews (CDSR) Issue 3 2017, part of The 
Cochrane Library (www.cochranelibrary.com) (searched 09.03.2017); 
 Database of Abstracts of Reviews of Effects (DARE) Issue 2 2015, part of The 
Cochrane Library (www.cochrenelibrary.com) (searched 15.02.2017); 
 Health Technology Assessment Database (HTA) Issue 4 2016 (searched 
15.02.2017); 
 PDQ-Evidence (searched 13.02.2017). 
See appendix 2 for the used search strategies. 
Search from other resources   
Grey literature:  
 World Health Organization (WHO) (http://www.who.int/) (searched 15.02.2017). 
 Gavi, the Vaccine Alliance (http://www.gavi.org) (searched 15.02.2017). 
 United Nations Children's Funds (UNICEF) (http://www.unicef.org/) (searched 
15.02.2017). 
 PATH Vaccine Resources Library (http://www.path.org/) (searched 15.02.2017). 
 US Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov/) 
(searched 15.02.2017). 
 The Communication Initiative Network (http://www.comminit.com/) (searched 
15.02.2017). 
 Grey Literature Report (http://www.greylit.org) (searched 15.02.2017). 
 OpenGrey (http://www.opengrey.eu/) (searched 15.02.2017). 
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 Electronic Development and Environment Information System 
(http://www.eldis.org/) (searched 15.02.2017). 
 Immunization basics (http://www.immunizationbasics.jsi.com) (searched 
15.02.2017). 
Trial registries:  
 Word Health Organization (WHO) International Clinical Trials Registry Platform 
(ICTRP) (http://www.who.int/ictrp/en/) (searched 15.02.2017). 
 ClinicalTrials.gov, US National Institutes of Health (NIH) (http://clinicaltrials.gov/) 
(searched 15.02.2017). 
Reference lists: We searched the reference lists of potentially eligible studies and 
relevant previous reviews. 
Data collection and analysis   
Selection of studies   
Two authors (LA and BK) screened the search outputs to select potentially eligible 
studies. LA then obtained the full text of potentially eligible studies and two authors (LA 
and VN) independently conducted the final study selection for inclusion in the review. 
We resolved any disagreements regarding the inclusion of studies by discussion or by 
consulting a third author (BK and CW). We used a PRISMA flow chart to summarise the 
search and selection of studies for the review. We included a table of all included 
studies in the review and documented the reasons for exclusion of studies. 
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Data extraction and management   
Two authors (LA and VN) independently extracted data from selected studies using an 
adapted version of the Cochrane data extraction form. Disagreements on study 
selection and data extraction were resolved by consensus between the two review 
authors, failing which a third author (BK) arbitrated. Prior to use, we piloted the data 
extraction form on four studies identified randomly from the list of included studies. 
The data extraction form included the following items: 
 Setting of the study (city and country) 
 Type of study: individual RCT, cRCT, non-RCT, CBA, or ITS studies 
 Type of participants: adolescents, parents/caregivers, health care providers 
 Type of interventions: name of intervention, frequency, timing, delivery method, 
venue of delivery 
 Type of outcomes measured: vaccine coverage, knowledge, attitudes and 
beliefs, cost of intervention, adverse effects of the intervention, adverse events 
following immunisation, equity. 
Assessment of risk of bias in included studies   
We applied the Cochrane EPOC 'Risk of bias' criteria (127) for RCT, non-RCT, CBA, 
and ITS studies, as appropriate. For each included study, we reported our assessment 
of risk of bias, i.e. low, high, or unclear risk for each domain, together with a descriptive 
summary of the information that influenced our judgement. Two review authors (LA and 
VN) applied the criteria independently and discussed any disagreements with a third 
review author (BK or CW). 
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Measures of intervention effect   
We expressed the result of each study as a risk ratio with its corresponding 95% 
confidence interval (CI) for dichotomous data. We grouped studies with broadly similar 
types of participants, interventions, study designs, and outcomes to get feasible results 
for an overall estimate of effect. See Table 2 for measures of effect specified in the 
protocol, but not used in the review. 
Unit of analysis issues   
We did not encounter 'unit of analysis' issues in this review. Four included studies were 
cRCTs based on matched pairs of clusters (128-131). We did not re-analyse these data 
as matching cannot be considered in re-analyses in such studies unless the raw data 
are available. The studies, however, conducted appropriate analyses of the data, and 
we have provided the results as reported in the studies. See Table 2 for methods 
specified in the protocol, but not used in the review. 
Dealing with missing data   
We did not experience any missing data thus we did not contact the primary study 
authors for missing data. In Table 2, we have indicated methods specified in the 
protocol, but not used in the review. 
Assessment of heterogeneity   
We reviewed heterogeneity in the type of intervention, the type of setting, study design, 
and risk of bias of included studies to make an assessment of the extent to which the 
included studies were similar to each other. We examined the levels of heterogeneity 
between study results using the Chi² test of homogeneity (with significance defined at 
60 
 
the alpha level of 10%). We quantified any statistical heterogeneity between study 
results using the I² statistic. We regarded heterogeneity as substantial if the I² was 
greater than 50% (126). 
Assessment of reporting biases   
Test for asymmetry with a funnel plot was not feasible because the number of included 
studies for each meta-analysis was less that the recommended 10 studies. We have 
archived methods for assessing reporting biases in Table 2, for use in future updates of 
this review. 
Data synthesis   
We pooled data from studies of similar study designs, similar interventions, similar 
participants, and similar outcomes in a meta-analysis using the random-effects model; if 
there was no significant statistical heterogeneity, methodological difference, or high risk 
of bias. For outcomes with substantial variation between studies in the reported 
interventions, participants, study designs and outcome measures, we did not pool the 
results but summarised the findings in a narrative format. Overall, we interpreted the 
study findings by considering the methodological quality of the studies and the strength 
of the evidence. For each observed effect, we explicitly stated the strength of evidence 
and drew conclusions. See Table 2 for data synthesis methods specified in the protocol, 
but not used in the review. 
Subgroup analysis and investigation of heterogeneity   
We did not have sufficient data to conduct planned subgroup analyses (Table 2). 
However, we conducted a post-hoc subgroup analysis exploring the effect of variations 
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in the intervention (Analysis 5.1; Analysis 5.2; Analysis 5.3; Analysis 5.4) or comparison 
(Analysis 4.1) groups on vaccination coverage. We used the Chi² test for subgroup 
differences to test for subgroup interactions. 
Sensitivity analysis   
We planned to perform sensitivity analyses based on unit of analysis errors, risk of bias, 
and missing data (Table 2). However, available data were insufficient to perform these 
analyses. 
Summary of findings 
We created Summary of findings (SOF) tables for the main intervention and 
comparisons included the primary outcome: vaccination coverage. We used the 
Grading of Recommendation, Assessment, Development and Evaluation (GRADE) 
approach to assess the certainty of evidence at outcome level (132). Two review 
authors independently assessed the certainty of the evidence (high, moderate, low, and 
very low) using the five GRADE considerations (risk of bias, consistency of effect, 
imprecision, indirectness, and publication bias). We used methods and 
recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook 
for Systematic Reviews of interventions (126), and the EPOC worksheets (133), using 
the GRADEpro software. We resolved disagreements on certainty ratings by discussion, 
provided justification for decisions to downgrade the ratings using footnotes in the table, 
and made comments to aid readers' understanding of the review where necessary. We 
used plain language statements to report these findings in the review (134). 
Table 2: Unused methods (67) 
Method Approach 
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Measures of 
treatment effects 
We will express the result of each study as a mean difference with its 95% CI for 
continuous data. We will analyse ITS studies using a regression analysis with 
time trends before and after the interventions. We will present the results for the 
outcomes as change in level and slope. 
Unit of analysis 
issues 
If investigators report cluster-randomised trial data as if the randomisation was 
performed on the individuals rather than the clusters, we will request the intra-
cluster correlation coefficient (ICC) from the study authors; failing this, we will 
obtain external estimates of the ICC from similar studies or available resources. 
Once established, we will use the ICC to re-analyse the trial data to obtain 
approximate correct analyses. We will adjust the data by inflating the standard 
errors, i.e. multiplying them by the square root of the design effect. We plan to 
report the effect estimates and the corrected standard errors from cluster-
randomised trials with those from parallel-group design trials, noting that the 
analysis of data from that specific study suffers from unit of analysis error. If 
insufficient information is available to control for clustering in this way, we will 
enter data into RevMan using individuals as the unit of analysis. We will then 
perform sensitivity analyses to assess the potential bias that may have occurred 
as a result of the inadequately controlled clustered trials. We will also perform 
sensitivity analyses if we obtained the ICCs from external sources, to assess the 
potential biasing effects of inadequately controlled cluster-randomised 
trials. 
Dealing with missing 
data 
Where necessary, we will contact the corresponding authors of included studies 
to supply any unreported data. We will describe missing data and dropouts for 
each included study in a ’Risk of bias’ table, and discuss the extent to which the 
missing data could alter our results. For CBA studies where relative measures 
are not 
available, we will estimate the difference between outcome measures at two time 
points for both baseline and after the intervention and then compare the 
difference between the groups. On the other hand, if ITS studies are incorrectly 
analysed by the authors and provide the data points, we will re-analyse ITS 
studies using a regression analysis with time trends before and after the 
intervention, which adjust for autocorrelation and any periodic change. 
Assessment of 
reporting bias 
We will use a funnel plot to investigate the risk of publication bias by intervention 
type, provided 10 or more studies are included in the analysis for each 
intervention type. We will critically examine the funnel plot for asymmetry both 
visually and with the use of formal tests. For continuous and dichotomous 
outcomes, we will use the test proposed by Egger and the test proposed by 
Harbord, respectively. In situations where asymmetry is detected by either test or 
by visual assessment, we will perform further exploratory analyses to investigate 
it. This will include reviewing the included studies for small sample size studies 
and their intervention effect. 
Data synthesis We will report ITS studies as changes in level and slope. If ITS studies are 
incorrectly analysed by the authors and provide the data points, we will re-
analyse them using a regression analysis with time trends before and after the 
intervention, which adjust for autocorrelation and any periodic change. 
Subgroup analysis 
and investigation of 
heterogeneity 
Where sufficient data are available, we will conduct subgroup analyses, which will 
explore the effects of; vaccine given including frequency of the vaccine; 
availability of a policy on adolescent vaccination including vaccination schedule; 
equity (school-based interventions or mass campaign programmes); and country 
income status (World Bank classification as either HICs or LMICs). 
Sensitivity analysis Where sufficient data are available, we will conduct, if applicable, a sensitivity 
analysis to establish whether the meta-analysis results for the treatment effect 
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are influenced by study designs and overall risk of bias. We will perform 
sensitivity analyses by excluding studies with a particular study design and 
studies with high risk of bias. 
 Results   
Description of studies   
Results of the search  
We identified 24,656 records from the electronic databases and other sources. After 
excluding 3,132 duplicates, we screened 21,524 records, and found that 21,459 records 
were not relevant to our review question. We reviewed the remaining 65 potentially 
eligible full-text articles for inclusion and excluded 48 of them for reasons given in the 
table of excluded studies (Appendix 3). Sixteen studies met the inclusion criteria and 
were included in the review (Table 3). One study (135) is ongoing as at the time of 
completion of this review. The search process and selection of studies is presented in 
Figure 9. 
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Figure 9: Study flow diagram. 
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Included studies   
Study design and setting 
Sixteen studies met the review inclusion criteria. Eight studies were RCTs with 
individuals as the unit of randomisation (136-143); four studies were cRCTs that used 
health facilities or schools as the unit of randomisation (128-131); three studies were 
non-RCTs with at least two intervention and two control arms (144-146); and one study 
(147) was a CBA study with two intervention and two control arms. 
Twelve studies were conducted in the United States of America (USA) (128, 131, 136, 
137, 139-141, 143-147); one study was conducted in Australia (142); one study was 
conducted in Sweden (129); one study was conducted in the United Kingdom (UK) 
(138); and one study was conducted in Tanzania (130). 
Participants 
Two studies enrolled girls only (130, 136), five enrolled boys and girls (129, 138, 142, 
145, 146), three enrolled parents (131, 137, 140), and two enrolled healthcare providers 
(143, 147). 
Four studies enrolled mixed participants, comprising of adolescents and parents (141), 
adolescents and healthcare providers (128), and parents and healthcare providers (139, 
144). The healthcare providers included physicians, nurses, and physician assistants as 
shown in the characteristics of included studies (Table 3).
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Table 3: Characteristics of included studies 
Study ID Study design Country Participants 
Intervention Comparison 
Duration of 
interventions 
Vaccine target Outcomes (assessed 
similarly) 
Cates 2014 
(144) 
Non-
randomised 
trial 
USA Parents & health 
providers 
Mult-faceted 
providers and 
parents 
Usual care 
Three months HPV Vaccination coverage 
Diclemente 
2015 (136) 
Randomized 
trial 
USA Adolescents 
Health education Usual care 
30 minutes HPV Vaccination coverage 
Fiks 2016 
(147) 
Controlled 
before-after 
study 
USA Health Provider 
Provider 
incentives 
Usual care 
1 year HPV Vaccination coverage 
Cost 
Gargano 2015 
(137) 
Randomised 
trial 
USA Parents 
Health education Usual care 
2 years Tdap, MCV, 
HPV, Influenza 
Knowledge & attitude 
Grandahl 
2016 (129) 
Cluster-
randomised 
trial 
Sweden Adolescents 
Health education Usual care 
30 minutes HPV Vaccination coverage 
Mantzari 
2015 (138) 
Randomised 
trial 
United 
Kingdom 
UK 
Adolescents 
Financial 
incentives 
Usual care 
6 months HPV Vaccination coverage 
Paskett 2016 
(139) 
Randomized 
trial 
USA Parents and 
health providers 
Multi-faced 
providers and 
parents 
Usual care 
- HPV Vaccination coverage 
Knowledge & attitude 
Perkins 2015 
(128) 
Cluster-
randomised 
trial 
USA Adolescent and 
health providers 
Multi-component 
provider 
intervention 
Usual care 
2 years HPV Vaccination coverage 
Rickert 2015 
(140) 
Randomised 
trial 
USA Parents 
Health education Usual care 
I hour HPV Adverse effects  
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Schwarz 2008 
(141) 
Randomised 
trial 
USA Adolescents and 
caregivers 
Health education 
plus financial 
incentives 
Usual care 
21 months HepB Vaccination coverage 
Knowledge & attitude 
Skinner 2000 
(142)  
Randomized 
trial 
Australia Adolescents 
Health education Usual care 
1 year HepB Vaccination coverage 
Knowledge & attitude 
Staras 2015 
(145) 
Non-
randomised 
trial 
USA Adolescents 
Health education Usual care 
3 months HPV Vaccination coverage 
Szilagyi 2015 
(143) 
Randomised 
trial 
USA Health providers 
Provider prompts Usual care 
2 month Tdap, MCV, 
HPV, Infleunza 
Vaccination coverage 
Wilson 2005 
(146) 
Non-
randomised 
trial 
USA Adolescent 
Mandatory school 
entry vaccination 
Usual care 
- HepB, Td, and 
MMR 
Vaccination coverage 
Winer 2016 
(131) 
Cluster-
randomised 
trial 
USA Parents 
Health education Usual care 
30–40 min HPV Vaccination coverage 
Watson-Jones 
2012 (130) 
Cluster-
randomised 
trial 
Tanzania Adolescents 
Class-based 
vaccination 
Age-based 
vaccination 
12 months HPV 
Vaccination coverage 
Cost 
Adverse events  
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Interventions and comparisons 
1) Recipient-oriented interventions 
The recipient-oriented intervention studies assessed health education (129, 131, 136, 
137, 140, 142, 145), financial incentives (138), health education and financial incentives 
(141), and a school entry law mandating vaccination (146); compared to usual care. 
In four of the five health education studies, participants in the intervention arm received 
structured 30-40 minutes interactive education on the target VPD, vaccine 
recommendations, vaccine schedule, and vaccine efficacy and safety. Participants in 
the comparison "usual care" group received general health education or education on 
the prevention of a specific non-vaccine related condition (129, 131, 136, 145). In the 
fifth study, participants in the education arm received a complex multi-component 
intervention that included a resource fact sheet and assessment; an information video 
and questions designed to engage the adolescent audience; small group discussions; 
and an activity to locate resource information on the Internet. However, both the 
intervention and comparison arms received information brochures consisting of one-
page folded coloured leaflets; outlining in simple terms, the risks of the target disease 
and the benefits and side effects of vaccination (142). 
2) Provider -oriented interventions 
The provider-oriented intervention studies assessed provider prompts (143), incentives 
(147), and a multi-faceted intervention (128); compared to usual care. 
3) Recipient and provider (multi-faceted)-oriented interventions  
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Two studies assessed multi-faceted interventions aimed at both recipients and 
providers of vaccination services (139, 144); compared to usual care. 
4) Health system intervention 
One study compared a class-based vaccination strategy to an age-based strategy 
(130). 
Outcomes 
All sixteen studies reported data on the primary outcome of interest, vaccination 
coverage. Eleven studies (128-131, 136, 138-140, 144, 145, 147) evaluated completion 
of the HPV vaccination schedule. Three studies (141, 142, 146) assessed uptake of 
vaccines against hepatitis B virus. Finally, three studies (137, 143) reported data on 
uptake of tetanus-diphtheria-acellular- pertussis (Tdap), meningococcal conjugate 
vaccine, HPV, and influenza vaccines. 
Other pre-defined outcome measures reported by the included studies are: knowledge, 
attitudes, beliefs, and practice (137, 139, 141, 142); cost of the intervention (130, 147); 
adverse events following immunisation (130); and adverse effects of the intervention 
(140). 
Pre-defined outcomes not reported by the included studies are incidence of vaccine-
preventable diseases and equitable uptake of immunisation. 
Excluded studies   
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We excluded 48 studies and the reasons are provided in the table of excluded studies 
(Appendix 3). The most common reasons for exclusion were ineligible study designs 
and interventions.  
Risk of bias in included studies   
We summarised the risk of bias assessment in each of the included studies (Figures 10 
and 11). 
Allocation (selection bias)   
The risk of selection bias (random sequence generation) was low for nine studies (128, 
129, 131, 136, 138-140, 142, 143), unclear for three studies (130, 137, 141), and high 
for four studies (144-147). 
The risk of selection bias (allocation concealment) was low for six studies (129, 130, 
136, 138, 140, 143), unclear for seven studies (131, 137, 139, 141, 142, 144, 146), and 
high for three studies (128, 145, 147). 
Blinding (performance bias and detection bias)   
Risk of performance bias (blinding of participants and personnel) was low for two 
studies (138, 143), unclear for nine studies (128, 131, 136, 137, 139, 141, 142, 145, 
146), and high for five studies (129, 130, 140, 144, 147). 
The risk of detection bias (blinding of outcome assessments) was low for two studies 
(129, 136), unclear for twelve studies (128, 131, 137-146), and high for two studies 
(130, 147). 
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Incomplete outcome data (attrition bias)   
The risk of attrition bias (incomplete outcome data) was low for ten studies (130, 131, 
136, 138-143, 147), unclear for four studies (128, 129, 144, 146), and high for two 
studies (137, 145). 
Selective reporting (reporting bias)   
Selective reporting was categorised as low risk in twelve studies (128-130, 136, 138, 
139, 141, 143-147) and unclear in four studies (131, 137, 140, 142). 
Other potential sources of bias   
All studies reported similar baseline characteristics between the intervention and control 
groups. In Addition, all studies reported no differences in the outcome measures at 
baseline and during intervention. One study (RCT (58)) reported a possible 
contamination of controls with the interventions, but none of the other studies reported 
contamination of control the interventions assessed. We did not have reasons to 
indicate that other biases were introduced into the remaining studies, over and above 
the ones reported above.  
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Figure 10: Risk of bias graph: review authors' judgements about each risk of bias 
item presented as percentages across all included studies. 
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Figure 11: Risk of bias summary: review authors' judgements about each risk of 
bias item for each included study. 
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 Effects of interventions   
1. Recipient-oriented interventions 
1.1 Health education compared to usual care on vaccination coverage 
Four studies (RCT(136); cRCT(129, 131); nRCT(145)) show that health education 
probably improves HPV vaccination coverage (3876 participants: RR 1.56, 95%CI 1.26 
to 1.93; I2 = 17%; moderate certainty evidence; (Figure 12 Analysis 1.1) (Summary of 
findings; Table 4). Our main concern with the evidence was the high risk of bias in the 
included studies. However, one large study (RCT(142)) suggests that a multi-
component health education intervention probably leads to a marginal decrease in the 
uptake of three doses of the hepatitis B vaccine, compared to simplified information 
leaflets on the vaccine (17411 participants: RR 0.98, 95%CI 0.97 to 0.99; moderate 
certainty evidence; (Figure 13 Analysis 1.2) (Summary of findings; Table 4). 
Figure 12: Analysis 1.1: Human papillomavirus (HPV) vaccine series 
 
Figure 13: Analysis 1.2: Immunisation rate of Hepatitis B vaccine (HPV 3 dose) 
 
Table 4: Summary of findings :Vaccination education compared to usual care 
Population: Adolescents and parents 
Setting: Australia, Sweden, and United States of America 
Intervention: Vaccination education 
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Comparison: Usual care 
Outcomes Absolute effects* 
(95% CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Certainty of 
the evidence 
(GRADE)** Comments With 
usual 
care 
With health 
education 
Uptake of human 
papillomavirus 
vaccine 
75 per 
1,000 
117 per 
1,000 
(95 to 145) 
RR 1.56 
(1.26 to 
1.93) 
3876 
(4 studies) 
⊕⊕⊕⊝ 
Moderate 1 
Health education 
probably improves 
vaccine uptake. 
Uptake of three 
doses of hepatitis B 
vaccine 
756 per 
1,000 
741 per 
1,000 
(726 to 748) 
RR 0.98 
(0.96 to 
0.99) 
17411 
(1 study) 
⊕⊕⊕⊝ 
Moderate 1 
Health education 
probably leads to a 
marginal decrease in 
vaccine uptake. 
*The anticipated absolute effect in the intervention group (and its 95% confidence interval) is based 
on the assumed likelihood of being vaccinated in the usual care group and the relative effect of the 
intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio 
** GRADE Working Group grades of evidence 
High certainty = This research provides a very good indication of the likely effect. The likelihood that the 
effect will be substantially different† is low. 
Moderate certainty = This research provides a good indication of the likely effect. The likelihood that the 
effect will be substantially different† is moderate. 
Low certainty = This research provides some indication of the likely effect. However, the likelihood that it 
will be substantially different† is high. 
Very low certainty = This research does not provide a reliable indication of the likely effect. The 
likelihood that the effect will be substantially different† is very high. 
†Substantially different = a large enough difference that it might affect a decision 
Footnotes 
1 Downgraded by 1 level due to high risk of bias in included study. 
 
76 
 
1.2 Health education compared to usual care on KAP 
One study (RCT(137)) determined the relationship between attitudes of parents of 
middle- and high-school students and acceptance of school-located vaccination clinics 
for all four recommended adolescent vaccines (HPV, meningococcal conjugate, Tdap, 
and Influenza). The study suggests that perceived severity of illness and intention to 
vaccinate may lead to parental acceptance of school-located vaccination clinics. 
Another study (RCT(142)) reveals that a specifically designed hepatitis B vaccine 
education curriculum package may improve knowledge of the targeted disease and 
vaccination among students. 
1.3 Health education compared to usual care on adverse events 
One study (RCT(140)) reported that health education did not have any adverse events 
in relation to adolescent vaccination. Health education plus financial incentives 
1.4 Financial incentives compared to usual care on vaccination coverage 
One study (RCT(138)) found that financial incentives may improve coverage with the 
first dose of the HPV vaccine (500 participants; RR 1.45, 95%CI 1.05 to 1.99; Figure 14 
Analysis 2.1). We judged the certainty of the evidence as low (Summary of findings 
Table 5), because of concerns regarding study limitations and imprecision of the effect. 
Figure 14: Analysis 2.1, HPV vaccine initial uptake 
 
 
 
77 
 
Table 5: Summary of findings: Financial incentives compared to no incentives  
Patient or population: Adolescents 
Setting: United Kingdom 
Intervention: Financial incentives 
Comparison: No incentives 
Outcomes Absolute effects* (95% 
CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Certainty of 
the evidence 
(GRADE)** Comments With no 
incentive 
With 
financial 
incentives 
Uptake of human 
papillomavirus 
vaccine 
196 per 
1,000 
284 per 
1,000 
(206 to 390) 
RR 1.45 
(1.05 to 
1.99) 
500 
(1 study) 
⊕⊕⊝⊝ 
Low1,2 
Financial 
incentives may 
improve 
vaccination 
coverage. 
*The anticipated absolute effect in the intervention group (and its 95% confidence interval) is based 
on the likelihood of being vaccinated in the "no incentive" group and the relative effect of the intervention 
(and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio 
** GRADE Working Group grades of evidence 
High certainty = This research provides a very good indication of the likely effect. The likelihood that the 
effect will be substantially different† is low. 
Moderate certainty = This research provides a good indication of the likely effect. The likelihood that the 
effect will be substantially different† is moderate. 
Low certainty = This research provides some indication of the likely effect. However, the likelihood that it 
will be substantially different† is high. 
Very low certainty = This research does not provide a reliable indication of the likely effect. The 
likelihood that the effect will be substantially different† is very high. 
†Substantially different = a large enough difference that it might affect a decision 
Footnotes 
1 Downgraded by 1 level for high risk of bias in included study. 
2 Downgraded by 1 level for imprecision of findings. 
 
1.5 Health education and financial incentives compared to usual care on vaccination 
coverage 
A small study (RCT(141)) compared health education and financial incentives to usual 
care, and reveals that the intervention may improve completion of the full series of three 
doses of the hepatitis B vaccine (104 participants: RR 1.38, 95%CI 0.96 to 2.00; Figure 
15 Analysis 3.1). We judged the certainty of the evidence on the effects of the 
intervention as low (Summary of findings Table 6, because of concerns regarding the 
high risk of bias in the included study and imprecision of the findings. 
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Figure 15: Analysis 3.1, Immunisation rate of Hepatitis B vaccine (3 dose) 
  
Table 6: Summary of findings: Vaccination education plus financial incentives 
compared to usual care 
  
Population: Adolescents and parents 
Setting: United States of America 
Intervention: Vaccination education plus financial incentives 
Comparison: Usual care i.e. education on a non-vaccine topic 
Outcomes Absolute effects* (95% 
CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Certainty of 
the evidence 
(GRADE)** Comments With 
usual 
care 
With health 
education and 
incentives 
Uptake of three 
doses of 
hepatitis B 
vaccine 
451 per 
1,000 
622 per 1,000 
(433 to 902) 
RR 1.38 
(0.96 to 
2.00) 
104 
(1 study) 
⊕⊕⊝⊝ 
Low 1,2 
Health education plus 
financial incentives 
may improve 
vaccination coverage. 
*The anticipated absolute effects in the intervention group (and its 95% confidence interval) is based 
on the likelihood of being vaccinated in the usual care group and the relative effect of the intervention 
(and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio 
** GRADE Working Group grades of evidence 
High certainty = This research provides a very good indication of the likely effect. The likelihood that the 
effect will be substantially different† is low. 
Moderate certainty = This research provides a good indication of the likely effect. The likelihood that the 
effect will be substantially different† is moderate. 
Low certainty = This research provides some indication of the likely effect. However, the likelihood that it 
will be substantially different† is high. 
Very low certainty = This research does not provide a reliable indication of the likely effect. The 
likelihood that the effect will be substantially different† is very high. 
†Substantially different = a large enough difference that it might affect a decision 
Footnotes 
1 Downgraded by 1 level for high risk of bias in included study. 
2 Downgraded by 1 level for imprecision of findings. 
1.6 Health education and financial incentives compared to usual care on KAP 
The study by Schwarz and colleagues (RCT(141)) suggests that a culturally appropriate 
educational video on hepatitis B vaccine may improve vaccine knowledge and may 
improve return rates for the vaccine. 
1.7 Mandatory vaccination versus usual care on vaccination coverage 
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Wilson et al (nRCT(146)) assessed the effect of mandatory hepatitis B vaccination for 
elementary school entry in the state of Missouri in the USA. The study compared 
students in the ninth grade (affected by the hepatitis B vaccination law) and 12th grade 
(not affected by the law) in the state.  The study showed that making vaccinations 
mandatory probably improves vaccination coverage (6462 participants: RR 4.24, 95%CI 
3.94 to 4.56; Figure 16 Analysis 4.1). 
In addition, the study compared the 9th grade in Missouri (affected by the mandatory 
vaccination law) to 9th grade in the state of Kansas (not affected by the law); and 
confirmed that mandating vaccination probably improves uptake of the vaccine (6462 
participants: RR 3.92, 95%CI 3.65 to 4.20; Figure 16 Analysis 4.1). 
We judged the certainty of the evidence as moderate (Summary of findings Table 7, 
because of the high risk of bias in the included study. 
Figure 16: Analysis 4.1, Immunisation rate of Hepatitis B vaccine (HPV 3 dose). 
 
Table 7: Summary of findings: Mandatory vaccination versus usual care   
Population: Adolescents 
Setting: United States of America 
Intervention: School entry law mandating vaccination 
Comparison: Usual care 
Outcomes Absolute effects* (95% 
CI) 
Relative 
effect 
№ of 
participants 
Certainty of 
the evidence 
Comments 
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With 
usual 
care 
With 
mandatory 
vaccination 
(95% CI) (studies) (GRADE)** 
Uptake of three 
doses of 
hepatitis B 
vaccine 
172 per 
1,000 
729 per 1,000 
(677 to 784) 
RR 4.24 
(3.94 to 
4.56) 
6462 
(1 study) 
⊕⊕⊕⊝ 
Moderate1 
Mandating 
vaccination probably 
improves vaccination 
coverage. 
*The anticipated absolute effects in the intervention group (and its 95% confidence interval) is based 
on the likelihood of being vaccinated in the no-intervention group and the relative effect of the 
intervention (and its 95% CI). 
Missouri mandated hepatitis B vaccination for elementary school entry in 1997 and for middle school in 
1999. Kansas mandated hepatitis B for elementary school entry in 2004, after this study. 
CI: Confidence interval; RR: Risk ratio 
**GRADE Working Group grades of evidence 
High certainty = This research provides a very good indication of the likely effect. The likelihood that the 
effect will be substantially different† is low. 
Moderate certainty = This research provides a good indication of the likely effect. The likelihood that the 
effect will be substantially different† is moderate. 
Low certainty = This research provides some indication of the likely effect. However, the likelihood that it 
will be substantially different† is high. 
Very low certainty = This research does not provide a reliable indication of the likely effect. The 
likelihood that the effect will be substantially different† is very high. 
†Substantially different = a large enough difference that it might affect a decision 
Footnotes 
1 Downgraded by 1 level for high risk of bias in the included study. 
 
2. Provider-oriented interventions 
2.1 Provider prompts compared to usual care on vaccination coverage 
Szilagyi et al (RCT (143)) assessed the impact of provider prompts compared to usual 
care on the uptake of various recommended adolescent vaccines (Figure 17-20 
Analysis 5.1-5.4). The study shows that provider prompts probably make little or no 
difference to the uptake of Tdap (3520 participants: RR 1.05, 95%CI 0.99 to 1.11; 
Figure 18 Analysis 5.2); meningococcal (3520 participants: RR 1.05, 95%CI 0.99 to 
1.11; Figure 19 Analysis 5.3); HPV (1771 participants: RR 1.06, 95%CI 0.87 to 1.30; 
Figure 17 Analysis 5.1), and influenza (3520 participants :RR 1.05, 95%CI 0.96 to 1.15; 
Figure 20 Analysis 5.4) vaccines. We judged the certainty of the evidence as moderate 
(Summary of findings Table 8), because of concerns regarding imprecision of findings. 
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Figure 17: Analysis 5.1, HPV vaccination uptake 
 
 Figure 18: Analysis 5.2, Tdap vaccination uptake 
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Figure 19: Analysis 5.3, MCV4 vaccination uptake 
 
Figure 20: Analysis 5.4, Seasonal influenza vaccination uptake 
 
Table 8: Summary of findings: Provider prompts compared to usual care   
Population: Healthcare workers 
Setting: United States of America 
Intervention: Provider prompts 
Comparison: Usual care 
Outcomes Absolute effects* 
(95% CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Certaintyof 
the evidence 
(GRADE)** Comments With 
usual 
care 
With 
provider 
prompts 
Uptake of 
Tdap vaccine 
914 
per 
1,000 
960 per 
1,000 
(905 to 
RR 1.05 
(0.99 to 
1.11) 
3520 
(1 study) 
⊕⊕⊕⊝ 
Moderate1 
Provider prompts probably 
make little or no difference to 
uptake of Tdap vaccine 
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1000) 
Uptake of Men 
vaccine 
893 
per 
1,000 
938 per 
1,000 
(884 to 
991) 
RR 1.05 
(0.99 to 
1.11) 
3520 
(1 study) 
⊕⊕⊕⊝ 
Moderate1 
Provider prompts probably 
make little or no difference to 
uptake of the meningococcal 
conjugate vaccine 
Uptake of 
HPV3 
470 
per 
1,000 
498 per 
1,000 
(409 to 
611) 
RR 1.06 
(0.87 to 
1.30) 
1771 
(1 study) 
⊕⊕⊕⊝ 
Moderate1 
Provider prompts probably 
make little or no difference to 
completion of HPV vaccine 
schedule 
Uptake of 
seasonal 
influenza 
vaccine 
399 
per 
1,000 
419 per 
1,000 
(383 to 
459) 
RR 1.05 
(0.96 to 
1.15) 
3520 
(1 study) 
⊕⊕⊕⊝ 
Moderate1 
Provider prompts probably 
make little or no difference to 
uptake of the seasonal 
influenza vaccine 
*The anticipated absolute effects in the intervention group (and its 95% confidence interval) is based 
on the likelihood of being vaccinated in the usual care group and the relative effect of the intervention 
(and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; Tdap: tetanus-diphtheria-acellular pertussis; Men: meningococcal 
conjugate vaccine; HPV3: three doses of human papillomavirus vaccine. 
** GRADE Working Group grades of evidence 
High certainty = This research provides a very good indication of the likely effect. The likelihood that the 
effect will be substantially different† is low. 
Moderate certainty = This research provides a good indication of the likely effect. The likelihood that the 
effect will be substantially different† is moderate. 
Low certainty = This research provides some indication of the likely effect. However, the likelihood that it 
will be substantially different† is high. 
Very low certainty = This research does not provide a reliable indication of the likely effect. The 
likelihood that the effect will be substantially different† is very high. 
†Substantially different = a large enough difference that it might affect a decision 
Footnotes 
1 Downgraded by 1 level for imprecision of findings. 
 
2.2 Provider incentives compared to usual care on vaccination coverage  
One study (CBA (147)) looked at the effect of maintenance of certification (MOC) 
programme contingent on captured opportunities for HPV vaccination i.e. visits at which 
an eligible adolescent patient saw a paediatrician or nurse practitioner and received a 
dose of the HPV vaccine. MOC clinicians increased their captured opportunities for HPV 
vaccination, relative to nonparticipating clinicians, by 5.7 percentage points for the first 
dose of HPV given during preventive visits and by 0.7 and 5.6 percentage points for the 
first and second doses of HPV given during acute care visits. Therefore, compared to 
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usual care, MOC programmes may lead to an increase in captured opportunities for 
HPV vaccination. 
Fiks et al (CBA (147)) evaluated the costs required to implement the MOC programme. 
The authors calculated the total cost of each of the following components: creation of 
the performance feedback reports, time spent on creating and delivering the educational 
content, and time spent by participating providers on (1) group calls, (2) reviewing data, 
and (3) planning/ implementing practice change. The estimated total cost of the MOC 
programmes was $17,887 ($662 per participant), of which $17,064 was for participant 
time spent on the programmes. 
2.3 Multi-component provider interventions compared to usual care on vaccination 
coverage 
Perkins 2015 (cRCT (128)) assessed the effects of a four-component provider 
intervention package (education session, repeated contacts, individualized feedback, 
and incentives) and found that the intervention may improve the uptake of the next 
needed HPV vaccine dose. 
3. Provider and recipient-oriented interventions 
3.1 Provider and parent multifaceted intervention compared to usual care on vaccination 
coverage 
Cates et al (nRCT (144)) assessed the effects of a social marketing intervention among 
parents and providers and Paskett et al (RCT (139)) assessed the effects of multi-
component education of both providers and parents. Combining the data shows that 
using a multi-faceted provider and parent intervention probably improves HPV 
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vaccination coverage (two studies, 26206 participants: RR 1.42, 95%CI 1.26 to 1.60; I2 
= 0%: Figures 21 Analysis 6.1). We judged the certainty of the evidence as moderate 
(Summary of findings Table 9), because of concerns regarding high risk of bias in the 
included studies. 
Figure 21: Analysis 6.1, HPV vaccination uptake 
  
Table 9: Summary of findings: Provider & parent multi-faceted intervention 
compared to usual care  
  
Population: Healthcare workers and parents 
Setting: United States America 
Intervention: Multi-faceted intervention 
Comparison: Usual care 
Outcomes Absolute effects* (95% 
CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Certainty of 
the evidence 
(GRADE)** Comments With 
usual 
care 
With multi-
faced 
intervention 
HPV vaccine 
uptake 
51 per 
1,000 
73 per 1,000 
(65 to 82) 
RR 1.42 
(1.26 to 
1.60) 
26206 
(2 studies) 
⊕⊕⊕⊝ 
Moderate 1 
Multi-faceted 
intervention probably 
improves HPV 
vaccination coverage 
*The anticipated absolute effects in the intervention group (and its 95% confidence interval) is based 
on the likelihood of being vaccinated in the usual care group and the relative effect of the intervention 
(and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio 
** GRADE Working Group grades of evidence 
High certainty = This research provides a very good indication of the likely effect. The likelihood that the 
effect will be substantially different† is low. 
Moderate certainty = This research provides a good indication of the likely effect. The likelihood that the 
effect will be substantially different† is moderate. 
Low certainty = This research provides some indication of the likely effect. However, the likelihood that it 
will be substantially different† is high. 
Very low certainty = This research does not provide a reliable indication of the likely effect. The 
likelihood that the effect will be substantially different† is very high. 
†Substantially different = a large enough difference that it might affect a decision 
Footnotes 
1 Downgraded by 1 level for high risk of bias in the included studies. 
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3.2 Provider and parent multifaceted intervention compared to usual care on KAP 
Paskett 2016 (RCT (139)) suggests that multi-component education of both providers 
and parents may increase knowledge about HPV infection and HPV vaccine among 
providers and parents. 
4. Health systems interventions 
4.1 Class-based compared to age-based school vaccination on vaccination coverage 
Watson-Jones et al (cRCT (130)) assessed the effect of two HPV vaccine delivery 
strategies and showed that class-based delivery probably leads to higher HPV vaccine 
uptake than an age-based delivery strategy (one study, 5537 participants: RR 1.09, 
95%CI 1.06 to 1.13; Figure 22 Analysis 7.1). We judged the certainty of the evidence 
as moderate (Summary of findings Table 10), because of concerns regarding high risk 
of bias in the included study. 
 
Figure 22: Analysis 7.1, HPV vaccination uptake 
 
 
Table 10: Summary of findings: Class-based compared to age-based HPV vaccine 
delivery  
Population: Adolescents 
Setting: Tanzania 
Intervention: Class-based vaccination 
Comparison: Age-based vaccination 
Outcomes Absolute effects* (95% 
CI) 
Relative 
effect 
(95% CI) 
№ of 
participants 
(studies) 
Certainty of 
the evidence 
(GRADE)** 
Comments With age-
based 
delivery 
With 
class-
based 
delivery 
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HPV 
vaccination 
uptake 
721 per 
1,000 
786 per 
1,000 
(764 to 
815) 
RR 1.09 
(1.06 to 
1.13) 
5537 
(1 study) 
⊕⊕⊕⊝ 
Moderate1 
Class-based vaccination 
probably leads to higher 
HPV vaccine uptake than 
age-based vaccination. 
*The anticipated absolute effects in the intervention group (and its 95% confidence interval) is based 
on the likelihood of being vaccinated in the comparison group and the relative effect of the intervention 
(and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio 
**GRADE Working Group grades of evidence 
High certainty = This research provides a very good indication of the likely effect. The likelihood that the 
effect will be substantially different† is low. 
Moderate certainty = This research provides a good indication of the likely effect. The likelihood that the 
effect will be substantially different† is moderate. 
Low certainty = This research provides some indication of the likely effect. However, the likelihood that it 
will be substantially different† is high. 
Very low certainty = This research does not provide a reliable indication of the likely effect. The 
likelihood that the effect will be substantially different† is very high. 
†Substantially different = a large enough difference that it might affect a decision 
Footnotes 
1 Downgraded by 1 level for high risk of bias in the included study. 
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The study by Watson-jones and colleagues (cRCT (130)) collected data on the costs of 
class-based versus age-based delivery of the HPV vaccine in Tanzania  found the 
class-based vaccination strategy to be less expensive. It costed 52 and 67 US Dollars 
per girl vaccinated in a class-based strategy in urban and rural schools, respectively; 
compared to 87 and 98 US Dollars respectively, for the age-based delivery system. 
Watson-jones and colleagues study (cRCT(130)) reported 11 AEFI. One AEFI was 
considered to be related to HPV vaccination. The AEFI consisted of a generalized rash 
after the first dose of an HPV vaccine in a 12-year-old student. This resolved within a 
week without treatment. The student was not given further doses of the vaccine. The 
study did not report if the 11 AEFIs were in the age-based or class-based group for 
delivering HPV vaccines. 
Discussion   
Summary of main results   
We found that educating adolescents and their parents about the importance of 
vaccinations, passing laws stating that adolescents must be vaccinated prior enrolment 
at school, or using class-based rather than age-based approaches for delivering 
vaccines probably improves adolescent vaccination coverage. Adolescent vaccination 
coverage is also probably improved through targeting parents and healthcare providers 
with a combination of vaccination education, phone calls, and radio messages. In 
addition, providing adolescents and their parents with financial incentives alone or in 
combination with vaccination education may improve adolescent vaccination coverage. 
Finally, reminding healthcare providers to vaccinate adolescents when they open their 
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electronic medical charts probably makes little or no difference to adolescent 
vaccination coverage. From the data included in this review, we are uncertain about the 
costs of the interventions tested and their effects on knowledge and attitudes to 
adolescent vaccination. 
Overall completeness and applicability of evidence   
Our systematic review is comprehensive: we included all known types of interventions 
for improving vaccination coverage (except recipient-oriented reminders (122)), all 
vaccines recommended by WHO for boys and girls aged 10 to 19 years (36), and all 
settings. We identified only 16 eligible studies which showed possible benefits for the 
following interventions: recipient-oriented education, legislation, and financial incentives; 
provider education; and, tailored school outreach programmes. 
One study showed a complex hepatitis B vaccine education curriculum package has no 
benefit (142). The participants were 17,411 boys and girls in 235 schools in Melbourne, 
Australia. The adolescents in the intervention group received four structured lessons on 
hepatitis B vaccine, including: (1) a resource fact sheet and assessment, (2) an 
information video and questions designed to engage the adolescent audience, (3) a 
small group discussion, and (4) an activity to locate resource information on the 
Internet. In addition, adolescents in both the intervention and comparison arms received 
the usual government information brochures. The latter were one-page folded coloured 
leaflets, outlining in simple terms, the risks of hepatitis B and benefits and side effects of 
vaccination. The authors found a 2% relative decrease in the uptake of three doses of 
the hepatitis B vaccine in the intervention compared to the usual care group (142). This 
might be an indication that interventions for improving immunisation coverage 
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(irrespective of the audience) need to be comprehensive, and yet be as simple as 
possible. Rosenbaum and colleagues have shown that non-research individuals 
struggle to understand the text and numbers (148). They recommend that to render 
summaries of health information easier to assimilate and more useful to end users, the 
summaries needs to clear, and easy to read or scan quickly. 
This review has several limitations. Firstly, 15 of the 16 included studies were 
conducted in HICs, mainly the USA, in which vaccination services are readily available 
to adolescent girls and boys. Such a scenario is not necessarily possible in all other 
settings; therefore, the findings from these studies need to be interpreted with caution 
when applied to different settings. Secondly, there is limited information from the studies 
on the cost-effectiveness of the interventions tested. The costs of interventions were 
reported in only two studies, including a provider incentive intervention (147) and a 
health system intervention (130). Although both studies focused on HPV vaccination, 
the costs varied, due to diversity in interventions, study settings, and methods of 
calculating costs and items included in the calculations. Therefore, when applying the 
findings of this review to any setting, local costings should be undertaken; particularly in 
settings differing from those of the original investigations. Thirdly, the studies included in 
this review did not report information on equity. It is possible that the implementation of 
interventions may increase inequity if they are not adapted to populations in remote and 
under-served areas in countries or if there is substantial variability in socio-economical 
characteristics among populations receiving the interventions. Given these contextual 
issues, any adolescent vaccination programme implemented based on our review 
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findings should include a monitoring component to assess the performance of the 
intervention within the given context.  
One study in our review was conducted in a country defined by the World Bank as LMIC 
(130). The study compared class-based and age-based strategies for delivering HPV 
vaccines among 5,537 girls in 134 primary schools in northwest Tanzania. There was a 
9% relative increase in vaccination coverage among eligible girls in schools assigned to 
a class-based approach, compared to girls in schools using an age-based strategy. This 
is an important finding and is readily applicable to other LMICs that do not have 
established immunisation programmes for adolescents, but have introduced or are 
contemplating to introduce HPV vaccination (149) and other vaccines for adolescents. 
School health programmes can have an advantage of integrating various existing health 
services at minimal increase in cost (101). In line with our findings, a previous review of 
school-based programmes in 17 countries found that school-based programmes lead to 
substantial increases in HPV vaccination coverage (150).  
Although the effect sizes reported in this review are small to moderate, even relatively 
small effect sizes for interventions aimed at increasing uptake of adolescent vaccines 
are clinically important in large populations. We therefore believe that this review is an 
important resource for countries and international organisations, in the context of the 
GVAP; a "framework to prevent millions of deaths by 2020 through more equitable 
access to existing vaccines for people in all communities" (151). 
Certainty of evidence   
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Using the GRADE approach, we judged the certainty of the evidence on the effects of 
included interventions on our primary outcome (adolescent vaccination coverage) as 
either moderate or low. Among the interventions targeting adolescents and their 
communities, we judged the certainty of the evidence as moderate for education (Table 
4 Summary of findings) and legislation mandating vaccination (Table 7 Summary of 
findings); and low for financial incentives (Table 5 Summary of findings) and a 
combination of education and financial incentives (Table 6 Summary of findings). 
Regarding provider-oriented interventions, we assessed the certainty as moderate for 
provider prompts (Table 8 Summary of findings). For the combination of recipient and 
provider interventions, we assessed the certainty of evidence as moderate (Table 9 
Summary of findings). Lastly, on health system interventions, we judged the certainty of 
the evidence as moderate for class-based compared to age-based delivery of vaccines 
to adolescents (Table 10 Summary of findings). Our main concerns with the evidence 
related to study limitations. Most of the included studies have an unclear or high risk of 
bias. The main limitations were non-randomisation, non-concealment of allocation, and 
no blinding among outcome assessors (Figure 10 and 11). 
Potential biases in the review process   
We minimised potential biases in the review process by adhering to Cochrane 
guidelines (126). We conducted comprehensive searches without limiting the searches 
to a specific language. Two authors independently assessed study eligibility, extracted 
data, and assessed the risk of bias in each included study. The eligible cRCTs reported 
that they adjusted for cluster effects. However, there is some level of subjectivity in the 
determination of concerns that are serious enough to require rating down (or up) the 
93 
 
evidence; and it is possible that others would have arrived at slightly different levels of 
certainty of evidence. 
Agreements and disagreements with other studies or reviews   
Few recent systematic reviews have assessed the effectiveness of interventions for 
improving adolescent immunisation coverage (119-122, 152). Das and colleagues 
searched three databases for studies published up to December 2014 and included 23 
studies on the effectiveness of interventions to improve vaccination coverage among 
adolescents. The authors reported evidence of moderate certainty from 13 studies, 
suggesting that vaccination requirement for schooling, immunisation reminders, and 
national permissive recommendation increase vaccination coverage in adolescents 
(120). Smulian and colleagues, in the second review, searched five databases and 
included 34 intervention studies published to May 2015. The authors report that many 
types of intervention strategies (targeting recipients, providers, and the health system) 
lead to increases in HPV vaccination coverage in different settings (152). In the third 
review, Jacobson Vann and colleagues searched four databases to January 2017; for 
trials, CBA studies and ITS evaluating vaccination-focused recipient reminders in 
children, adolescents, and adults in any setting. The review included 10 relevant studies 
showing high certainty evidence that reminders improve adolescent vaccination 
coverage (122).  
In the fourth review, Walling and colleagues searched three databases for studies 
published to April 2014 and included 51 studies on the interventions that have increased 
HPV vaccination uptake coverage among adolescents and young adult. The authors 
reported that school health programmes increase vaccination coverage in adolescents 
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(119). Crocker-Buque and colleagues is the fifth review that searched close to nine 
databases until June 2016 but only looked at Organisation for Economic Co-operation 
and Development countries only. The review looked at interventions to reduce 
inequalities in vaccine uptake in children and adolescents. The study concluded that 
multicomponent interventions can be used to increase vaccination uptake, however the 
author did not specify which intervention work best from adolescent in relation to 
children (121). 
The reviews by Das et al (120) and Smulian et al (152) have some overlap with our 
review in terms of included studies, but many studies included in the two reviews do not 
meet the EPOC criteria for inclusion of studies in systematic reviews of effects (125). 
Had we included recipient-oriented reminders in our review, there would have been 
enhanced overlap between our review findings and those from the Jacobson et al (122) 
review, specifically, in terms of studies that assessed this intervention for improving 
adolescent vaccination coverage. Our systematic review therefore complements earlier 
relevant reviews on the topic.  
In addition to the summary of evidence, we further assessed the quality of the five 
related reviews using A MeaSurement Tool to Assess Systematic Reviews scale 
(AMSTAR2) tool (153). Summary on the quality of the systematic review with 
justification together with description on the evidence is elaborated in Table 11 below. 
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Table 11: Descriptive summary on the evidence of the existing systematic review 
Study 1D 
No of studies 
included 
Duration of 
study Population 
Target 
vaccines 
Quality assessment 
of systematic 
reviews by AMSTAR Quality assessment  justification 
Walling 2016 
(119)  51 studies 2006-2015 
Men and/or 
women 11–26 y 
old HPV Moderate 
A comprehensive literature search 
strategy was not used and the author did 
not provide a list of excluded studies. It 
was not clear if the author performed 
investigation of publication bias. 
Das 2016 (120)  23 studies 
Inception of 
database to 2014 
Adolescents 
and youth 
Measles, 
MMR, TDap, 
Varicella, 
Rubella &  
HPV Moderate 
The author did not provide a list of 
excluded studies and it was not clear if 
the author performed investigation of 
publication bias. 
Crocker-Buque 
2017 (121) 41 studies 2008 and 2015 
Children and 
young people 
(CYP) from birth 
to 19 years 
Measles, 
MMR, TDap, 
Varicella, 
Rubella, 
HPV & 
Influenza Low 
The author did not provide a list of 
excluded studies and It was not clear 
what technique the author used for 
assessing the risk of bias. Additionally, it 
was not clear if the author performed 
investigation of publication bias.  
Jacobson Vann  
2018 (122) 75 studies 
update to Jan 
2017 
Children (birth 
to 18 years) or 
adults (18 years 
and up All vaccines High 
All the domains of AMSTAR was clearly 
addressed in this review 
Smulian et al 
2016 (152) 34 studies 2006 to 2015 Adolescents HPV Low 
The author did not provide a list of 
excluded studies and the author did not 
elaborate what technique they used for 
assessing the risk of bias and if they 
conducted investigation of publication 
bias. Additionally, the study did not report 
on the source of funding.  
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Furthermore, findings from our review as well as other related reviews on the topic 
supports our proposed logic model. Specifically, and as proposed in the logic model, 
various interventions show benefits in improving uptake of vaccines by adolescents. 
Nevertheless, neither data from our review nor from other related reviews is sufficient to 
support some of the outcomes (e.g. reduction of VPDs) or support some of the impacts 
(e.g. immunisation policies) of the various interventions as depicted in the proposed 
logic model. Regardless of this limitation, findings from our review can be used as a 
starting point to develop policies aimed at improving uptake of vaccines among 
adolescents. 
Authors' conclusions   
Implications for practice   
We found that educating adolescents and their parents about the importance of 
vaccinations, passing laws requiring adolescents to be vaccinated as a condition for 
school enrolment, or using a class-based approach for delivering vaccines probably 
increases the uptake of vaccines among adolescent girls and boys. The certainty of the 
evidence for these interventions was moderate, implying that monitoring of the impact is 
likely to be needed and an impact evaluation may be warranted if these interventions 
are implemented to improve uptake of vaccines by adolescents. 
In addition, we found low certainty evidence that adolescent vaccination coverage may 
be improved through providing adolescents and their parents with financial incentives, 
alone or in combination with education; giving incentives to providers of vaccination 
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services; and use of a multi-faceted package of interventions for providers of 
vaccination services, including education, repeated contacts, individualised feedback 
and incentives. The low certainty of the evidence for these interventions implies that an 
impact evaluation is warranted if any of the interventions is implemented for improving 
adolescent vaccination coverage. 
Implications for research   
Although the effect of interventions for improving adolescent vaccination coverage is 
context-specific, most of the currently available evidence on interventions is from HICs. 
Therefore, to have a global picture, there is a need for rigorous evaluations on 
interventions to improve adolescent vaccination in LMICs. Given that there is little or no 
evidence from existing studies on the costs of implementing the identified interventions, 
future studies should include this important aspect in the design. Other aspects to 
include in the future studies are socio-cultural and economic status as well as equity.  
In addition, to strengthen the current evidence base, there is a need for appropriate 
design, implementation and reporting of rigorous evaluations on interventions for which 
this review has found low certainty evidence of benefits (e.g. recipient incentives, 
provider incentives, optimal combination of effective interventions, etc.), moderate 
certainty evidence of little or no benefits (provider prompts), possibility of harm (multi-
component hepatitis B education), and interventions for which we found no eligible 
studies (e.g. expansion of access to adolescent vaccination services, integration of 
adolescent vaccination with other services). 
Contributions 
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Leila Abdullahi developed the protocol with support from Prof. Greg Hussey, Dr. 
Benjamin Kagina and Prof. Charles Wiysonge. Leila Abdullahi and Valentine Ndze 
screened titles, abstracts, and extracted data in duplicate. Benjamin Kagina and 
Charles Wiysonge arbitrated where discrepancies occurred. Leila Abdullahi wrote the 
final draft with support from Prof. Greg Hussey, Dr. Benjamin Kagina, Prof. Charles 
Wiysonge and Dr. Valantine Ndze. 
Differences between protocol and review   
A new author was added during the review process i.e. Valantine N Ndze. In the review 
we did not conduct subgroup and sensitivity analyses, as specified in the protocol, due 
to lack of data. See Table 2 for methods specified in the protocol, but not used in the 
review. 
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Chapter 4 
Knowledge, attitudes and practices on adolescent vaccination among 
adolescents, parents and teachers in Africa: a systematic review 
About this chapter: 
In this chapter, we conducted a comprehensive, up-to-date qualitative and quantitative 
systematic review on knowledge, attitudes and practices on adolescent vaccination 
among parents, teachers and adolescents in Africa. 
Publication: The systematic review and its protocol are both published, and the 
citations are shown below: 
Systematic review: Abdullahi LH, Kagina BM, Cassidy T, Adebayo EF, Wiysonge CS, 
Hussey GD. Knowledge, attitudes and practices on adolescent vaccination among 
adolescents, parents and teachers in Africa: A systematic review. Vaccine 2016; 
34(34):3950-60.  
https://doi.org/10.1016/j.vaccine.2016.06.023  
Systematic review protocol: Abdullahi LH, Kagina BM, Cassidy T, Adebayo EF, 
Wiysonge CS, Hussey GD. Knowledge, attitudes and practices on adolescent 
vaccination among parents, teachers and adolescents in Africa: a systematic review 
protocol. Systematic Reviews 2014 3:100 
https://doi.org/10.1186/2046-4053-3-100  
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Abstract 
Introduction: Vaccines are the most successful and cost-effective public health 
interventions available to avert morbidity and mortality associated with VPDs. Despite 
global progress in adolescent health, many adolescents in Africa still get sick and die 
from VPDs due to lack of vaccination. Adolescents, parents and teachers are key 
players in the development and implementation of adolescent vaccination policies. 
Optimal knowledge, attitudes and practices towards adolescent vaccination among 
these key players may improve vaccine uptake among adolescents. We conducted a 
qualitative and quantitative systematic review on knowledge, attitudes and practices of 
adolescent vaccination among adolescents, parents and teachers in Africa. 
Methods: We searched PubMed, Cochrane Central Register of Controlled Trials, 
Scopus, Web of Science, WHOLIS, Africa Wide and CINAHL for eligible quantitative 
studies (RCTs, CBAs, ITS, cohort, case-control and cross-sectional). In additional, from 
the same databases, we searched qualitative primary studies (focus group discussions, 
interviews, direct observation, case studies, ethnography and action research). There 
was no time restriction applied to the search. We also checked reference lists of 
included studies for eligible studies and searched grey literature. Two authors 
independently screened the search outputs, selected studies and extracted data; 
resolving discrepancies by consensus and discussion. Qualitative data were analysed 
using thematic analyses where applicable, while analyses from quantitative studies 
used different methods based on the type of outcomes. 
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Results: We included 18 cross-sectional studies in this review. The included studies 
were conducted in 10 out of the 54 countries in Africa. The 18 studies focused on a wide 
range of adolescent vaccines. Thirteen studies evaluated vaccines against HPV, while 
each of the remaining five studies, evaluated vaccines against rabies, HIV, tetanus 
toxoid, tuberculosis and adolescent vaccines in general. Among the key players, we 
found low to moderate levels of knowledge about adolescent vaccination. Positive 
attitudes and practices towards adolescent vaccination, especially against HPV were 
reported. Despite the low knowledge, our results showed high levels of acceptability to 
adolescent vaccination among adolescents, parents and teachers.  
Conclusions: It was evident in our review that all key demographics (parents, 
adolescents and teachers) were receptive towards adolescent vaccines. We propose 
relevant policy makers in Africa to consider continuous education programmes such as 
those aimed to inform the parents, adolescents and teachers on adolescent vaccination.  
Key words: Adolescents, parents, teachers, knowledge, attitudes and practice, 
vaccination barriers, Africa 
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Background  
There is evidence that vaccination during childhood, may in some instances, induce a 
short-lived immunity (16, 43-45). To ensure vaccine-induced immunity persists beyond 
childhood through to late adulthood, booster doses (for example during adolescence) of 
some vaccines (such as tetanus and pertussis) are recommended (16, 43-45). 
However, such booster vaccine doses needed during adolescence are not widely given, 
particularly in Africa (43). Both programmatic and individual challenges may partly 
explain the lack of booster vaccination during adolescence in Africa (14).  
The WHO defines adolescents as young persons aged 10 to 19 years (2, 154). Taking 
this definition, and looking at age-specific global data reported in 2018, adolescents, 
accounted for nearly 25% of the world’s population (155). Furthermore, adolescent 
population growth in Africa is reported to be the fastest in the world (155). From a 
vaccination standpoint, the public health authorities in Africa need to respond 
appropriately to the rapid growth of the adolescent population.  
If booster adolescent vaccines are successfully introduced in Africa, enormous public 
health benefits such as reduced transmission and treatment costs of VPDs will be 
achieved (43, 44). Additional public health benefits of adolescent vaccination 
programmes are: primary immunisation (new vaccines such as those against HPV) and 
catch-up immunisation (such as hepatitis B vaccines) (42, 44).   
Data from settings where adolescent immunisation programmes have existed show that 
unique challenges are faced when vaccinating adolescents (60, 63). Therefore, public 
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health authorities in Africa need to consider developing adolescent immunisation 
programmes that consider the challenges of targeting adolescents for immunisation.  
Challenges of adolescent immunisation include: a) lack of relevant vaccination 
knowledge among key players (adolescents, parents and teachers) (42, 59, 60, 66, 156-
161); b) negative attitude towards vaccination among adolescents, parents and 
teachers (156-158, 160, 161); and, c) anti-vaccination practices among adolescents, 
parents and teachers (156). Teachers are crucial players, especially for adolescent 
vaccines delivered through school programmes (65, 162). We summarize these 
challenges using knowledge, attitude and practices (KAP). 
A decision-making axis is known to exist among adolescents, parents or guardians and 
the teachers (60, 161). For example, for an adolescent to decide on being vaccinated or 
not, support from the parent, the teacher or even both is crucial. The decision by the 
adolescent accepting or rejecting vaccination, as well as the parent or teacher 
supporting the decision, is influenced by the KAP among the three key players. We 
propose that if two or all three key players (adolescents, parents and teachers) have 
optimal KAP towards vaccination, uptake of vaccines by adolescents would significantly 
increase in most settings.  
The assessments of knowledge and attitude among adolescents, parents, and 
healthcare workers, towards HPV vaccines are well documented (60, 157-161). In 
contrast, and to the best of our knowledge, assessments of KAP among adolescents, 
parents and teachers on the other adolescent vaccines are lacking. We therefore 
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conducted a systematic review on KAP towards adolescent vaccination among 
adolescents, parents and teachers in Africa. 
Objectives 
Primary objective 
a) Assess the KAP among adolescents, parents and teachers on the adolescent 
vaccination in Africa 
Secondary objective 
b) Assess the association between KAP on adolescent vaccination among the key 
players with vaccination coverage among adolescents in Africa 
Methodology 
This review protocol was published in the PROSPERO International Prospective 
Register of Systematic Reviews (http://www.crd.york.ac.uk/PROSPERO), registration 
number CRD42014010395. We used the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) checklist (Appendix 4).  
Types of studies selected 
For quantitative studies, we included RCTs, CBAs, ITS, cohort studies, case-control 
studies, and cross-sectional studies. Focus group discussions, interviews, direct 
observation, case studies, ethnography and action research were considered for 
selection as qualitative studies.  
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Study participants 
Adolescents, parents and teachers were considered as the study participants. We used 
the WHO definition of adolescents (young persons aged 10 to 19 years) (154). The 
person who nurtures or looks after a child or plays the role of a guardian to the child 
was considered as the parent. We defined a teacher as a professional who teaches or 
instructs an adolescent at a formal school (162). 
Primary outcomes 
 KAP among the study participants which meet at least one of the following 
definitions:   
 Knowledge: Information possessed on adolescent vaccination.  
 Attitudes: Opinion on adolescent vaccination/vaccines that involves a vaccine-
related act or its omission. 
 Practices: Observable actions towards adolescent vaccination. 
Secondary outcome 
 Vaccination coverage with a clear definition of numerator and within a specified 
period. 
Study settings 
Any country in Africa 
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Search strategy 
All the electronic searches were conducted on 29 August 2014. The detailed search 
strategy is included in the protocol previously published (Appendix 5) (163). We 
developed a sensitive search strategy for both qualitative and quantitative studies that 
combined relevant medical subject headings (MeSH) and free-text terms (163). The 
terms used were related to KAP towards adolescent vaccination among parents, 
teachers and adolescents. In addition, individual names for all African countries were 
used in the search process. We did not use date restrictions during the search. 
The peer reviewed articles in the following electronic databases were screened:  
 PubMed  
 Cochrane Central Register of Controlled Trials (CENTRAL)  
 Scopus  
 Web of Science  
 World Health Organization Library Information System WHOLIS  
 Africa Wide  
 CINAHL  
In addition, we searched web sites and databases for grey materials; WHO 
(http://www.who.int/); GAVI (http://www.gavialliance.org/); UNICEF 
(http://www.unicef.org/); PATH Vaccine Resources Library (http://www.path.org/); US 
Centres for Disease Control and Prevention (CDC) (http://www.cdc.gov/); The 
Communication Initiative Network (http://www.comminit.com/); and, Immunization 
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Basics (http://www.immunizationbasics.jsi.com/Index.html). Reference lists of relevant 
reviews and all eligible search records were also assessed for relevant studies.  
Study selection 
Two authors screened the titles and abstracts of the search records using a pre-
designed screening guide. The two authors identified potentially eligible studies and 
retrieved full texts of all records deemed potentially eligible by the two authors. Then, 
the two authors independently examined all the studies for eligibility and compiled a list 
of studies that met the inclusion criteria. Finally, the two authors compared the lists and 
resolved discrepancies by discussion and consensus. 
A PRISMA flow chart showing a summary of the records searched and selected was 
generated (Figure 23).   
Data extraction 
Two authors independently extracted data from the selected studies using standardised 
data-extraction forms (163). Disagreements between the two authors were resolved by 
consensus, failing which a third author arbitrated. 
Assessment of the risk of bias and synthesis of evidence 
The risk of bias for the included studies was assessed using the Critical Appraisal Skills 
Programme (CASP) for assessing the methodological quality of the qualitative studies 
(164). The quality assessment tool by Hoy et al., 2012 was used for observational 
studies (165). For each study, two authors independently provided an assessment of 
the level of the risk of bias (i.e. low, high, or unclear). The two authors compared the 
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results of the risk of bias assessments and resolved any discrepancies by discussion 
and consensus; and if this failed to resolve the disagreement, a third author arbitrated. 
The quality of evidence for our findings was evaluated using Confidence in the Evidence 
from Reviews of Qualitative research (CERQual). The CERQual approach was used to 
describe how much confidence to place in individual review findings from the synthesis 
of qualitative evidence (166). The Hoy et al., 2012 tool, modified by Werfalli and 
colleagues, allows a scoring system that categorizes high risk studies if the overall 
score is 0-5 points, moderate risk if overall score is 6-8 and, low risk if overall score is 
>8 points (Table 11) (167).  
Table 12: Risk of bias and quality assessment tool for observational studies 
(cross-sectional studies) 
Items  Quality 
Score 
External Validity (4 points) 
1. Was the study's target population a close representation of the national population in relation to 
relevant variables? 
(1 point) 
2. Was the sampling frame a true or close representation of the target population?  (1 point) 
3. Was some form of random selection used to select the sample, OR was a census undertaken?  (1 point) 
4. Was the likelihood of nonresponse bias minimal?  (1 point) 
 
Internal Validity (6 points) 
1. Were data collected directly from the subjects (as opposed to a proxy)?  (1 point) 
2. Was an acceptable case definition used in the study?  (1 point) 
3. Was the study instrument that measured the parameter of interest shown to have validity and 
reliability?  
(1 point) 
4. Was the same mode of data collection used for all subjects?  (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest appropriate?  (1 point) 
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate?  (1 point) 
Overall 
score  
Quality 
0-5 points  Low Risk: Further research is very unlikely to change our confidence in the estimate 
6-8 points  Moderate Risk: Further research is likely to have an important impact on our confidence in the 
estimate and may change the estimate 
>8 points  High Risk: Further research is very likely to have an important impact on our confidence in the 
estimate and is likely to change the estimate. 
Source: http://dx.doi.org/10.1136/bmjopen-2013-004747 (167) 
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Qualitative and quantitative data analyses 
Qualitative analysis was based on thematic synthesis of qualitative data which was 
independently coded by two authors. The resulting themes are discussed. Quantitative 
analysis was based on the types of outcome variables as well as the study designs. A 
pooled statistical analysis was not possible due to high level of heterogeneity. None of 
the studies were similar enough to combine in a meta-analysis. We used the Fisher’s 
exact test to compare the level of knowledge among the key demographics stratified by 
the study settings. There were not sufficient data to conduct any subgroup analyses. 
We therefore provided a narrative summary of the results. 
Results 
Search of relevant records  
Our search yielded 922 records from all databases and grey literature. After removing 
five duplicates, we screened 917 records; 896 of the records were excluded based on 
eligibility criteria that were evaluated from titles and abstracts. We retrieved the full text 
of 21 potential eligible records; four articles of which were from the search of reference 
lists. Of the 21 records, 18 studies met our inclusion criteria and three studies were 
excluded because:  a) the population studied was not well defined (168); b) it was a sub 
study of an included study (160); or, c) the outcome was not KAP (169).  
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Figure 23: The PRISMA diagram shows a summary the search and screening of 
the relevant records. 
 
Study settings 
The majority (6/18 i.e. 33%) of the studies were conducted in South Africa (43, 157, 
158, 170-172). Cameroon (173, 174), Uganda (175, 176) and Nigeria (177, 178) each 
contributed two studies while the rest of the countries (Kenya, Ghana, Tanzania, 
Botswana, Mali and Malawi) had only one study (179-184). Included studies were 
therefore from 10 out of 54 countries in Africa (Figure 24).  
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Figure 24: Geographical distribution of the selected studies, types of study 
designs and vaccines investigated 
 
Additionally, we assessed the study settings information. Five studies (28%) were 
conducted in rural settings (157, 173, 174, 178, 183), three (16%) in urban (158, 170, 
181), five (28%) in both urban and rural (171, 172, 175, 176, 184) and five (28%) in peri-
urban settings (43, 177, 179, 180, 182) (Table 12).  
Table 13: Summary of included studies- demographic characteristics 
Study ID 
Study country 
and settings Study design 
Target age 
group 
Sample 
size 
Anti-rabies vaccines 
Dzikwi A et al 2012 (177) Nigeria,           
peri-urban 
Cross-sectional study Adolescents 447 
General vaccines 
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Zipursky S et al 2010 (43) South Africa, 
urban 
Qualitative cross-
sectional study with 
focus groups 
Adolescents  63 
HIV Vaccines 
    Sayles J at al 2009 (171) South Africa, 
urban and rural 
Qualitative cross-
sectional study with 
focus groups 
Parents 42 
HPV vaccine (cervical cancer) 
Ayissi C et al 2012 (173) Cameroon,     
rural 
Cross-sectional study Adolescents  553 
Becker-Dreps S et al 2010 
(179) 
Kenya,             
peri-urban  
Cross-sectional study Parents 147 
Coleman M et al 2011 
(180) 
Ghana,            
peri-urban  
Cross-sectional study Parents 264 
DiAngi Y et al 2011 (181) Botswana,    
urban 
Cross-sectional study Parents 376 
Francis S et al 2010 (172) South Africa, 
urban 
Cross-sectional study Parents  86 
Francis S et al 2013 (170) South Africa, 
urban  
Qualitative cross-
sectional study with 
focus groups  
Parents. 24 
Galagan S et al 2012 (175) Uganda,        
urban and rural 
Cross-sectional study Parents   1489 
Katahoire R et al 2008 
(176) 
Uganda,        
urban and rural 
Qualitative cross-
sectional study with 
focus groups and key 
informants 
Adolescents, 
parents & 
teachers 
178 
Katz I et al 2013 (158) South Africa, 
urban 
Qualitative cross-
sectional study with In-
depth survey 
Adolescents& 
parents 
77 
Poole D et al 2013 (182) Mali,                Cross-sectional study Adolescents& 51 
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peri-urban parents  
Ports K et al 2013 (183) Malawi,          
rural 
Qualitative interview Parents 30 
Remes P et al 2012 (184) Tanzania,      
urban and rural  
Qualitative cross-
sectional Survey with 
focus group 
Parents, 
adolescents & 
teachers  
169 
Wamai R et al 2012 (174) Cameroon,     
rural 
Cross-sectional study Parents 317 
Tetanus toxoid  vaccines 
Orimadegun A et al 2014 
(178) 
Nigeria,           
rural 
Cross-sectional study Adolescents   851 
Tuberculosis vaccines 
Mahomed H et al 2008 
(157) 
South Africa, 
rural 
Qualitative cross-
sectional study with 
focus group 
Adolescents & 
parents.  
270 
 
Study characteristics of the included records 
All the 18 studies were cross-sectional design with 8 studies being qualitative cross-
sectional studies. Ten of the 18 studies utilized self-administered questionnaires and 
analysed the results quantitatively (172-175, 177-182). Six studies used in-depth 
interviews and were analysed qualitatively (43, 158, 170, 171, 183, 184). Two studies 
combined data collection methods of self-administered questionnaire and focus group 
discussion (157, 176). Combined, a total of 5434 participants (median 173.5, range 24 
to 1489 per study) were studied from the included records. 
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Adolescent vaccines studied from the included records 
The HPV vaccine was investigated in 13 (72%) of the studies (158, 170, 172-176, 179-
184). Each of the five remaining studies investigated vaccines against TB (157), tetanus 
(178), rabies (177) and HIV (171), and adolescent vaccines in general (43). In all 
studies, participants did not reveal any preference on certain vaccines over others, 
including booster vaccines.  
Aims of the included studies 
The outcomes of all the included studies were based on the aim of the studies (43, 157, 
158, 170-184). Broadly, the aims of the included studies were to assess the knowledge, 
attitude and awareness/acceptability of a specific vaccine preventable disease i.e. HPV, 
TB, tetanus, HIV, rabies and the associated vaccines. Three studies aimed to evaluate 
the association of the previous interventions and level of knowledge as well as 
awareness (173-175). 
Reported outcomes from the included studies 
Three studies (173-175) were interventional: evaluating sensitization campaigns (157, 
158, 170, 171, 173-175, 177-183) and communication strategies (175) to enhance 
knowledge, attitudes and practices to promote uptake of adolescent vaccines. These 
three studies (173-175) already had an existing vaccination programme in place when 
the studies were conducted (Table 13). All other included studies did not report any 
existing vaccination programme during the study periods (Table 13). 
Sixteen studies assessed knowledge (43, 157, 170-174, 176-184) and a similar number 
of studies evaluated attitudes and practices (43, 157, 158, 170-175, 177-183) as 
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outcomes. Two studies evaluated knowledge only among teachers (176, 184) while 
nine studies investigated KAP among adolescents (43, 157, 158, 173, 176-178, 182, 
184). Fourteen studies reported KAP on adolescent vaccination among parents (157, 
158, 170-172, 174-176, 179-184) (Table 12).  
The 13 studies on HPV-vaccine focused on three main sub-themes: Knowledge of HPV 
vaccination or cervical cancer, attitude towards HPV vaccines and practice of HPV 
vaccination. The remaining five studies focused on KAP of other adolescent vaccines 
(TB, tetanus, HIV, rabies and adolescent vaccines in general). None of the included 
studies evaluated vaccination coverage among adolescents. 
Table 14: Summary of included studies- interventions and knowledge, attitude 
and practice outcomes 
116 
 
Study ID 
(Country) 
 Aim of the study Interventions Existing 
vaccination 
programme 
Outcomes evaluated 
Knowledge Attitude and practice 
Ayissi C et al 
2012 
(Cameroon) 
(173) 
To measure the effectiveness of 
the CBCHS sensitization 
campaign intervention and to 
gauge the level of awareness 
about HPV and HPV vaccine  
CBCHS 
sensitization 
campaign 
Community based 
programme 
High knowledge on cervical cancer 
and HPV vaccine. Awareness of HPV 
(86.8%), cervical cancer (82.3%), and 
prevention of HPV infections through 
vaccination (75.9%) 
A positive attitude towards HPV 
vaccine. Most adolescents 
(80%) recommend girls of ages 
9–13 years be vaccinated 
against HPV infections 
Becker-Dreps 
S et al 2010 
(Kenya) (179) 
Assess vaccine acceptability in 
community 
None None Low knowledge of HPV vaccine and 
knowledge of cervical cancer. 15% had 
heard of cervical cancer and none on 
HPV vaccine. 
95% of women had a positive 
attitude and were willing to 
have their daughters vaccinated 
with HPV vaccine, with 
preference for an inexpensive 
vaccine requiring fewer doses. 
Coleman M et 
al 2011 
(Ghana) (180) 
To assess knowledge, attitudes 
and acceptability of human 
papillomavirus (HPV) vaccination 
None None 89% of the women had a high 
knowledge on cervical cancer in 
Ghana; however, 45% of the women 
had moderate knowledge on HPV 
vaccine. 
76% of the women had a 
positive attitude and believed 
that all women regardless of 
their sexual practices should 
receive it. However, they were 
very concerned” about 
unknown side effects 
associated with the vaccine. 
DiAngi Y et al 
2011 
(Botswana) 
(181) 
To examine HPV vaccine 
acceptability for adolescent girls 
and its predictors among 
healthcare-seeking adults 
None None Low knowledge on HPV and HPV 
vaccine. 35% had knowledge on HPV 
while 9% were aware on HPV vaccine; 
however, 75% wanted more 
information about it. 
88% of the parents had a 
positive attitude; they would get 
HPV vaccine for their 
adolescent daughters mostly if 
it were available with other 
childhood vaccines. However, 
there was a negative attitude 
among a few (22%) stating their 
daughter would be more likely 
to have sex if they got the 
vaccine 
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Dzikwi A et al 
2012 
(Nigeria) (177) 
To obtain baseline information 
about the knowledge and practice 
about rabies 
None None There was a moderate (50%) among 
formal schools’ goers to low (32%) 
among informal education settings 
knowledge on rabies.  
Positive attitude with 63% and 
87% of the children bitten by 
dogs in the formal and informal 
schools respectively received 
hospital treatment or African 
treatment. 
Francis S et al 
2013 (South 
Africa) (170) 
To compare findings about 
cervical cancer prevention, HPV, 
and the acceptance of the HPV 
vaccine among residents 
None None There was lack of awareness and 
understanding about HPV and its 
association with cervical cancer. 
There were positive thoughts 
about a vaccine to prevent 
cancer and concern that the 
receipt of the HPV vaccine may 
influence adolescent sexual 
behaviour. 
Galagan S et 
al 2012 
(Uganda) (175) 
 
 
 
To evaluate the association 
between Information, education 
and communication materials and 
activities and community 
influencers with initial uptake of 
HPV vaccine. 
Promoting HPV 
vaccines through a 
variety of 
communication 
strategies. 
Pilot vaccination 
programme 
N/A There were positive attitude In 
Uganda with high uptake 85% 
(year 1) and 82% (year 2) if the 
parent had had contact with a 
person promoting the vaccine. 
Katz I et al 
2013 
(South Africa) 
(158) 
 
To elucidate factors influencing 
HPV vaccine uptake among a 
sample of low-income 
adolescents receiving the vaccine 
for the first time 
None None N/A There is a negative attitude 
among boys assuming that that 
HPV only affects girls only. 
Mahomed H et 
al 2008 
(South Africa) 
(157) 
To determine knowledge levels 
about TB and vaccines amongst 
adolescents, their attitudes and 
that of their parents towards 
research and invasive procedures 
None None Knowledge of tuberculosis was 
moderate (63%) but knowledge of 
vaccines was poor 41% 
There was a positive attitude 
among the participants as they 
were willing to participate in 
research or get vaccinated if 
they were well informed about 
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benefits and safety. 
 
Orimadegun A 
et al 2014 
(Nigeria) (178) 
 
To evaluate the understanding of 
adolescent girls in high school 
about tetanus and identify fac- 
tors associated with knowledge of 
the disease 
None Health facility 
programme for 
child bearing 
women but not for 
adolescent girls 
64% of the respondents had poor 
knowledge while 40.4% claimed they 
knew about tetanus as an ‘acute 
serious disease’; however only 46% of 
them correctly defined it. 
Over half (56.2%) of 
respondents had negative 
attitudes towards introduction of 
“tetanus immunisation to 
students in the school. 
Poole D et al 
2013 
(Mali) (182) 
 
 
To assess HPV knowledge and 
HPV vaccine acceptability 
None None Low knowledge on HPV & HPV 
vaccine; 49% knew HPV causes 
cervical cancer, 14% did not know who 
was susceptible to HPV infection and 
only 9.8% of participants heard of 
cervical cancer. 
Positive attitude among all 
(100%) participant; they 
reported being willing to receive 
HPV vaccination. However, 
68% would only receive 
immunisation against HPV if the 
vaccine were available at no 
cost to participant. 
Ports K et al 
2013 
(Malawi) (183) 
 
To elucidate potential barriers and 
facilitators to human 
papillomavirus (HPV) vaccination 
None None All the women heard about cervical 
cancer; however, women’s knowledge 
about HPV and cervical cancer was 
limited. 
Women were extremely 
accepting of vaccines and 
efforts to prevent cervical 
cancer since it was perceived to 
be a serious health concern. 
Sayles J at al 
2009 
(South Africa) 
(171) 
To identify key barriers and 
motivators to future HIV vaccine 
uptake among a population that 
interfaces with the health system 
None None Low level of knowledge on HIV 
vaccines. HIV vaccine had not really 
been heard about before 
75% of participants were willing 
with their friends/family to take 
an approved HIV vaccine if 
available. 
Wamai R et al 
2012 
(Cameroon) 
(174) 
To measure the effectiveness of 
the CBCHS sensitization 
programme intervention in 
educating the parents on HPV, 
cervical cancer and HPV vaccines 
CBCHS 
sensitization 
campaign 
programme 
Community based 
programme 
High knowledge 75% & 90% among 
parents/guardians about HPV & 
cervical cancer, and the use of the 
HPV vaccine against HPV infections. 
Positive attitude among parents 
to vaccinate their daughters; 
however cost of the vaccine 
may be the most influential 
factor in parents’ decisions to 
vaccinate their daughters. 
119 
 
 
 
 
 
 
 
Zipursky S et 
al 2010 
(South Africa) 
(43) 
To find out about knowledge and 
attitudes of adolescents towards 
vaccines 
None None Knowledge of vaccines and 
immunisation issues was low amongst 
the adolescents 
There is a high level of 
acceptability of vaccines, which 
increased once their purpose 
and preventative nature was 
explained.  
Francis S et al 
2010 (South 
Africa) (172) 
To examine knowledge, attitudes 
and beliefs around HPV and 
cervical cancer 
None None Moderate knowledge;61% of 
participants heard of cervical cancer 
while low knowledge; 29% heard of 
HPV infection 
46% willing to vaccinate their 
child. expressed interest in 
vaccinating their child if they 
had access to the HPV vaccine 
Katahoire R et 
al 2008 
(Uganda) (176) 
To gauge the policy 
environment—structures and 
processes required for policy 
formulation for HPV vaccine 
introduction 
None None Majority of respondents were unaware 
that cervical cancer is caused by HPV. 
None 
Remes P et al 
2012 
(Tanzania) 
(184) 
To learn what people knew about 
cervical cancer and HPV 
vaccination 
None None Generally, most welcomed a vaccine 
to prevent cervical cancer and most 
parents said they would agree to have 
their daughter vaccinated although 
some adopted a “wait and see” 
approach. Most had a strong belief that 
vaccines prevent diseases 
None 
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KAP towards adolescent vaccination 
From the 18 records included for our review, 12 (78%) evaluated knowledge of 
adolescent vaccines among parents (157, 170-172, 174, 176, 179-184), and 8 (44%) 
among adolescents (43, 157, 173, 176-178, 182, 184) and 2 (11%) among teachers 
(176, 184).  
Our limited sample size could not allow us to reliably compare the KAP between the 
represented countries. However, in all study settings and countries, sub-optimal 
knowledge about the VPDs and the associated vaccines was prevalent (157, 170, 
172, 176, 178-183). We used a Fisher's exact test to compare the level of knowledge 
stratified by the study settings. There was no difference in the level of knowledge by 
participants living in rural, urban and peri-urban (Appendix 6, supplementary table 
1b). 
Elements of knowledge frequently assessed were by asking parents, adolescents 
and/or teachers if they were aware of HPV. In addition, study populations were 
asked if they could correctly identify HPV as the causative agent of cervical cancer. 
Optimal knowledge on vaccination can be considered as basic and correct 
understanding of the disease, aetiology of the disease and the existing preventative 
vaccination measures available against the disease. In all studies on HPV, even 
though the study participants reported to be aware of cervical cancer, the 
participants were unaware of the HPV and vaccine to prevent the virus, as well as 
how the two are linked to cervical cancer (158, 170, 172-176, 179-184). Some study 
participants were reported to think that HPV vaccination could negatively influence 
the sexual behaviour and in general, cancer only affects women (170, 181). A similar 
observation was noted among study participants with moderate knowledge on TB 
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disease but low knowledge about the vaccines against TB (157). Two studies (11%) 
did not assess knowledge but assessed attitudes and practices towards adolescent 
vaccines (158, 175).  
Levels of knowledge among parents (157, 170-172, 174, 176, 179-184), adolescents 
(43, 157, 173, 176-178, 182, 184) and teachers (176, 184) were mixed ranging from 
low, moderate and high. There were no standardized criteria for categorizing 
knowledge as low, moderate or high across studies. However, we observed that the 
term low knowledge was generally used when less than 50% of participants had 
adequate knowledge on the specific information of the vaccine under evaluation. 
Similarly, the terms moderate and high knowledge were used when the participants 
with adequate specific information of the vaccine under evaluation was between 51-
70% and from 71% upwards respectively.  
Three studies (17%) demonstrated high levels of knowledge (two on HPV vaccines 
(173, 174) and three on cervical cancer (173, 174, 180) among parents and 
adolescents. Five studies (28%) reported moderate levels of knowledge, of which 
three were among parents, one study among teachers and three studies among 
adolescents on vaccines against HPV (172, 180, 184), rabies among adolescents 
(177) and TB disease among parents and adolescents (157). Levels of knowledge 
among parents, teachers and adolescents on vaccines against HPV and/or cervical 
cancer, TB, HIV and tetanus were found to be low in eleven (61%) studies (43, 157, 
170-172, 176, 178, 179, 181-183). We used a Fisher's exact test to assess if the 
level of knowledge was different among the three key participants. The level of 
knowledge did not differ among parents, teachers and adolescents (Appendix 6, 
supplementary table 1a).  
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Sixteen (89%) studies focused on attitudes and practices toward adolescent 
vaccines like tetanus, TB and cervical cancer among parents, adolescent and 
teachers (43, 157, 158, 170-175, 177-183)] while two (11%) studies did not assess 
attitudes or practices (176, 184). Most studies 14 (88%) showed that participants had 
positive attitudes towards vaccination against HPV, tetanus, TB and HIV (43, 157, 
158, 171-175, 177-180, 182, 183). 
Adolescents largely (58%) reported a positive attitude on vaccination against HPV 
(43, 157, 158, 173, 177, 178, 182). The two studies conducted among teachers did 
not report any outcomes on attitudes and practices on adolescent vaccination (Table 
13). Two (11%) studies reported negative attitudes towards HPV vaccines. Negative 
attitudes were beliefs that the vaccine might negatively influence adolescent sexual 
behaviour and that cancer only affects girls (170, 181). 
Main themes 
A) Acceptability and willingness to vaccinate adolescents: high acceptance levels of 
the HPV vaccine was reported among adolescents, reflecting a positive attitude 
(157, 170-172, 174, 179-183). In general, the data showed willingness by parents to 
get the adolescents vaccinated against HPV. Additionally, both parents and 
adolescents indicated willingness to accept HPV vaccination if the doctors 
recommended it (173, 180) and, if part of other childhood vaccines (181). In general, 
included studies did not report accessibility to vaccination services as well as the 
cost of the vaccines. However, three (17%) studies indicated that participants would 
agree to be vaccinated against HPV if access to the vaccine was easy and came at 
no extra cost (174, 179, 182). Regardless of vaccine acceptability, vaccine safety 
and sides effects were a major concern in one of the studies (180). 
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B) Need for education and awareness of adolescent vaccination: two studies 
suggested an increased need of education and awareness about cervical cancer, 
HPV and HPV vaccination (173, 174). Furthermore, participants in the studies with 
existing vaccination programmes reported a high level of knowledge (173-175). 
Existing programmes can therefore be used as a platform to educate and raise 
awareness on adolescent vaccines. Parents, teachers and adolescents understood 
the importance of being knowledgeable on adolescent vaccines, particularly HPV, its 
characteristics and associated risks, and the benefits of the HPV vaccine (158, 170, 
172-174, 176, 179-184). 
Quality assessment of the included studies 
All eight qualitative studies reported the aims of the studies and described the study 
methods. Ethics approvals, informed consents and confidentiality were reported in 
six studies while two studies did not report any information regarding ethics. All the 
eight studies described the recruitment process of the study participants. Largely, 
non-compliance with quality criteria for most records was due to unclear reporting of 
the methodology.  
Most of the qualitative studies (7/8 i.e. 88%) explained a minor concern on the 
assessment of methodological limitations, relevance, coherence, and adequacy of 
data. Six and one study had a minor and moderate methodological limitation 
respectively. All the studies were relevant to the African settings and data were 
reasonably consistent within and across all studies. Overall, all the studies had a rich 
data that addressed the research question and aim. Figure 25 and 26 show the 
details of the quality assessment of both the qualitative and quantitative studies 
respectively. 
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Figure 25: Risk of bias graph for qualitative studies                                
 
Figure 26: Risk of bias graph for quantitative studies 
 
Synthesis of evidence 
We scored the strength of the evidence for qualitative studies using CERQual (166) 
whereas for quantitative studies, we used the Hoy et al., scoring principles (165). We 
then classified the overall strength of evidence as high, moderate, low, or not clearly 
stated (165). The quality of evidence for quantitative studies was low, which implies 
‘further research is very unlikely to change our confidence in the estimate’ (Table 
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14). The confidence of evidence for qualitative studies was moderate, suggesting 
that ‘the review finding is a reasonable representation of the phenomenon of interest’ 
(Table 15). 
Table 15: Quality of evidence for quantitative studies 
Total no. 
of studies 
10 studies 
Overall 
score 
5 (Low risk) 
Overall 
score  
Quality 
0-5 points  Low Risk: Further research is very unlikely to change our confidence in the estimate 
6-8 points  Moderate Risk: Further research is likely to have an important impact on our confidence in the 
estimate and may change the estimate 
>8 points  High Risk: Further research is very likely to have an important impact on our confidence in the 
estimate and is likely to change the estimate. 
Source: https://www.ncbi.nlm.nih.gov/pubmed/22742910 (165) 
Table 16: Summary of finding table on the quality of evidence 
Summary of finding on the quality evidence of qualitative studies 
Population: Adolescents, teachers and parents 
Settings: South Africa [five studies], Uganda [one studies], Tanzania and Malawi [one study each] 
Intervention: No intervention 
Comparison: No comparison 
Outcomes Impacts No of 
Participants 
(studies) 
Quality of the 
evidence 
(CERQUAL) 
Knowledge, 
attitude and 
practice   
All studies showed an increase KAP toward 
adolescent vaccine but the impact is not 
evident in these studies 
669 
participants 
(8 studies) 
⊕⊕⊕⊝ 
Moderate* 
* We rated down the quality of the evidence by one points, because of minor concern on the 
assessment of methodological limitations in included studies. 
The CERQual approach—Definitions of levels of confidence in a review finding. 
High confidence: It is highly likely that the review finding is a reasonable representation of the 
phenomenon of interest. 
Moderate confidence: It is likely that the review finding is a reasonable representation of the 
phenomenon of interest 
Low confidence: It is possible that the review finding is a reasonable representation of the 
phenomenon of interest. 
Very low confidence: It is not clear whether the review finding is a reasonable representation of the 
phenomenon of interest. 
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Source: https://doi.org/10.1186/s13012-017-0690-9 (166) 
Discussion 
After a comprehensive assessment of 922 relevant records from several databases 
and grey literature, only 18 studies were included in our review. The included studies 
were conducted in 10 out of 54 African countries. The lack of many included studies 
and representation of only 10 countries highlight the enormous gap in adolescent 
vaccination research in the continent. Participants reported willingness to be 
vaccinated against HPV if access to the vaccine was easy and at no cost while 
vaccine safety and side effects were reported as major concerns in one study. 
Doctors’ recommendations on the need to be vaccinated as well as including 
adolescent vaccines in routine programmes were noted factors that could improve 
uptake of vaccines by adolescents. 
Our review showed low to moderate level of knowledge and positive attitudes among 
parents and adolescents on vaccination. However, we could not evaluate if the KAP 
could influence vaccine uptake as no study had assessed the association of these 
outcomes. Recommendations to be vaccinated, including having adolescent 
vaccines in the routine schedule, ease of access to vaccines as well as provision of 
free adolescent vaccination were reported as factors that may improve uptake of 
vaccines by adolescents.  
Irrespective of the study setting or country, there was a general lack of 
understanding of the vaccines and VPDs among the study participants. It appeared 
that participants from the rural settings were more likely to have a positive attitude 
towards vaccination, as well as to vaccinate their adolescents compared to 
participants in the urban settings. Two of the three studies that reported to have an 
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existing vaccination programme reported a high level of knowledge on the HPV 
disease and HPV vaccine, suggesting the importance of the existing programmes on 
improving KAP. 
Like a previous systematic review (68), our review identified low to moderate levels 
of knowledge, positive attitudes and practices on adolescent vaccines, especially 
against cervical cancer. Despite the low knowledge, there were high levels of 
acceptability of adolescent vaccination among teachers, parents and adolescents. 
We found that parents, teachers and adolescents understood the importance of 
being knowledgeable on adolescent vaccines, particularly against HPV. Sensitization 
programmes and communication strategies were reported as viable interventions to 
enhance knowledge and attitudes and promote improved coverage of adolescent 
vaccination. 
Africa has many public health challenges, among them, high burden of VPDs. Our 
findings show that research on adolescent vaccination is lacking in Africa. It was 
encouraging to find that both parents and adolescents have positive attitude towards 
HPV vaccination. These findings agree with high HPV vaccination coverage reported 
by the five countries that had introduced the HPV vaccine in Africa (130, 173, 185-
189). We propose that the lessons learnt from the HPV vaccination programme in 
Africa be used to develop and implement adolescent vaccination programmes in the 
continent.  
Other adolescent vaccinations against TB, tetanus, rabies and HIV were reported by 
the included studies. HIV and TB are endemic in Africa and the vaccines against 
these diseases are in advanced development stages; therefore, more research on 
adolescent vaccination in Africa is critical (16, 45). In Africa, tetanus vaccines are 
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currently given at health facilities and to antenatal mothers (178). There is need for 
local evidence on whether booster tetanus vaccines should be introduced to 
adolescents and possibly via school-based programmes as is the case in some 
settings (178). African countries with existing maternal tetanus vaccination 
programmes, and those that have introduced school-based adolescent HPV 
vaccination programmes will experience benefits of increased knowledge and 
awareness towards adolescent immunisation, and this will make it easier for the 
adolescents to accept other vaccines, such as tetanus, when required.  
The findings of our review are subject to several limitations. We searched only for 
papers and reports written in English. However, we crosschecked reference lists of 
the relevant records to identify any additional studies. Some studies did not clearly 
distinguish between attitudes and practices as outcomes. Therefore, in this review, 
we could not report these outcomes entirely separate. The quality of evidence from 
the included studies was not strong to give us confidence in making 
recommendations on this topic. However, continuous educational programmes to 
improve KAP on adolescent vaccination among the key stakeholders may prove to 
be a valuable health investment by the African governments. 
Conclusion 
There are two main themes that emerged in this review. Firstly, there are high levels 
of acceptability and willingness to vaccinate adolescents against HPV by all the three 
key groups: adolescents, teachers and parents. This holds true even when 
knowledge levels are low. Secondly, it is evident in the review that all the three key 
groups need to be educated more on adolescent vaccination as well as increased 
129 | P a g e  
 
awareness on the topic. Although attitudes were generally positive, lack of optimal 
knowledge may lead to misconceptions, which in turn hinders vaccine uptake. 
Contributions 
Leila Abdullahi wrote the protocol with supervision from Greg Hussey and Benjamin 
Kagina. Leila Abdullahi conducted the data extraction and risk of bias assessment 
alongside Tali Cassidy and Esther Adebayo in duplicate. Leila Abdullahi wrote the 
drafts of the review with support from Tali Cassidy, Esther Adebayo, Greg Hussey, 
Charles Wiysonge and Benjamin Kagina.  
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Chapter 5 
Challenges and lessons learnt during the introduction of human 
papillomavirus (HPV) vaccination programmes in Africa; A cross-sectional 
study 
About this chapter: 
We conducted a cross-sectional study to investigate the experiences, challenges 
and lessons learnt by key stakeholders (government representatives, funding 
agencies, National Immunisation Technical Groups (NITAGs) and implementing 
agencies) of the African countries that had introduced HPV vaccine to the adolescent 
population. The results generated from this study are useful to other countries that 
are planning to implement HPV vaccination into their national programme, especially 
in Africa. In addition, the study findings can help countries to better plan current and 
future HPV as well as other adolescent vaccine introduction.   
Publication: The study will be submitted to the Human Vaccines and 
Immunotherapeutics Journal. 
 
 
 
 
 
 
131 | P a g e  
 
Abstract 
Introduction: Infection with HPV significantly increases the risk of developing 
cervical cancer later in life. Therefore, globally, the introduction of HPV vaccine 
targeted to pre-adolescent and adolescent girls has been on the rise since the 
licensure of the vaccines from 2006 to 2009. However, the introduction of HPV 
vaccines has been relatively slow in Africa. As of the end of 2016, only eight of the 
54 African countries were reported to have introduced HPV vaccination at a national 
level. Our study aimed to investigate the experiences, challenges and lessons learnt 
by the key participants during national HPV vaccine introduction in Africa.  
Methods: A questionnaire was administered to selected key participants from eight 
African countries. The eight countries had successfully introduced HPV vaccine at a 
national level by the end of 2016. We used in-depth interviews and self-administered 
online questionnaires for data collection and analysis. Data reporting was blinded 
with no naming of the country or the key participants. Narrative and thematic 
reporting were used to describe the results. Permission to conduct the study was 
obtained from the Humans Research Ethics Committee (HREC) of the University of 
Cape Town. 
Results: We obtained results from six of the eight targeted countries. The 
challenges reported during HPV vaccination programmes were: identifying the target 
population, using school-based vaccine delivery strategy, obtaining political support, 
the need to integrate HPV vaccination with existing school health programmes and 
engaging diverse stakeholders. These challenges were similar in all the six 
countries. Lesson learnt was school-based delivery strategy is a successful 
approach for national HPV vaccination. Another lesson was that, identifying the girls 
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for vaccination at schools was less challenging if implemented through a class-based 
and not an age-based approach. 
Conclusions: Most African countries do not have established platforms to deliver 
vaccines to pre-adolescent and adolescent populations. The successful introduction 
of HPV vaccine through school-based vaccination strategies among African 
countries may have created a platform to deliver other adolescent vaccines. The 
similarity of the study findings across the six participating countries further 
strengthens the need to document and disseminate the challenges and lessons 
learnt during HPV vaccine introduction in Africa. Documentation and dissemination 
of the challenges as well as lessons learnt is useful to other countries in Africa that 
plan to introduce the HPV vaccination programme, and possibly, other adolescent 
vaccines. 
Key words: HPV vaccine, Implementation, Immunisation programmes, School-
based vaccination, adolescents 
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Background  
Implementation of global, regional and national immunisation policies plays an 
important role in combating the burden of VPDs (190). An important policy strategy 
to combat VPDs in many countries is the strengthening of the EPI which in turn 
support the introduction of new vaccines. African countries have traditionally lagged 
behind the HICs in the introduction of new vaccines (191). It is therefore not 
surprising that even after several years post HPV vaccine licensure, only a handful of 
African countries had introduced the vaccine as at 2016 (62).  In Africa, introduction 
of new vaccines such as that against HPV may be accelerated in countries with 
functional NITAGs. 
The NITAGs are established and mandated to give advice to the national health 
departments on immunisation, with the aim of strengthening the EPI and as a result, 
advocate for the introduction of new vaccines (74). Functional NITAGs collaborate 
with the departments of health and other key stakeholders to strengthen the EPI. 
This collaboration is essential for the introduction of new vaccines, as well as 
expansion of immunisation services to all populations. South Africa, one of the very 
first countries to introduce national HPV vaccination programme to school-aged girls 
in Africa has one of the oldest NITAG in the region (192). 
In Africa, similar to many other regions, the primary focus of EPI is the delivery of 
immunisation services to children, and not to adolescents, adults and the elderly (5). 
As a result of the EPI focus to children, structured delivery of immunisation services 
to the adolescents is suboptimal in many African countries (193). As new vaccines 
targeting adolescents such as against HPV become available (37), there is need to 
expand the delivery of immunisation services to the adolescent population.  
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African countries continue to record a more rapid increase of adolescent population 
than countries in other continents (3). There is evidence on the benefits of 
vaccinating adolescents, which include boosting of the waning immunity induced 
during childhood (36, 42). Furthermore, initiatives on immunisation, such as GIVS, 
GVAP and SDGs have supported the call to extend immunisation services to 
adolescents (16, 17, 30). Therefore, African countries will need to invest more 
resources and develop national immunisation policies that specifically target 
adolescents.   
In this study, we evaluated the lessons and challenges learnt by a few African 
countries that had nationally implemented vaccination against HPV as at 2016. 
Infection with HPV significantly increases the risk of developing cervical cancer later 
in life (29). Additionally, HIV infected men as well as men who have sex with other 
men have an increased risk of anal, penile and throat cancers associated with HPV 
infection (194).  
Globally, cancer of the cervix is the fourth most common cancer among women 
(195). In 2012, cervical cancer accounted for 15% of all cancers among women 
(195). In Africa, programmes to combat cancer are compounded by multiple health 
priorities (196). Vaccinating adolescents against HPV offers an effective intervention 
of preventing cervical cancer in all settings (99, 197).  
The primary target group for HPV vaccination is girls aged 9–13 years (198), prior to 
the onset of sexual activity (75, 76). Despite the HPV vaccines’ proven safety, 
efficacy and cost-effectiveness, only eight African countries had reported HPV 
vaccine introduction at a national level by the end of 2016 (99).  The countries were: 
Libya, Lesotho, Rwanda, Uganda, South Africa, Botswana, Mauritius and Seychelles 
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(99). The delay in HPV vaccine introduction among African countries could be due to 
many reasons such as awareness, resource limitations and absence of adolescent 
vaccination programmes (43). 
The national departments of health, funding and implementing partners as well as 
NITAGs are key stakeholders in the introduction of HPV vaccines in Africa. To our 
knowledge, the experiences, challenges and lessons learnt by the key stakeholders 
involved in HPV vaccine introduction in Africa are not aggregated. Findings from our 
study are useful to other countries that will introduce HPV vaccines in Africa.  
Objective 
To investigate the reported experiences, challenges and lessons learnt during HPV 
vaccine introduction by eight African countries. 
Methods 
In this study, we adhered to the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines (Appendix 7).  
Ethics  
Prior to the start of the study, ethical approval was obtained from the HREC of the 
Faculty of Health Sciences, University of Cape Town (HREC Ref: 703/2015) 
(Appendix 10). Written participation consent forms were obtained from the study 
participants. Example of participant information and consent form are available on 
Appendix 8. Confidentiality was observed during the interview process with the use 
of blinded transcripts.  
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Inclusion criteria 
All countries in Africa that had implemented national HPV vaccination programme in 
2016. 
Sample size 
This was not a hypothesis testing study. Hence, we did not calculate the required 
sample size. Our target sample size was all countries in Africa with national HPV 
vaccination programme as at 2016. From the eight countries that had implemented 
national HPV vaccination programme in Africa, one key representative (convenient 
sampling) was invited to participate. 
Study design and period 
A cross-sectional study conducted between 2015 and 2016.  
Recruitment of the study participants 
In November 2015, we identified and sent invitations to key representative from five 
African countries. In addition, in November 2016, we invited key representatives from 
additional three African countries. All invited representatives were from countries that 
had introduced national HPV vaccination in 2016. The selection of the 
representatives was done through referral sampling (contacts from academics, 
implementing agencies and governments). The key representatives were defined as 
members of NITAGs, officials from the departments of health at national level as well 
as from international organisations such as the WHO and UNICEF. To participate in 
the study, the key representatives must have been actively involved in the 
introduction of the HPV vaccination programme in the selected countries.  
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Questionnaire administration 
Prior to interviewing the participants, a questionnaire was developed and pretested. 
The pretesting was aimed at enhancing clarity and accuracy of the data collection 
process. The pretesting was done by administering the questionnaire to four different 
persons involved in the implementation of HPV vaccination programme in South 
Africa. During the pretesting process, we developed an interviewer guide with a set 
of questions aimed at helping the interviewer to direct the conversation towards the 
topics of interest. The interview guides are shown in Appendix 9.  
One of the study team members (LHA) administered the questionnaires to all the key 
representatives. Five representatives from five countries were interviewed via face-
to-face while attending a vaccinology course held in South Africa. One 
representative from the sixth country completed the questionnaire remotely after we 
sent the questionnaire via email.  
Missing data 
Two representatives from the seventh and eighth countries never responded to the 
questionnaires we sent to them via email. Follow up telephone calls to these two 
representatives to get them complete the questionnaires were unsuccessful.  
Data management and analysis 
Five of the face-to-face interviews were digitally recorded. The digitally recorded data 
were coded with ATLAS (version 6) for analysis. From the questionnaire completed 
and sent via email, data was abstracted for analysis and reporting. Data reporting 
was blinded: no naming of the country or the participant. Narrative reporting and 
grouped themes were used to describe the results based on the most common 
words and terms that were similar and repetitively used by the key representatives.  
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Results 
In total, six key representatives out of the eight targeted provided data for this study. 
The six representatives were from six different countries. The descriptive 
characteristics of the six representatives interviewed are shown in Table 16.  
Table 17: Characteristics of the key stakeholders interviewed 
Country 
code 
Type of 
organisation 
Position held 
by the representative 
Role in HPV vaccination 
programme 
    
A Government Programme manager Adviser on implementation of 
programme 
B Government EPI director In-charge of implementation 
of programme 
C  International 
organisation 
New vaccine focal person Adviser on implementation of 
programme 
D Government Programme manager In-charge of implementation 
of programme 
E Government Programme manager In-charge of implementation 
of programme 
F Government Programme manager In-charge of implementation 
of programme 
From the six participants interviewed, information about the targeted population for 
vaccination as well as the HPV vaccination delivery strategy used is provided in 
Table 17.   
Table 18: Characteristics of the population targeted for vaccination and 
delivery strategies used to deliver HPV vaccine 
Countries Sex targeted Vaccine delivery  
approach 
Target age 
group 
    
A Female School-based  9-13 
B Female School-based  9 
C  Female School-based    10 
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D Female School-based    12 
E Female School-based   9-13 
F Female School-based  9-12 
Challenges during the implementation of the national HPV vaccination 
programme 
Using data collected from the six countries, we grouped the challenges and lessons 
learnt during the implementation of the national HPV vaccination programme into 
themes. Thematic challenges and lessons reported by the participants were very 
similar in all the six countries (Table 18).  
The participants from all the countries reported the following as challenges: 
identifying the target population group for HPV vaccination, obtaining political 
support, using school-based vaccine delivery strategy, integrating HPV vaccination 
programme with existing school health programmes, and engaging multiple 
stakeholders. 
Identifying the target age group 
All the countries represented in this study opted to deliver HPV vaccination through 
the school-based strategy and targeted girls only. At schools, there was need to 
correctly identify girls aged between 10 to 13 years who are the target group for HPV 
vaccination. To identify the girls, a challenge was encountered. The challenge was 
on whether to use grade-based or age-based approach to identify the girls for HPV 
vaccination.  
For example, during the piloting of the HPV vaccination, country A (Table 17) started 
with age group 9 to18 years but due to logistic constraints, this target age group 
could not be optimally reached. Hence, some girls missed the intended HPV vaccine 
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at school and were referred to the nearest health facilities. Subsequently, during the 
national roll out, all the six countries reported that HPV vaccination programme was 
implemented using class-based approach. This approach presumed that the 
targeted (10-13 years old) age group, which is recommended for HPV vaccination by 
WHO (198), will be found in a given class.  
The HPV vaccination schedules were synchronized with the academic calendar to 
avoid loss to follow-up. In addition, school teachers played a crucial role to assist in 
the follow-up and regularly communicated information on the vaccination dates to the 
targeted girls. Primary schooling in all the six participating countries is compulsory, 
hence school-based strategy was chosen as the most efficient strategy to reach the 
highest number of targeted girls with HPV vaccination. The school-based delivery 
strategy was complemented by an outreach strategy, like health facility strategies to 
vaccinate non-school going girls. 
Using school-based vaccine delivery strategy 
In Africa, as is the rest of the world, the EPI routinely focusses on delivering 
vaccination services to children. In the absence of an existing vaccination platform to 
reach pre-adolescent and adolescent girls with HPV vaccines, new vaccine delivery 
strategy was needed. During the period of HPV vaccine introduction by the African 
countries, there was evidence from high income countries such as Canada showing 
school-based programme is feasible (199).  
Participants in our study reported the introduction of HPV vaccines through the 
school-based strategy required the departments of health and education to develop 
a new collaborative partnership. The collaborative partnership involved the 
department of health’s EPI programme take lead with HPV vaccine demonstration 
initiatives while the department of education led the school-based initiatives such as 
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engagements with the learners and their parents.  The co-ordination of these inter-
departmental initiatives for optimal delivery of HPV vaccination was reported as a 
challenge. Prior engagement meetings between officials from both departments were 
necessary to ensure complete and on time dosing of the HPV vaccines to the 
targeted girls. Such engagement meetings were reported to be operationally 
demanding and time consuming. 
Obtaining political support  
During the pilot phase, all the six countries reported the demonstration results of 
HPV vaccination programme were shared with parliamentarians to solicit for political 
support. The parliamentarians showed interest in the vaccination programme from 
the start and this political support facilitated the necessary commitment from the 
government to scale up to the national level. Political leadership may change after a 
limited period whereas the vaccination programme is a long-term intervention. The 
participants indicated that a possible lack of political support in the future could 
compromise the national HPV vaccination programme. 
Integrating HPV vaccination with existing school health programmes  
Some countries have existing school health programmes (such as vision screening, 
deworming and nutritional supplementations) for school-aged children who may also 
be the target group for HPV vaccination. Country B, as an example reported to have 
a vision screening programme among grade 5 learners at primary schools. Grade 5 
learners were also targeted by the HPV vaccination programme in the country. Most 
of the existing school health programmes are characterized by a single visit to the 
institutions by the health care providers as opposed to HPV vaccination which, 
depending on whether two or three doses, requires more than a single visit. 
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Furthermore, health service teams from the department of health and not the HPV 
vaccination teams are involved with the existing school health programmes. The use 
of two different teams from one department of health visiting the same school with 
different aims was reported as a challenge. In country B for example, there was an 
observed need to harmonize the implementation of these two health programmes 
(vision screening and HPV vaccination). Although this was reported as a challenge in 
terms of logistics, it can also be an opportunity to integrate the provision of school 
health services.  Therefore, future plans by many countries are to have new school-
based health interventions piggy back on the HPV vaccination programme, provided 
the additional logistical challenges are addressed. 
Engaging multiple stakeholders  
Multiple stakeholder engagement was mentioned as a challenge by all participants. 
Unlike an established EPI where delivery of vaccination services is routinely 
common and generally accepted, HPV vaccination was different in many ways, 
among them being the targeted population (adolescents) and delivery through the 
schools. The multiple stakeholders engaged included parliamentarians, key officials 
from the department of education including the school heads and teachers, learners 
as well as the parents. Engaging the diverse stakeholders was reported as time 
consuming and laborious. Additionally, obtaining consents to get vaccinated (which 
is not the case with EPI) was also needed from learners and their parents.  This was 
reported as a challenge.    
The participants voiced funding challenges that required collaboration of local and 
international organisations to secure complementary financial, technical and 
operational support.  
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Table 19: Documented experiences during the implementation of the national HPV vaccination programme 
Identifying the 
target age group 
Using school-based 
vaccine delivery strategy  
Obtaining the 
political will 
Integrating HPV 
vaccination with existing 
school health programmes 
Engaging multiple 
stakeholders 
Challenges experienced 
Target age of 9-13 
years- routinely, this 
age group is not 
targeted for 
vaccination among 
African countries. A 
new strategy was 
therefore needed to 
correctly identify the 
age group, and this 
proved to be a 
challenge.   
School-based vaccine 
delivery strategies - unlike 
EPI which is well 
established among many 
African countries, routine 
school vaccination 
programme is not well 
established. Participants 
interviewed reported the 
extensive consultative 
planning that preceded the 
vaccination as a challenge.     
Parliamentarians 
involved during HPV 
implementation plan- 
the benefits of 
political support are 
well recognized in 
promoting 
vaccination 
programmes. The 
participating 
stakeholders raised 
concerns of the hard 
work needed to gain 
the support of 
prominent politicians 
during the 
implementation of 
the HPV vaccination 
Integration of the HPV 
vaccination with existing 
school health programme- 
School-based vaccinations 
as well as provision of other 
health services inadvertently 
results to disruption of 
learning. To minimize the 
learning disruptions while 
maximizing the benefits, HPV 
vaccination can be delivered 
together with other existing 
school-based health 
programmes. Planning how 
best to achieve the 
integration of all health 
programmes at school was 
identified as a future 
challenge as well as an 
Several key stakeholders 
that were engaged 
included, officials from the 
departments of education 
as well as the school 
heads and teachers, 
parents as well as 
partners of the 
departments of health-
sustained and diverse 
stakeholder engagements 
was noted as a challenge 
and crucial element to the 
success of HPV 
vaccination. Maintaining 
multiple stakeholder 
engagement was listed as 
a challenge.  
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opportunity. 
Lessons learnt 
Feasible to select 
eligible girls based 
on grade/class as 
opposed to the 
specific age by use 
of the birth records. 
Schools can successfully 
be used as a venue for 
HPV vaccinations. This is 
applicable in countries 
where primary school 
enrolment is high.  
Political 
endorsement is 
critical to community 
acceptance. The 
political 
endorsements 
received during the 
HPV vaccination 
programmes can be 
expanded to include 
other vaccines to 
strengthen 
immunisation 
through political 
support. 
Integration can reduce the 
costs of the programme. 
There exists an opportunity 
to provide additive health 
services together with the 
HPV vaccination programme. 
The integration is seen as an 
opportunity to improve health 
service delivery to the school 
going children with minimal 
disruption to the educators 
and learners.  
Coordination of various 
stake holders is crucial for 
successful 
implementation of national 
HPV vaccination 
programme 
145 | P a g e  
 
Lessons learnt during the implementation of national HPV vaccination 
programmes in the six countries 
Lesson 1: In school, identifying eligible girls for HPV vaccination based on the 
grade/class is more feasible than by age. However, some eligible girls born after mid-
year are likely to be missed during HPV vaccination if already in the higher grade. The 
proportion of this missed population need to be quantified.  
Lesson 2: School-based delivery strategies can be successfully used to deliver HPV 
vaccines to learners among African countries with high primary school enrolment. In 
case of missed vaccination opportunities, healthcare facilities can be used as venues 
for catch up vaccinations. Delivery of HPV vaccines through school-based programmes 
may also achieve high coverage levels, if there is high school enrolment in the targeted 
age group. 
Lesson 3: Obtaining political support during the implementation of the HPV vaccination 
programme is crucial. In addition, political endorsement by national and district 
government leaders is critical for community acceptance. 
Lesson 4: Integrating HPV vaccine programme to existing school-based health 
programmes is a logistical challenge but also, an opportunity as the integration can 
reduce the costs of the health programmes delivered to school-aged learners. 
Lesson 5: Adequate preparation, engaging diverse and relevant stakeholders including 
teachers and parents is crucial to ensure the successful implementation of an HPV 
vaccination programme. 
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Lesson 6: Additional support from local and international partners is needed to ensure 
sustainability of the HPV vaccination programmes. Support by local partners is crucial to 
ensure HPV vaccines get to the hard to reach populations in a timely manner. 
Discussion 
In this study, we identified the challenges and lessons learnt during the implementation 
of HPV vaccination programmes. Inter-departmental co-ordination, identifying the target 
age group for HPV vaccination, obtaining political support and engaging diverse 
stakeholders were reported as the main challenges. The challenges were similar among 
the African countries that have implemented HPV vaccination programme. The 
similarities of the challenges across the study countries were surprising as the 
continent’s immunisation challenges are not homogenous (200). However, in general, 
countries in Africa have many similar competing public health priorities and the 
continent has lagged with DTP3 coverage (200-202).  
The delivery of HPV vaccines to the school girls required prior engagements and the co-
ordination of the departments of health and education. Both departments had to plan 
around the timing of vaccinating the girls during the school period. Additionally, the 
departments of health had to plan on logistical delivery of the vaccines and the health 
workers to the schools.  Despite these challenges, our results suggest good leadership 
and careful co-ordination could overcome these challenges. Furthermore, lessons learnt 
from this co-ordination can be used to integrate existing and future school-based health 
interventions with HPV vaccination to expand the delivery of vaccines to the 
adolescents (203, 204).  
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The WHO guidelines recommend the ideal target population for HPV vaccination be 10-
13 years old, before onset of sexual activity (198). However, among the participating 
countries, it was difficult to accurately establish the right age of the girls before sexual 
activity. This is likely to be the case among many African countries not participating in 
this study. Research on sexual debut years for adolescents in Africa can guide optimal 
choice of age to initiate HPV vaccination.  
A few African countries that started to pilot HPV vaccination with age-based approach 
used the birth date records to identify the age of the girls eligible for vaccination. This 
age-based approach presented a challenge as the birth date records were often not 
available. On the other hand, the challenge with the class-based approach was that 
children who are born mid-year may miss vaccination as they will have moved to the 
next class not targeted for HPV vaccination. Hence, if the missed targeted population is 
large, the effectiveness of HPV vaccination programmes in such countries will be sub-
optimal, not forgetting that boys are not targeted by the programme. The approach to 
select girls for HPV vaccination based on grade as opposed to age through school-
based vaccination strategy appeared universally ideal in our study.  
The study participants alluded to the huge effort needed to obtain political support as 
well as reach a consensus among diverse and key stakeholders. In all the participating 
countries, endorsement of the HPV vaccination programme by the politicians was a pre-
requisite. Political leadership that understands and embraces the value and public 
health benefits of immunisation is therefore crucial for national HPV vaccination 
programme in Africa. 
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Resource mobilisation for HPV vaccination programmes required engagements of 
diverse stakeholders. Broadly, advocacy and communication were needed to address 
this challenge. Many African countries, with support from international partners have 
made considerable progress to strengthen advocacy and communication on 
immunisation services (200). However, in Africa, as is the case globally much more 
effort is still needed to improve advocacy and communication on vaccination (205, 206). 
The lesson learnt from this challenge was the support by local and international 
partners, including politicians is crucial to initiate and sustain the HPV vaccination 
programmes in Africa. The sustainability will need strengthened advocacy and 
communication, not just for HPV vaccination, but for other routine immunisation 
services. 
In this study, primary schooling in all the six countries was compulsory. This made the 
school-based vaccination strategy the preferred method to reach the highest number of 
targeted girls with HPV vaccination. However, school-based vaccination strategies may 
not be entirely successful in countries with suboptimal school attendance rate. There is 
a study that has shown supplementary immunisation activities (SIAs) including the use 
of outreach health facilities could be an option to target non-school going adolescents 
(207). 
We propose collaboration among African countries to document and share the lessons 
learnt during HPV vaccine introduction. There is a recent study showing high inter 
country collaboration on immunisation research in Africa (208). We identify 
collaborations that document and share immunisation research information as platforms 
to foster further discussions on the introduction of other adolescent vaccines. The 
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lessons learnt by the countries included in this study can be of great use to other African 
countries planning to introduce national HPV vaccination programmes.  
Conclusion 
All the six countries used schools as the main sites for vaccination. Most targeted girls 
attended school due to the universal and free primary education programme in these 
countries. Schools therefore provided an easy and convenient site to access the eligible 
population. The school team that included the head teachers, teachers and school 
management embraced the HPV vaccination programme. The school team worked 
closely with the department of health to ensure there was minimal disruption of classes 
and the vaccination day does not coincide with important school programme like exam 
sessions. For situation where targeted learners are inevitably absent on vaccination 
days, health facility approach can be used to catch up and mop up. 
Limitations and validity of the study 
Out of 54 African countries, findings for this study are from six countries only, for 
reasons already provided in the methods section. This limitation is further compounded 
by the fact that we only interviewed one representative per country. Therefore, 
extrapolation of the findings to the entire continent must be done with caution. Another 
limitation is the use of questionnaires alone to collect data, without conducting focus 
group discussions. This was because of resource limitations. 
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Chapter 6 
Discussion and conclusion 
About this chapter: 
The chapter summarizes all the key findings from the PhD project and implications for 
policy and practice. We also discuss the projects’ strengths and limitations. 
 
The purpose of the PhD thesis was to characterize adolescent immunisation in the 
Decade of Vaccines. We used multiple approaches to successfully achieve this. Results 
and discussions of each of the approach are provided in detail in each of the chapters. 
Therefore, in this final chapter, we provide a succinct summary of the key findings as 
well as recommendations for considerations on adolescent immunisation by the policy 
makers. 
Key findings: 
There are several public health reasons suggesting that immense benefits could be 
achieved if adolescent immunisation is implemented in all settings. Recently the global 
community through a number of initiatives have advocated for adolescent immunisation 
to reduce the burden of VPDs among adolescents. The rapid introduction of HPV 
vaccination programme in many countries attests to this commitment. However, many 
other vaccines that are beneficial to adolescents are not routinely provided to this 
population in many countries. As a result, there exist an adolescent immunisation gap. 
We recommend more effort from individual countries and more support by the global 
community to address the immunisation gap.  
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In many settings, there is paucity of data on the vaccination coverage among 
adolescents, especially in LMICs. This is partly because routine adolescent 
immunisation is not well established in LMICs. Nevertheless, we can assume that apart 
from HPV vaccine, uptake of other adolescent vaccines is low in many countries. We 
showed that diverse barriers can contribute to suboptimal uptake of adolescent 
vaccines. These barriers are likely to be context specific. Understanding and removing 
these barriers are key steps to address the immunisation gap. We therefore recommend 
improved research, advocacy, communication and engagement by all immunisation 
stakeholders to address the adolescent immunisation gap. 
Existing research from HICs shows different types of strategies or interventions can be 
effective in improving the uptake of vaccines among adolescents. However, research on 
strategies to improve vaccine uptake among adolescents in LMICs is limited. In LMICs, 
we recommend context specific research to translate evidence into action, 
concomitantly addressing the adolescent immunisation gap.   
Optimal stakeholder knowledge on vaccines and VPDs is crucial for adolescent 
immunisation programmes. Educating the key stakeholders, in particular parents, 
teachers and adolescents, can positively influence the attitudes and practice towards 
vaccination and may have several long-term benefits. For example, well informed 
adolescents as future parents, are more likely to encourage their children to be 
vaccinated. We recommend countries to develop and implement educational 
programmes, aimed at enhancing relevant knowledge on vaccines, immunisation as 
well VPDs among the key stakeholders.  
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In Africa, as is the case in many other LMICs, introduction of HPV vaccines is seen as 
an ideal platform to build adolescent immunisation as well as provide other health 
interventions targeted towards adolescents. There were significant challenges 
experienced during the introduction of national HPV vaccination programme in these 
African countries. From the challenges experienced, key lessons were learnt, among 
them being that schools are convenient sites to access and vaccinate adolescents. 
School-based vaccination platform can be supplemented by health facilities and 
outreach programmes to reach all the adolescents.  
We recommend African countries planning to implement national HPV vaccination to 
document and publicly disseminate the experiences and lessons learnt in the 
implementation process. Collation and dissemination of such information, together with 
our findings will be very useful to many other African countries planning to do likewise. 
Importantly, the information can be used by all countries in Africa to develop evidence-
based adolescent immunisation programmes. 
Between 2015 and 2016, we conducted a study on challenges faced by eight African 
countries that had introduced national HPV vaccination programme. Worrying, no 
additional countries in Africa are reported to have introduced HPV vaccine two years 
later (2018). This is a big concern considering the documented benefits of HPV 
vaccination programmes in Africa. We recommend strong advocacy programmes in 
Africa to address the adolescent immunisation gap.   
Strengths of the projects 
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1. We used evidence-based approach to answer most of our research questions. 
Evidence-based research is a robust method used to generate information that in 
turn, can be used to strengthen an immunisation programme. 
2. There is paucity of knowledge on adolescent immunization, mostly in Africa. 
Hence this study contributes to the knowledge base in the field. 
3. In chapter 5 the focus was on countries in Africa implementing HPV vaccination. 
The experiences and challenges are useful for other countries planning to do so 
as well. 
 
Limitations of the projects 
1. Majority of available evidence on adolescent immunisation was for HPV vaccine. 
There was limited information on a catch up, booster or future adolescent 
vaccines 
2. HPV implementation in Africa is a new concept and its implementation is 
happening slowly hence paucity of data. 
3. In Chapter 5 as an example, we found that the respondents gave similar 
experiences and challenges of a school based programme as a successful 
platform therefore, the study might not have information for the countries that 
need to try other methods of implementing HPV vaccination like health facility 
based programme. 
Contributions 
Leila Abdullahi wrote this chapter under the supervision of Prof. Greg Hussey, Dr. 
Benjamin Kagina and Prof. Charles Wiysonge. 
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Appendices 
Appendix 1: Methodological Expectations of Cochrane Intervention Reviews 
(MECIR) Checklist. (Chapter 3) 
  
 
Methodological Expectations of 
Cochrane Intervention Reviews  
Intervention Cochrane Review - checklist for authors 
This checklist is designed to help you (the authors) complete your Cochrane Review. Please complete 
each item in the checklist by entering Y (or N/A if item is not applicable to your Cochrane Review) into 
the blue shaded cells before checking your Cochrane Review into Archie, and email the completed 
checklist to: cohg@manchester.ac.uk.  The editorial team will return your Cochrane Review to you if the 
form is incomplete or not received. There is a ‘Notes’ section at the end of the form to alert the editorial 
team to the reason for any incomplete checks. 
The checklist should be used in conjunction with the Cochrane Handbook for Systematic Reviews of 
Interventions (www.cochrane-handbook.org) and the Methodological Expectations of Cochrane 
Intervention Reviews (MECIR; ww.editorial-unit.cochrane.org/mecir). MECIR includes methodological 
standards for the conduct of reviews (items C1-C80) and for the reporting of reviews (items R1-R108). 
Cochrane Review title: Improving vaccination uptake among adolescents 
Cochrane Review number: N/A 
Contact person: Leila H Abdullahi 
Date: 27/12/2018 
1. General 
1.1 Y All the authors listed on the Cochrane Review have seen and approved this version of the 
Cochrane Review, and take full responsibility for the accuracy of its contents. 
1.2 Y Incorporated any standard text provided by the Cochrane Review Group (CRG). 
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1.3 Y Activated the relevant headings in RevMan and completed each section. 
1.4 Y Completed a validation check in RevMan (File menu > Reports > Validation report), and made 
corrections where possible. 
1.5 Y Completed a spell check in RevMan (Tools menu > Check spelling). 
1.6 Y The text is clearly written and all technical and medical terms are explained for non-expert readers. 
2. Title and review information 
(see Cochrane Handbook Section 4.2; MECIR standards R1, R2, R35) 
2.1 Y Title is the same as the published Cochrane Protocol, unless a change has been agreed with 
the CRG. 
2.2 Y Authors are listed in the correct order and have agreed to the order in which they are listed. 
2.3 Y Names and details of all authors and the contact person appear correctly, or the CRG has 
been notified of any necessary corrections. 
2.4 Y Entered the last date on which every component of your search was up-to-date in the ‘Date 
of search’ field. If your sources were searched on several different dates, entered the earliest 
date. 
2.5 Y Completed the ‘Next stage expected’ field, estimating when you will update the Cochrane 
Review (usually after two years). 
3. Abstract 
(see Cochrane Handbook Section 11.8; MECIR standards R3 to R13) 
3.1 Y Included 1000 words or fewer (though with a preference for them to be up to 700 words 
only).  
Background 
3.2 Y Explained the context or elaborated on the context, purpose and rationale of the review.  
Objectives 
3.3 NA Expressed in the form ‘To assess the effects of [intervention or comparison] for [health 
problem] for/in [types of people, disease or problem and setting if specified]’. 
Search methods 
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3.4 Y Provide the date of the last search from which records were incorporated into the review, and an 
indication of the databases and other sources searched. 
Selection criteria 
3.5 Y Summarize eligibility criteria of the review including information on study design, population and 
comparison. 
Data collection and analysis 
3.6 Y Summarize any noteworthy methods for selecting studies, collecting data, evaluating risk of bias and 
synthesising findings. For many reviews it may be sufficient to state “We used standard methodological 
procedures expected by The Cochrane Collaboration”. 
Main results 
3.7 Y Included the total number of studies and participants. 
3.8 Y Provide a brief description of key characteristics that will determine the applicability of a body of 
evidence (e.g. age, severity of condition, setting, study duration). 
3.9 Y Provide a comment on the risk of bias. 
3.10 Y Report findings for all primary outcomes irrespective of strength and direction of the result, and 
availability of data. 
3.11 Y Ensure that any findings related to adverse effects are reported. If adverse effects data were sought, 
but availability of data was limited, this should be reported. 
3.12 Y Included the same summary statistics as those in the review, and presented statistics in a standard way 
(e.g. ‘OR 2.31; 95% CI 1.13 to 3.45’).  Ensure that readers will understand the direction of benefit and 
the measurement scale used and that confidence intervals are included where appropriate. 
3.13 Y Included risks of events (percentage) or averages (for continuous data) for both comparison groups.  
3.14 Y Ensure that key findings are interpretable or are re-expressed in an interpretable way. For instance, 
they might be re-expressed in absolute terms (e.g. assumed and corresponding risks, NNTs, group 
means), and outcomes combined with a standard scale (e.g. SMD might be re-expressed in units that 
are more naturally understood. 
3.15 Y If overall results are not calculated, included a qualitative assessment or a description of the range and 
pattern of the results. 
3.16 Y Added no information that is not in the Cochrane Review. 
Authors’ conclusions 
3.17 Y Included a succinct conclusion drawn directly from the findings of the review. 
3.18 Y Avoided giving advice or recommendations. 
3.19 Y Included any important limitations of data and analyses. 
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3.20 Y Ensure that reporting of objective important outcomes, results caveats, and conclusion is consistent 
across the text, abstract, PLS and SOF. 
4. Plain Language Summary 
(see Cochrane Handbook Section 11.9) 
 
4.1 Y The Plain Language Summary title is the same as the Cochrane Review title, or restates the 
title using plain language terms. 
4.2 Y Included 400 words or fewer, and considered using section headers to aid readability. 
4.3   Y Included a statement about why the review is important (e.g. a plain language definition of 
and background to the healthcare problem, signs and symptoms, prevalence, description of 
the intervention and comparison and the way they are used, and the questions to be 
answered by the review). 
4.4 Y Included the date up to which studies have been searched and incorporated. 
4.5 Y Included the main findings of the review (e.g. numerical summaries in a general and easily 
understood format), including the primary outcome and adverse effects, even if the results 
were not statistically significant or no results were found. The word ‘risk’ has been avoided 
when reporting harms. 
4.6 Y Included the total number of studies and participants. 
4.7 Y Included a brief comment on any limitations of the review (e.g. studies with a high risk of 
bias, inconsistent results between trials, deviations from the intended population or 
intervention, imprecise results). 
4.8 Y The results and conclusions are consistent with those in Cochrane Review text and abstract. 
4.9 Y Added no information that is not in the Cochrane Review or abstract. 
5. Background, Objectives and Methods 
(see Cochrane Handbook Section 4.5; MECIR standards R19 to R54) 
5.1 Y All sections are the same as those in the published Cochrane Protocol, or any changes have been noted in 
the ‘Differences between protocol and review’ section, including new methods added and planned 
methods that could not be implemented (e.g. due to lack of data). 
5.2 Y Changed the text referring to the methods of the Cochrane Review from the future tense to the past 
tense. 
5.3 Y Consulted the CRG Trials Search Co-ordinator regarding implementation of the search strategy. 
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5.4 Y In the ‘Search methods for identification of studies’ section, reported the date range for which each 
source was searched, and the dates on which each search was conducted. 
5.5 Y In the ‘Search methods for identification of studies’ section, included a link to the Appendix containing 
the complete set of search terms used in each electronic database. 
6. Results 
(see Cochrane Handbook Section 4.5) 
6.1 Description of studies 
(see MECIR standards R55, R56, R57, R58, R59, R61) 
6.1.1 Y Reported the outcomes of the search, including the total number of hits found from 
electronic databases, the number of potentially relevant studies found from other sources, 
the number of records remaining after duplicates were removed, the number of papers 
retrieved in full text, the number of papers excluded at each stage with the reasons for 
exclusion, and the final number of included studies. 
6.1.2 Y Included links to the ‘Characteristics of included studies’, ‘Characteristics of excluded studies’ 
and, if appropriate, ‘Characteristics of studies awaiting classification’ and ‘Characteristics of 
ongoing studies’ tables. 
6.1.3 Y If contact with the authors of any included studies was attempted, reported how many were 
contacted and what responses were received. 
6.1.4 Y Given a brief overview of the studies included in the Cochrane Review, including the number 
of participants, and the comparability of their populations, settings and interventions. 
6.1.5 Y No results from studies have been reported in this section. 
6.2 Risk of bias of included studies 
(see MECIR standards R73 to R74) 
6.2.1 Y Given a concise summary of general risk of bias in the results of included studies, including 
variability across studies and any important flaws in individual studies. 
6.2.2 Y The summary of the risk of bias is consistent with the information presented in the ‘Risk of 
bias’ tables. 
6.2.3 Y Included a link to the ‘Characteristics of included studies’ table. 
6.2.4 Y If any ‘Risk of bias’ figures have been created, included a link to these. 
6.3 Effects of interventions 
(see MECIR standards R75 to R77, R79 to R91, R95 to R98) 
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6.3.1 Y Summarised the results in a structured way (e.g. organised by comparison and then 
outcome). 
6.3.2 Y Reported the outcomes in the same order as listed in the ‘Types of outcome measures’ 
section, and primary and secondary outcomes are identified. 
6.3.3 Y Reported the available results for each comparison, outcome and subgroup described in the 
Cochrane Protocol, including those for which no results were found and those that were not 
statistically significant. 
6.3.4 Y Reported the results using the statistics and methods described in the ‘Methods’ section. 
6.3.5 Y Ensure that all statistical results presented in the main review text are consistent between the 
text and the ‘Data and analysis’ tables. 
6.3.6 Y Explain how studies measuring an outcome of interest using different scales (such as 
alternative rating scales that measure symptoms or behaviour) were combined, stating 
whether positive or negative values reflect benefit or harm. 
6.3.7 Y Ensure that key findings are interpretable, or are re-expressed in an interpretable way (MECIR 
standard R88). 
6.3.8 Y Comment on the potential impact of studies that apparently measured outcomes but did not 
contribute data that allowed the study to be included in synthesis. 
6.3.6 Y Included links to all analyses, figures, tables, appendices. 
6.3.7 Y Restrict the number of Tables and Figures to a small number to convey key findings without 
affecting the readability of the results. 
6.3.8 Y Presented the number of studies and participants included, as well as a measure of 
uncertainty (e.g. 95% confidence interval), for each result. 
6.3.9 Y Conducted sensitivity analyses as described in the Cochrane Protocol, if appropriate, and 
reported the results. 
6.3.10 Y Investigated heterogeneity as described in the Cochrane Protocol, if appropriate, and 
reported the results. 
6.3.11 Y Investigated the possible impact of bias on results as indicated in the Cochrane Protocol, 
including possible biases relating to study design and reporting bias. 
6.3.12 Y Not confused ‘no evidence of effect’ with ‘evidence of no effect’. 
6.3.13 Y Clearly identified any post-hoc analyses that were not planned at the Cochrane Protocol 
stage. 
6.3.14 Y Not included any interpretation of results. 
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6.3.15 Y Referred to the Summary of findings table(s) and included links. 
7. Discussion 
(see Cochrane Handbook Section 4.5; MECIR standards R99, R100) 
7.1 Y Included the standard headings when writing the Discussion  
7.2 Y Briefly summarised the included studies and their results in plain language, including the risk 
of bias, areas of uncertainty and completeness of the available evidence. 
7.3 Y Checked that this section does not include any new results not reported in the previous 
section. 
7.4 Y Considered both the statistical significance and clinical or policy implications of the results. 
7.5 Y Considered the context and applicability and context of the results to different groups (e.g. 
consumers, carers, policy makers, health professionals, vulnerable/disadvantaged groups). 
7.6 Y Discussed the strengths and limitations of the Cochrane Review. 
7.7 Y Discussed the findings in the context of current knowledge, including other reviews in the 
field. 
8. Authors’ conclusions 
(see Cochrane Handbook Section 4.5; MECIR standards R101, R102) 
8.1 Y Implications for practice: Avoided making recommendations and limited conclusions to those 
that can be supported by the findings of the Cochrane Review. 
8.2 Y Implications for research: If recommending additional research, specific suggestions about 
how the research should be conducted (e.g. study designs, outcome measurements) as well 
as what research should be conducted (e.g. different populations, interventions) have been 
made. 
9. Acknowledgements 
(see Cochrane Handbook Section 4.5; MECIR standard R103) 
9.1 Y Acknowledged those people who contributed to the Cochrane Review but are not named as 
authors, and included the reasons for acknowledging each person. 
9.2 Y Permission has been granted from all the people named to include them in this section. 
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10. Contributions of authors 
(see Cochrane Handbook Section 4.5; MECIR standard R104) 
10.1 Y Described each author’s contribution to the design and development of the Cochrane 
Protocol and the Cochrane Review. 
11. Declarations of interest 
(see Cochrane Handbook Section 4.5; MECIR standard R105) 
11.1 Y Completed for each author, noting present or past affiliations that that may lead to a real or 
perceived conflict of interest, including whether authors are investigators on studies likely to 
be included in the review. If no potential conflicts are identified for a particular author, “None 
known” has been stated. 
12. Differences between protocol and review 
(see Cochrane Handbook Section 4.5; MECIR standards R79; R106; R107) 
12.1 Y Reported any changes in the Cochrane Review authorship since the Cochrane Protocol was 
published. 
12.2 Y Reported any differences in the methods used between the Cochrane Protocol and the 
Cochrane Review, including anything that was changed, added or removed from the proposed 
methods. 
12.3 Y Given a rationale for any differences between the Cochrane Protocol and the Cochrane 
Review, and the rationale is not driven by the findings of the Cochrane Review. 
13. Tables 
13.1 Characteristics of included studies 
(see Cochrane Handbook Section 11.2; MECIR standards R60, R62 to R70) 
13.1.1 Y The table does not include study results or information that should be included in the ‘Risk of 
bias’ assessment. 
13.1.2 Y If appropriate, any available information on study funding has been included in an extra row 
in the table. 
13.1.3 Y Avoided using abbreviations or acronyms and, where used, the full term has been provided in 
the footnotes. 
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Methods 
13.1.4 Y Listed the study design (e.g. “randomised controlled trial”), including whether the study 
differs from a standard parallel group design (e.g. cross-over or cluster-randomised), and the 
duration of the study including start and end dates if available. 
Participants 
13.1.5 Y Stated the number of participants and described their location, context, health status, age, 
and sex. Enough information has been provided for users of the Cochrane Review to 
determine the applicability of the study to their population, and to allow exploration of 
differences across studies. 
Interventions 
13.1.6 Y Described each intervention group in the study in enough detail for each intervention to be 
replicated in practice (if possible), including dose/frequency, components, mode of 
administration, and duration of each intervention. 
Outcomes 
13.1.7 Y Listed either the outcomes from the study that are considered in the Cochrane Review, or all 
outcomes measured or reported in the study. For each outcome, the time points measured 
have been described, as well as the tools, units and definitions used to measure the outcome. 
13.2 Risk of bias 
(see Cochrane Handbook Chapter 8; MECIR standard R72) 
13.2.1 Y Activated rows in the table to assess sequence generation, allocation concealment, blinding, 
incomplete outcome data, selective outcome reporting and other issues. 
13.2.2 Y Judged each parameter of the Risk of Bias table appropriately to indicate whether the study is 
at high, low or unclear risk of bias. 
13.2.3 Y In each judgement, the evidence of bias, the likely direction of bias, and the likely magnitude 
of bias have been taken into consideration, and judgements are consistent with Table 8.5.c of 
the Handbook. 
13.2.4 Y Provided detailed, clearly identified quotes from the study text and additional comments 
where necessary to support each judgement. 
13.2.5 Y Avoided using abbreviations or acronyms and, where used, provided the full term in the 
footnotes. 
Random sequence generation (selection bias) 
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13.2.6 Y Described the method for generating the allocation of participants to the intervention groups, 
and whether it was random, quasi-random or non-random. 
Allocation concealment (selection bias) 
13.2.7 Y Described whether the assignment of participants to intervention groups was concealed 
throughout the recruitment and allocation process (before the interventions began). 
Blinding of participants and personnel (performance bias) 
13.2.8 Y Described who was blinded or masked during the conduct of the trial, including an 
assessment of the success of blinding. 
13.2.9 Y Considered the possible impact of blinding for each outcome reported in the Cochrane 
Review and, if appropriate, created additional rows in the table for outcomes at different 
levels of risk. 
Blinding of outcome assessment (detection bias) 
13.2.10 Y Described who was blinded or masked during the outcome assessment and analysis of the 
trial, including an assessment of the success of blinding. 
13.2.11 Y Considered the possible impact of blinding for each outcome reported in the Cochrane 
Review and, if appropriate, created additional rows in the table for outcomes at different 
levels of risk. 
Incomplete outcome data (attrition bias) 
13.2.12 Y Described the completeness of the available data, including information about withdrawals, 
exclusions, imputation of missing data and ‘as treated’ analysis. 
13.2.13 Y Included an assessment of the possible impact of the incomplete data based on the 
proportion of missing values (dichotomous), the plausible effect size (continuous), the 
balance of missing data between intervention groups, and the reasons for incompleteness. 
13.2.14 Y Considered the possible impact of incomplete outcome data for each outcome and time point 
reported and, if appropriate, created additional rows in the table for outcomes or time points 
at different levels of risk. 
Selective reporting (reporting bias) 
13.2.15 Y Considered availability of the study protocol, and whether there is any evidence of outcomes 
added, not reported, reported incompletely, or reported using measures, methods or subsets 
of data that were not pre-specified. 
Other bias 
13.2.16 Y Described any other concerns about the study (e.g. baseline imbalance, early stopping) have 
been described. 
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13.2.17 Y Issues that do not have direct implications for bias (e.g. sample size, ethical approval) have 
not been included. 
13.3 Characteristics of excluded studies 
(see Cochrane Handbook Section 4.6.3; MECIR standard R57) 
13.3.1 Y Listed studies that may appear to meet the eligibility criteria, but which were excluded. 
13.3.2 Y Given a brief reason why each study was excluded from the Cochrane Review (e.g. 
inappropriate comparator intervention). If a reason applies to more than one study, it is 
expressed in the same way each time. 
13.3.3  Further information about the studies (e.g. location or results) has not been included. 
13.4 Characteristics of studies awaiting classification 
(see Cochrane Handbook Section 4.6.4; MECIR standard R58) 
13.4.1 Y Provided detailed information, if possible, similar to the Characteristics of included studies 
table. 
13.4.2 Y In any blank cells, “Not yet assessed” or “Not known” has been stated as appropriate. 
13.5 Characteristics of ongoing studies 
(see Cochrane Handbook Section 4.6.5; MECIR standard R59) 
13.5.1 Y Provided detailed information, if possible, similar to the Characteristics of included studies 
table. 
13.5.2 Y In any blank cells, “Not yet assessed” or “Not known” has been stated as appropriate. 
13.6 Summary of findings 
(see Cochrane Handbook Section 11.5 and Section 12.2; MECIR standards R97, R98) 
13.6.1 Y Included a ‘Summary of findings’ table in the Cochrane Review. Additional ‘Summary of 
findings’ tables have been included if the Cochrane Review includes more than one major 
comparison or substantially different populations. 
13.6.2 Y Briefly described the population, setting and intervention in the studies relevant to each 
table. 
13.6.3 Y Selected a maximum of seven important outcomes to be reported in each table, and included 
these outcomes whether or not data were found in the included studies. 
13.6.4 Y Included one or more adverse effect outcome in each table. 
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13.6.5 Y Named each outcome in plain language, and clearly described any tools, units and definitions 
used to measure the outcome, including the direction of benefit and upper and lower limits 
of any numerical scales. 
13.6.6 Y Selected an assumed risk for each outcome based on either the control group risk(s) in the 
included studies, or an external source (e.g. well-conducted epidemiological study), and have 
included a footnote explaining the choice. 
13.6.7 Y Checked that all results appear correctly and are consistent with the results presented in the 
‘Data and analyses’ and ‘Results’ sections of the Cochrane Review. 
13.6.8 Y Entered a GRADE assessment for each outcome, including footnotes to explain judgements. 
13.6.9 Y Included comments explaining any additional information required by the reader, including 
explanations for any outcomes for which results cannot be displayed in the standard format. 
13.6.10 Y Included explanations of any abbreviations in footnotes. 
13.6.11 Y Footnotes are referenced in the text using superscript letters (e.g. a) 
13.7 Additional tables  
(see Cochrane Handbook Section 4.6.7) 
13.7.1 Y Each table has a brief and informative heading. 
13.7.2 Y Cells in the table containing row or column headings are formatted in heading style, by 
selecting Toggle heading/cell from the Table menu in RevMan. 
13.7.3 Y Included explanations of any abbreviations in footnotes. 
13.7.4 Y If footnotes have been used, these are referenced in the text using superscript letters (e.g. a). 
13.7.5 Y Where possible, ‘non-essential’ tables moved to the ‘Appendices’. 
14. References  
All sources of information in the Cochrane Protocol must be appropriately referenced to prevent 
plagiarism. All reference citation IDs and references in the reference list must be consistent with the 
Cochrane Style Guide (http://www.cochrane.org/sites/default/files/uploads/Cochrane-Style-Guide_4-1-
edition.pdf). In particular, please check the following items: 
14.1 In the text 
14.1.1 Y Checked that a link has been created wherever a reference citation ID appears in the text of 
the Cochrane Review using the Find and Mark Links tool. 
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14.1.2 Y Grouped reference citation IDs and links in the text in alphabetical or chronological order, 
surrounded by round brackets and separated by semi-colons. 
14.2 In the reference lists 
(see Cochrane Handbook Section 4.7; MECIR standard R71; Style guide) 
14.2.1 Y Reference citation IDs are in the correct format (first author or group abbreviation and year 
of publication, e.g. Smith 1983 or UKPDS 1990) 
14.2.2 Y Included each journal title in full, with no abbreviations. 
14.2.3 Y Checked how each reference is displayed to remove unnecessary punctuation. 
14.2.4 Y Where applicable, listed the first six authors before using ‘et al.’ 
14.2.5 Y Written the page numbers correctly (e.g. 354-7). 
14.2.6 Y Included the date accessed in any references to web pages. 
References to studies 
14.2.7 Y Grouped all the references relevant to each study under a single study ID. 
14.2.8 Y If two or more references are listed under a study ID, one has been nominated as the primary 
reference. 
14.2.9 Y Specified whether data for each study includes published, unpublished or both sources, and 
whether unpublished data were sought. 
Additional references 
14.2.10 Y Included other references cited in the text of the review, aside from studies assessed for 
inclusion (e.g. cited in the ‘Background’ or ‘Methods’ sections). 
Other published versions of this review 
14.2.11 Y Included references to any previous or derivative published versions of this Cochrane Review. 
15. Data and analyses 
(see Cochrane Handbook Section 4.8; MECIR standards C51, R92, R93, R94) 
15.1 Y Comparison names are consistent with the ‘Objectives’, ‘Types of Interventions’ and ‘Effects 
of interventions’ sections. 
15.2 Y Presented the outcomes in the same order as the ‘Types of outcome measures’ and ‘Effects 
of interventions’ sections. 
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15.3 Y Outcome names are consistent with the ‘Types of outcome measures’ and ‘Effects of 
interventions’ sections. 
15.4 Y Outcome names include brief information on the tools, units, definitions, and time points, if 
appropriate. 
15.5 Y Changed the ‘Group’ labels on the forest plots from ‘Experimental’ and ‘Control’ to the actual 
intervention groups used in the comparison. 
15.6 Y Changed the ‘Graph’ labels on the forest plots from ‘Favours experimental’ and ‘Favours 
control’ to reflect the actual intervention group names. 
15.7 Y Checked that the ‘Graph’ labels indicate the correct direction of effect (for negative 
outcomes, the left side favours the experimental group; for positive outcomes, the left side 
favours the control group). 
15.8 Y Set the scale of each forest plot so the point estimates and confidence intervals can be seen 
clearly, and if possible so that the plots are consistent between outcomes on similar scales. 
15.9 Y Meta-analysis totals for outcomes or subgroups with only one included study are not 
displayed. 
15.10 Y Meta-analysis totals combining more than one measurement from the same individuals in the 
same study are not displayed. 
15.11 Y The statistical options used in the forest plots are correct and consistent with the ‘Methods’ 
section, including the statistical method (e.g. Peto or inverse variance), analysis model (e.g. 
fixed effect or random effects), and effect measure (e.g. risk ratio or odds ratio). 
15.12 Y Checked any outlying or unexpected results for data entry and transcription errors. 
16. Figures 
(see Cochrane Handbook Section 4.9 and the RevMan User Guide for specifications on size and 
resolution; MECIR standard R85) 
16.1 Y Permission received to reproduce any figures from external sources included in the Cochrane 
Review. 
16.2 Y Each figure has a brief caption describing the purpose of the figure, and acknowledging its 
source. 
16.3 Y All figures used are scaled so that a reader can see the complete picture within the RevMan 
window. 
16.4 Y All figures are of a sufficient resolution and quality for publication. 
202 | P a g e  
 
16.5 Y Restrict the number of figures and tables to a small number to convey key findings without 
affecting the readability of the text. 
17. Sources of support 
(see Cochrane Handbook Section 4.10; MECIR standard R108) 
17.1 Y Listed all sources of funding and in-kind support, including internal sources (e.g. the home 
institution of any author) and external sources (e.g. grant funding). 
18. Appendices 
(see Cochrane Handbook Section 4.12) 
18.1 Y The title of each appendix is clear and informative. 
18.2 Y Copied the complete set of search terms used for each electronic database into an Appendix. 
19. Style 
(see Cochrane Style Guide at http://www.cochrane.org/training/authors-mes/cochrane-style-resource) 
19.1 Y Removed all highlighting, notes and tracked changes from the Cochrane Review. 
19.2 Y All text uses the active voice (i.e. “two review authors extracted data”, not “data were 
extracted by two review authors”) 
19.3 Y Proofread the Cochrane Protocol carefully in accordance with the Cochrane Style Guide Basics. 
19.4   Y Explained all acronyms and abbreviations (e.g. World Health Organization (WHO)). 
19.5 Y If additional subheadings have been added, the appropriate Heading Style has been selected 
using the drop-down box on the RevMan toolbar. 
19.6 Y Written numbers up to and including ‘nine’ as words, and numbers 10 or higher as numerals 
(excluding those at the start of a sentence and numbers appearing in tables or figures). 
19.7 Y Included a space before and after all units of measurement and mathematical symbols (e.g. 5 
mL, P  = 0.03). 
19.8 Y If reporting P values, P is written in upper case and without a hyphen. 
 
203 | P a g e  
 
Appendix 2: Search term (Chapter 3) 
Medline, Ovid 
# Searches 
1 (vaccin* and (uptake or coverage)).ti. 
2 (vaccin* adj (uptake or coverage)).ab. 
3 or/1-2 
4 Immunization/ 
5 Immunization Schedule/ 
6 Immunization, Secondary/ 
7 Immunization Programs/ 
8 Immunotherapy, Active/ 
9 Vaccination/ 
10 Mass Vaccination/ 
11 or/4-10 
12 Diphtheria/ 
13 Tetanus/ 
14 Bordetella Infections/ 
15 Bordetella Pertussis/ 
16 Whooping Cough/ 
17 Measles/ 
18 Mumps/ 
19 Rubella/ 
20 Poliomyelitis/ 
21 Poliomyelitis, Bulbar/ 
22 Tuberculosis/ 
23 Tuberculosis, Pulmonary/ 
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24 Mycobacterium Tuberculosis/ 
25 Hepatitis A/ 
26 Hepatitis A virus/ 
27 Hepatitis A Virus, Human/ 
28 Hepatitis B/ 
29 Hepatitis B, Chronic/ 
30 Hepatitis B virus/ 
31 Chickenpox/ 
32 Papillomavirus Infections/ 
33 Herpesviridae Infections/ 
34 Herpes Simplex/ 
35 Herpes Genitalis/ 
36 Herpes Labialis/ 
37 Herpes Zoster/ 
38 Meningococcal Infections/ 
39 Meningitis, Meningococcal/ 
40 Neisseria meningitidis/ 
41 exp HIV Infections/ 
42 HIV/ 
43 HIV-1/ 
44 HIV-2/ 
45 Neoplasms/ 
46 or/12-45 
47 11 and 46 
48 Diphtheria-Tetanus-Acellular Pertussis Vaccines/ 
49 Diphtheria-Tetanus-Pertussis Vaccine/ 
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50 Diphtheria-Tetanus Vaccine/ 
51 Pertussis Vaccine/ 
52 Vaccines, Combined/ 
53 Diphtheria Toxoid/ 
54 Tetanus Toxoid/ 
55 Measles-Mumps-Rubella Vaccine/ 
56 Measles Vaccine/ 
57 Mumps Vaccine/ 
58 Rubella Vaccine/ 
59 Poliovirus Vaccines/ 
60 Poliovirus Vaccine, Oral/ 
61 Poliovirus Vaccine, Inactivated/ 
62 Tuberculosis Vaccines/ 
63 BCG Vaccine/ 
64 Viral Hepatitis Vaccines/ 
65 Hepatitis A Vaccines/ 
66 Hepatitis B Vaccines/ 
67 Chickenpox Vaccine/ 
68 Papillomavirus Vaccines/ 
69 Meningococcal Vaccines/ 
70 AIDS Vaccines/ 
71 or/48-70 
72 ((diphtheria? or tetanus or bordetella or pertussis or whooping cough or measles or mumps 
or rubella? or rubeola or mmr or polio* or infantile paralysis or tuberculosis or tuberculoses 
or bcg or calmette* or hepatitis or chickenpox or varicella or papilloma* or herpes or 
meningococcal or meningitidis or meningitis or acquired immunodeficiency syndrome or 
aids or human immunodeficiency virus or hiv? or cancer? or neoplasm?) adj3 (vaccin* or 
revaccinat* or immunization or immunisation or immunotherapy)).ti,ab. 
73 ((tripe or combin*) adj vaccin*).ti,ab. 
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74 or/72-73 
75 3 or 47 or 71 or 74 
76 Adolescent/ 
77 Adolescent Health Services/ 
78 (adolescent? or youth? or young adult? or teenager? or teen? or juvenile?).ti,ab. 
79 or/76-78 
80 75 and 79 
81 randomized controlled trial.pt. 
82 controlled clinical trial.pt. 
83 multicenter study.pt. 
84 pragmatic clinical trial.pt. 
85 non-randomized controlled trials as topic/ 
86 interrupted time series analysis/ 
87 controlled before-after studies/ 
88 (randomis* or randomiz* or randomly).ti,ab. 
89 groups.ab. 
90 (trial or intervention? or effect? or impact? or multicenter or multi center or multicentre or 
multi centre).ti. 
91 (controlled or control group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre test) 
and (posttest or post test)) or quasiexperiment* or quasi experiment* or evaluat* or time 
series or time point? or repeated measur*).ti,ab. 
92 or/81-91 
93 exp Animals/ 
94 Humans/ 
95 93 not (93 and 94) 
96 review.pt. 
97 meta analysis.pt. 
98 news.pt. 
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99 comment.pt. 
100 editorial.pt. 
101 cochrane database of systematic reviews.jn. 
102 comment on.cm. 
103 (systematic review or literature review).ti. 
104 or/95-103 
105 92 not 104 
106 80 and 105 
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Appendix 3: Table of excluded studies (chapter 3) 
Study ID Reason for exclusion 
Anjum 2012 (209)   This is a simple pre and post cross-sectional survey with no controls 
Bar-Shain 2015 (210)  The intervention is a reminder 
Bennett 2015 (211) The age of participants is 18-26 years, not separated to cater for 18-19 yrs 
Broutet 2013 (204) This is a review 
Catledge 2014 (212) This is a pre and post survey 
Chan 2015 (213)   This is a pre and post study 
Chapman 2010 (214) This is a pre- and post cross-sectional survey 
Chaves 2000 (215) This is written in Spanish 
Chou 2014 (216) This is a pre- and post-consultation surveys 
Chung 2015 (217) The intervention is a reminder 
Dawson 2015 (218) This is a pre and post intervention study 
Dempsey 2015 A (219)   This is a pre and post intervention study 
Dempsey 2015 B (220)  This is a pre and post study 
Donahue 2016 (221)   The intervention is a reminder 
Dorji 2015 (222)   This is a descriptive study, with no intervention and control arms 
Farmar 2016 (223)  This is a pre and post intervention study 
Fujiwara 2013 (224) This is a questionnaire survey, with no intervention and control 
Furlan 2010 (225)  This is published in Portuguese 
Gargano 2014 (226) This is a descriptive study with no intervention 
Gillespie 2011 (227) This is a questionnaire survey in an ineligible age group 
Gordon 2013 (228) This is a descriptive study, with no intervention 
Gottvall 2010 (229)  This is a quasi-experimental intervention study 
Hadley 2014 (230)  This is a descriptive study 
Hofman 2013 (231) This is a pre and post-test evaluation 
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Hull 2016 (232) This is a pilot cross over study 
Iqbal 2016 (233) The age group is 11-25 years and data not stratified by age group 
Kim 2015 (234)   This is a pre and post-test study 
Kwan 2011 (235)   This is a pre and post evaluation study 
Kwang 2016 (236) This is a pre and post study in an ineligible age group 
Lai 2013 (237)  This is a quasi-experimental time series study 
LaMontagne 2011 (187)   This was a cross-sectional study 
Marek 2012 (238) This is a simple pre-post survey 
Meneses 2015 (239) This is a re and post intervention with no control 
Moss 2012 (240) This is a pre and post intervention survey 
Ortiz 2016 (241)   This is a pilot cross sectional study 
Perkins 2016 (242) This is a cross sectional survey 
Pierre-Victor 2017 (243)   This a pre and post study 
Reiter 2011 (244) This is a pre and post evaluation study 
Ruffin 2015 (245) The intervention is a reminder 
Sales 2011 (246) This is a pre and post study 
Soldan 2006 (247) This is a review 
Spleen 2012 (248)   This is a pre-test/post-test assessment 
Stokley 2015 (249)  This is a review 
Szilagyi 2011 (250) The intervention is a reminder 
Tiro 2016 (251) This is a pre and post survey 
Unti 1997 (252)  This is a pre and post survey 
Won 2015 (253)  The outcomes in this study are trust and participation in school-located 
immunisation programmes, and none of our outcomes of interest is 
reported 
Zhou 2003 (254) This is a pre and post intervention survey 
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Appendix 4: PRISMA checklist (Chapter 4) 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  98 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
99-100 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  101-102 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
103 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
103 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
103-104 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
105 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
213 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
106 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
106 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
106 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
106 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  107 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
107 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page 
#  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
NA 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
NA 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
108 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
109-114 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  123 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
NA 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  NA 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  123-124 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
NA 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
125 
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Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
NA 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
127 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
127 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2  
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Appendix 5: Search strategy for PubMed database (chapter 4). 
Recent queries in PubMed (as of 20th April 2014) 
Search Query 
#7 ((((((((ALGERIA) OR (ANGOLA) OR (BENIN) OR (BOTSWANA) OR 
(BURKINA FASO) OR (BURUNDI) OR (CAMEROON) OR (CANARY 
ISLANDS OR "CANARY ISLANDS") OR ((CAPE VERDE) OR "CAPE 
VERDE") OR (CENTRAL AFRICAN REPUBLIC) OR (CHAD) OR 
(COMOROS) OR (CONGO) OR (DEMOCRATIC REPUBLIC CONGO) 
OR (DJIBOUTI) OR (EGYPT) OR ((EQUATORIAL GUINEA) OR 
"EQUATORIAL GUINEA") OR (ERITREA) OR (ETHIOPIA) OR (GABON) 
OR (GAMBIA) OR (GHANA) OR (GUINEA) OR ((GUINEA BISSAU) OR 
"GUINEA BISSAU") OR (IVORY COAST) OR ((COTE D'IVOIRE) OR 
"COTE D'IVOIRE") OR (KENYA) OR (LESOTHO) OR (LIBERIA) OR 
((LIBYA) OR (LIBIA) OR (JAMAHIRIYA) OR (JAMAHIRYIA)) OR 
(MADAGASCAR) OR (MALAWI) OR (MALI) OR (MAURITANIA) OR 
(MAURITIUS) OR (MOROCCO) OR ((MOZAMBIQUE) OR 
(MOCAMBIQUE)) OR (NAMIBIA) OR (NIGER) OR (NIGERIA) OR 
(REUNION) OR (RWANDA) OR ((SAO TOME) OR "SAO TOME") OR 
(SENEGAL) OR (SEYCHELLES) OR ((SIERRA LEONE) OR "SIERRA 
LEONE") OR (SOMALIA) OR ((SOUTH AFRICA) OR "SOUTH AFRICA") 
OR ((ST HELENA) OR "ST HELENA") OR (SUDAN) OR (SWAZILAND) 
OR (TANZANIA) OR (TANGANYIKA) OR (TOGO) OR (TUNISIA) OR 
(UGANDA) OR ((WESTERN SAHARA) OR "WESTERN SAHARA") OR 
(ZAIRE) OR (ZAMBIA) OR (ZIMBABWE) OR (AFRICA[MH]) OR 
(SOUTH* AND AFRICA*) OR (WEST* AND AFRICA*) OR (EAST* AND 
AFRICA*) OR (NORTH* AND AFRICA*) OR (CENTRAL* AND AFRICA*) 
OR (SUB SAHARAN AFRICA*) OR (SUBSAHARAN AFRICA*) OR 
(AFRICA*) NOT (((GUINEA PIG*) OR "GUINEA PIG*") OR 
((ASPERGILLUS NIGER) OR "ASPERGILLUS NIGERâ€))))) AND 
((((("Vaccination"[Mesh]) OR vaccination) OR "Immunization"[Mesh]) OR 
immunization) OR immunisation)) AND ((("Adolescent"[Mesh]) OR 
adolescent) OR teenager)) AND ((accept) OR ((((((((((((((((Attitude to 
Health[MeSH Terms]) OR "Health Knowledge, Attitudes, Practice"[Mesh]) 
OR Health Knowledge, Attitudes, Practice) OR Patient Acceptance of 
Health Care[MeSH Terms]) OR acceptance) OR acceptability) OR 
knowledge) OR awareness) OR belief*) OR attitude) OR perception) OR 
adherence) OR compliance) OR willingness) OR uptake) OR 
understanding))) AND (((((((((((("MC-4 vaccine" [Supplementary 
Concept]) OR meningococcal-conjugate (MCV4)) OR meningococcal-
conjugate) OR "Papillomavirus Vaccines"[Mesh]) OR "Influenza 
Vaccines"[Mesh]) OR "Tetanus"[Mesh]) OR tetanus) OR Influenza) OR 
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("Diphtheria"[Mesh] AND "Diphtheria-Tetanus-acellular Pertussis 
Vaccines"[Mesh])) OR "Pertussis Vaccine"[Mesh]) OR Diphtheria-
Tetanus-acellular Pertussis Vaccines) OR "Influenza, Human"[Mesh]) 
Sort by: [relevance] 
#6 (((ALGERIA) OR (ANGOLA) OR (BENIN) OR (BOTSWANA) OR 
(BURKINA FASO) OR (BURUNDI) OR (CAMEROON) OR (CANARY 
ISLANDS OR "CANARY ISLANDS") OR ((CAPE VERDE) OR "CAPE 
VERDE") OR (CENTRAL AFRICAN REPUBLIC) OR (CHAD) OR 
(COMOROS) OR (CONGO) OR (DEMOCRATIC REPUBLIC CONGO) 
OR (DJIBOUTI) OR (EGYPT) OR ((EQUATORIAL GUINEA) OR 
"EQUATORIAL GUINEA") OR (ERITREA) OR (ETHIOPIA) OR (GABON) 
OR (GAMBIA) OR (GHANA) OR (GUINEA) OR ((GUINEA BISSAU) OR 
"GUINEA BISSAU") OR (IVORY COAST) OR ((COTE D'IVOIRE) OR 
"COTE D'IVOIRE") OR (KENYA) OR (LESOTHO) OR (LIBERIA) OR 
((LIBYA) OR (LIBIA) OR (JAMAHIRIYA) OR (JAMAHIRYIA)) OR 
(MADAGASCAR) OR (MALAWI) OR (MALI) OR (MAURITANIA) OR 
(MAURITIUS) OR (MOROCCO) OR ((MOZAMBIQUE) OR 
(MOCAMBIQUE)) OR (NAMIBIA) OR (NIGER) OR (NIGERIA) OR 
(REUNION) OR (RWANDA) OR ((SAO TOME) OR "SAO TOME") OR 
(SENEGAL) OR (SEYCHELLES) OR ((SIERRA LEONE) OR "SIERRA 
LEONE") OR (SOMALIA) OR ((SOUTH AFRICA) OR "SOUTH AFRICA") 
OR ((ST HELENA) OR "ST HELENA") OR (SUDAN) OR (SWAZILAND) 
OR (TANZANIA) OR (TANGANYIKA) OR (TOGO) OR (TUNISIA) OR 
(UGANDA) OR ((WESTERN SAHARA) OR "WESTERN SAHARA") OR 
(ZAIRE) OR (ZAMBIA) OR (ZIMBABWE) OR (AFRICA[MH]) OR 
(SOUTH* AND AFRICA*) OR (WEST* AND AFRICA*) OR (EAST* AND 
AFRICA*) OR (NORTH* AND AFRICA*) OR (CENTRAL* AND AFRICA*) 
OR (SUB SAHARAN AFRICA*) OR (SUBSAHARAN AFRICA*) OR 
(AFRICA*) NOT (((GUINEA PIG*) OR "GUINEA PIG*") OR 
((ASPERGILLUS NIGER) OR "ASPERGILLUS NIGERâ€))) 
#5 ((((((((((("MC-4 vaccine" [Supplementary Concept]) OR meningococcal-
conjugate (MCV4)) OR meningococcal-conjugate) OR "Papillomavirus 
Vaccines"[Mesh]) OR "Influenza Vaccines"[Mesh]) OR "Tetanus"[Mesh]) 
OR tetanus) OR Influenza) OR ("Diphtheria"[Mesh] AND "Diphtheria-
Tetanus-acellular Pertussis Vaccines"[Mesh])) OR "Pertussis 
Vaccine"[Mesh]) OR Diphtheria-Tetanus-acellular Pertussis Vaccines) 
OR "Influenza, Human"[Mesh] 
#4 (accept) OR ((((((((((((((((Attitude to Health[MeSH Terms]) OR "Health 
Knowledge, Attitudes, Practice"[Mesh]) OR Health Knowledge, Attitudes, 
Practice) OR Patient Acceptance of Health Care[MeSH Terms]) OR 
acceptance) OR acceptability) OR knowledge) OR awareness) OR 
belief*) OR attitude) OR perception) OR adherence) OR compliance) OR 
willingness) OR uptake) OR understanding) 
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#3 (((((((((((((((Attitude to Health[MeSH Terms]) OR "Health Knowledge, 
Attitudes, Practice"[Mesh]) OR Health Knowledge, Attitudes, Practice) 
OR Patient Acceptance of Health Care[MeSH Terms]) OR acceptance) 
OR acceptability) OR knowledge) OR awareness) OR belief*) OR 
attitude) OR perception) OR adherence) OR compliance) OR willingness) 
OR uptake) OR understanding 
#2 (("Adolescent"[Mesh]) OR adolescent) OR teenager 
#1 (((("Vaccination"[Mesh]) OR vaccination) OR "Immunization"[Mesh]) OR 
immunization) OR immunisation 
 
Web sites and databases for grey materials: 
World Health Organisation (WHO) (http://www.who.int/), Global Alliance for Vaccine and 
Immunization (GAVI) (http://www.gavialliance.org/), United Nation Children’s Funds (UNICEF) 
(http://www.unicef.org/), PATH Vaccine Resources Library (http://www.path.org/), US Centers 
for Disease Control and Prevention (CDC) (http://www.cdc.gov/), The communication initiative 
network (http://www.comminit.com/), and Immunization basics 
(http://www.immunizationbasics.jsi.com/Index.html) 
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Appendix 6: Supplementary table 1a & b (Chapter 4) 
Supplementary Table 1a & b: Summary on the statistical fishers exact test on 
level of knowledge on the three key demographics i.e. (teacher or parents or 
adolescents) and settings. 
 
 
 
 
 
 
 
 
  
1 a) Use Fisher's exact test to test association between knowledge and participants as some cells are 
<5 
           |           participants 
 knowledge |         1          2          3 |     Total 
-----------+---------------------------------+---------- 
         1 |         9          1          4 |        14  
         2 |         3          1          3 |         7  
         3 |         2          0          1 |         3  
-----------+---------------------------------+---------- 
     Total |        14          2          8 |        24     Fisher's exact =                 0.831 
 
1 b) Use Fisher's exact test to test association between knowledge and setting as some cells are <5 
Variable Key 
Participants: 
1=parents  
2=teachers  
3=adolescents 
Knowledge: 
1=low  
2=moderate  
3=high 
Setting: 1=urban  
2=rural  
3=peri-urban  
4=urban & rural 
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           |            knowledge 
   setting |         1          2          3 |     Total 
-----------+---------------------------------+---------- 
         1 |         4          1          0 |         5  
         2 |         3          1          2 |         6  
         3 |         3          2          1 |         6  
         4 |         4          3          0 |         7  
-----------+---------------------------------+---------- 
     Total |        14          7          3 |        24       Fisher's exact =                 0.709 
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Appendix 7: STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies 
(Chapter 5) 
 
Item 
No Recommendation 
Page No 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 129 
(b) Provide in the abstract an informative and balanced summary of what was done and 
what was found 
130-131 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 132-134 
Objectives 3 State specific objectives, including any prespecified hypotheses 134 
Methods 
Study design 4 Present key elements of study design early in the paper 135 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
135 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants 135 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
NA 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
135 
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group 
Bias 9 Describe any efforts to address potential sources of bias NA 
Study size 10 Explain how the study size was arrived at 135 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
135 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding NA 
(b) Describe any methods used to examine subgroups and interactions NA 
(c) Explain how missing data were addressed 136 
(d) If applicable, describe analytical methods taking account of sampling strategy NA 
(e) Describe any sensitivity analyses NA 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, 
and analysed 
137 
(b) Give reasons for non-participation at each stage 137 
(c) Consider use of a flow diagram 137 
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Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
137-138 
(b) Indicate number of participants with missing data for each variable of interest 136 
Outcome data 15* Report numbers of outcome events or summary measures 137-138 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
NA 
(b) Report category boundaries when continuous variables were categorized NA 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
NA 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 
analyses 
138-145 
Discussion 
Key results 18 Summarise key results with reference to study objectives 145-147 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
148 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
148 
Generalisability 21 Discuss the generalisability (external validity) of the study results 148 
Other information 
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Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
149 
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Appendix 8:  Participant information and consent form (Chapter 5) 
TITLE OF THE RESEARCH PROJECT: Challenges and lessons learnt during the 
introduction of vaccines to adolescents in Africa: a focus on Human Papillomavirus 
(HPV) vaccines 
Investigator: Leila H Abdullahi 
Supervisors: Prof. Gregory D Hussey, Prof. Charles S Wiysonge and Dr. Benjamin M 
Kagina 
Address:  Vaccines for Africa Initiative (VACFA), Faculty of Health Sciences, 
 University of Cape Town, Anzio Road, Observatory 7925 
Contact number:  021 650 6066 
Introduction and aim of the study 
We are investigating the experiences, challenges and lessons learnt by the key 
stakeholders during the introduction of HPV vaccines.  We have selected you to take 
part in this research study because you are a key stakeholder.   
Please carefully read the form prior to consenting to participate.  
This study has been submitted to the Health Research Ethics Committee at University 
of Cape Town for review and approval (HREC REF 703/2015). The study will be 
conducted according to the standard ethical guidelines and principles. In addition you 
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have been granted permission from your national authorizing official. However, you may 
withdraw consent to participate at any time if you feel uncomfortable to participate. 
 The aim of this study is to investigate the challenges and lessons learnt by 
African countries during the introduction of HPV vaccine. 
 The study will take place in Cape Town, South Africa, where all the selected 
members will be invited to participate in the interview panel. Alternatively for 
those participants that cannot make it to Cape Town we will send self-
administered questionnaire via email. 
 Key stakeholders (government representatives, funding agencies, NITAGs and 
implementing agencies) from Lesotho, Libya, Rwanda, Uganda and South Africa 
have been selected to participate in this study. The interview will take 
approximately thirty minutes. 
Benefits:  There are no direct benefits to you as a participant. Your participation will 
help us to better understand the factors that hinder the introduction of HPV vaccines in 
Africa. This information will be published and made accessible to other African countries 
that are planning to implement HPV vaccination into their national programme. The 
information can help the countries to plan better on the HPV vaccines introduction. 
Risk: There are no risks.  
Voluntary participation and right to withdraw from the study: Your participation is 
completely voluntary. You have the right to withdraw your involvement at any time 
before or during the interview, if you do not wish to continue. 
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Confidentiality: The information provided will be blinded. We will not record your name 
or any other information that can identify you. Only the researchers will have access to 
the information from the questionnaires, which will be stored in a safe place. During the 
publication of the findings, we will not mention the names of the participants. 
Compensation: We will not provide money compensation for your participation in this 
study. For those participants who will come to Cape Town, the cost of flight and 
accommodation from and to your country will be covered as part of your sponsorship 
to attend the 11th annual African vaccinology course, hosted by VACFA and to be 
held in November 2015. 
Other additional information: 
 For other questions about the study, you may contact the investigators Leila H 
Abdullahi (email: leylaz@live.co.za.; phone: +27 21 406 6066) or Benjamin 
Kagina (email: benjamin.kagina@uct.ac.za; phone: + 27 21 4066066) in the 
Western Cape, South Africa. 
 You can contact the Health Research Ethics Committee through Ms. Lamees 
Emjedi phone: +27 21 406 6338 if you have any concerns or complaints that 
have not been adequately addressed by the investigators. 
 You will receive a copy of this information and consent form for your own 
records. 
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Consent form for individual participant 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled: challenges and lessons learnt during the introduction of 
vaccines to adolescents in Africa: a focus on Human Papillomavirus (HPV) vaccines). 
I declare that: 
 I have read and understood the information provided to me about the study 
as well as the consent form.  
 I understand the study team is interested in hearing my personal views, and 
my name will not be mentioned in any reports arising from this study. 
 I understand that my discussions with the study team will be recorded using a 
voice recorder and noted on paper or written version to complete when sent 
to you via email. 
 I had a chance and still have a chance to ask questions. All my questions 
have been/will be adequately answered. 
 I understand that taking part in this study is voluntary, I can withdraw my 
participation anytime and I have not been coerced to participate. The study 
might take 30 minutes and I have the right to withdraw from the study at any 
time. 
 I will not be penalised or prejudiced in any way after withdrawing from the 
study. 
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Signed at (place) ......................…..........  On (date) …………....………... 
 ..............................................................   ............................................................  
Signature of participant Signature of witness 
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Appendix 9: Questionnaire (Chapter 5) 
Study semi-structured in-depth interview guide on challenges experienced and 
lessons learnt during the introduction of vaccines to adolescents in Africa: a 
focus on Human Papillomavirus (HPV) vaccines 
For the following questions with response boxes , mark the appropriate box 
with an x to indicate your response. 
General information 
1. Category of the stakeholder 
Government representatives  
Funding agencies  
Implementing agencies  
NITAGs member  
Other   
2. What was your role during the HPV vaccine introduction…………………………… 
3. Vaccination target age group in your country………………….. 
4.  Vaccination target gender?  Female   Female and male  
5. How many doses? One   Two    Three  
6. Was there an evaluation study after successful introduction of HPV vaccine  
Yes    No  
7. If yes, what method of the evaluation was used? 
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A. Finance 
1. How were the costs of HPV vaccines financed in your country? E.g. 
Delivery costs and /or HPV vaccine costs 
2. Did your country develop a financial sustainability plan for the HPV 
vaccine programme 
B. Political 
1. Describe any political influence (negative or positive) that played a role 
during the introduction of HPV vaccine in your country? 
C. Health system delivery 
1. What were the various strategies used during HPV vaccination implementation 
E.g. Health facility based, school-based, outreach programmes like 
community visits, integrated services:  
2. Kindly explain the lessons and challenges you experienced on the strategies 
used to increase vaccination coverage among adolescents in your 
country/setting. 
D. Factors that affect the introduction of HPV 
1. What are the factors that hindered the introduction of HPV vaccine in your 
country? 
E.g. Religious, cultural, knowledge, finances, infrastructure, training of 
health staff etc. 
E. Challenges faced during HPV introduction 
1. Minor (defined as unforeseen or foreseen that could not stop introduction if not 
addressed). 
2. Major (defined as unforeseen or foreseen that needed to be overcome prior to 
the introduction). 
F. Lessons learned during HPV introduction 
1. What could you do differently if the process was to be repeated again 
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2. Advice or suggestions to other countries wanting to introduce HPV? 
G. Coverage (vaccination).  
1. What was the HPV vaccination coverage (dose 1) and (dose 2)? 
2. How was the vaccination coverage calculated? 
3. Other adolescents’ vaccines in consideration? 
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Appendix 10: Ethics approval (Chapter 5) 
 
